Unraveling the Complex Regulatory Relationships between Metabolism and Signal Transduction in Breast Cancer. by Wynn, Michelle L
Unraveling the complex regulatory relationships 





Michelle L. Wynn 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of  
Doctor of Philosophy 
(Bioinformatics) 








Professor Sofia D. Merajver, Co-Chair 
Associate Professor Santiago Schnell, Co-Chair 
Professor Philip C. Andrews 
Professor Charles F. Burant  



















The work presented in this thesis was funded in part by the Rackham 
Merit Fellowship, the Center for the Education of Women, the CCMB Pilot Grant 
Program, the National Science Foundation, the National Institutes of Health, and 
the Breast Cancer Research Foundation.  
I am indebted to a number of people for their help and support throughout 
my graduate career at the University of Michigan.  First, I would like to thank both 
my mentors, Santiago Schnell and Sofia Merajver.  I will be forever grateful for 
their mentorship and friendship. I am also grateful for the support I received from 
members of their laboratories. I am especially indebted to Lauren Van 
Wassenhove, Zhi Fen Wu, and Li Wei Bao for helping me with many of the cell 
culture experiments included in this work.  I also thank the other members of my 
thesis committee, Jennifer Linderman, Philip Andrews, and Charles Burant, for 
their continued advice and support over the last few years.  In addition, I owe a 
debt of gratitude to Alejandra Ventura, Megan Egbert, Firas Midani and Nikita 
Consul, all of whom helped in invaluable ways with theoretical modeling projects.  
A special thank you to Charles Evans is also required for performing LC-MS 
analysis as well as providing a frequent sounding board for metabolic questions.   
Finally, I am very grateful for my friends and family and am especially 







List of Tables ............................................................................................ vii 
List of Figures .......................................................................................... viii 
List of Appendices .....................................................................................xi 
List of Abbreviations ................................................................................. xii 
Abstract .................................................................................................... xiv 
Chapter 1 Background and Introduction .................................................... 1 
1.1 Background and significance ......................................................... 1 
1.2 Targeted cancer therapies ............................................................. 2 
1.3 Cancer systems biology................................................................. 3 
1.4 Modeling breast cancer complexity ............................................... 6 
Chapter 2 Logic-based models: a predictive and parameter-free network 
analysis method ......................................................................................... 9 
2.1 Introduction .................................................................................... 9 
2.2 Logic-based models approximate biochemical regulation ........... 13 
2.2.1 A basis for the Boolean approximation is also found in 
chemical reaction kinetics ................................................................. 15 
2.2.2 Predictive logic-based models in the literature ...................... 17 
2.3 Time in a Logic Model.................................................................. 19 
2.4 Building predictive logic-based models ........................................ 20 
iv 
 
2.5 Logic models have one or more fixed states known as attractors 26 
2.6 Biologically motivated examples .................................................. 29 
2.7 The use of Boolean models in dynamical systems ...................... 36 
2.8 Concluding theoretical remarks ................................................... 37 
Chapter 3 A Discrete Logic Model of the PI3K Signaling Pathway .......... 41 
3.1 Background ................................................................................. 41 
3.2 Methods ....................................................................................... 43 
3.3 Results ......................................................................................... 45 
3.3.1 Western blot analysis of each cell line ................................... 48 
3.3.2 PI3K pathway mutations in each cell line .............................. 48 
3.3.3 PI3K logic model.................................................................... 51 
3.3.4 PI3K and MAPK cross-talk logic model ................................. 54 
3.4 Discussion ................................................................................... 57 
3.4.1 Future directions .................................................................... 61 
Chapter 4 Targeted inhibitors can produce off-target effects and activate 
linked pathways by retroactivity ............................................................... 66 
4.1 Background ................................................................................. 66 
4.2 Methods ....................................................................................... 70 
4.3 Results ......................................................................................... 76 
4.3.1 Parameter ranges promoting off-target effects in cycle 2 ...... 76 
4.3.2 Varying a single parameter can produce a large change in the 
size of the off-target effect ................................................................ 80 
v 
 
4.3.3 The percentage of off-target effects decreased as the size of 
the vertical and lateral networks increased ....................................... 84 
4.3.4 Off-target effects from retroactivity can propagate down a non-
targeted cascade .............................................................................. 85 
4.4 Discussion ................................................................................... 87 
4.4.1 Conclusions ........................................................................... 89 
Chapter 5  Variations in carbon flux in distinct breast cancer phenotypes 
 ................................................................................................................. 92 
5.1 Background ................................................................................. 92 
5.2 Methods ....................................................................................... 94 
5.3 Results ......................................................................................... 96 
5.3.1 Natural abundance of stable isotopes ................................... 98 
5.3.2 Mass isotopomer analysis ..................................................... 98 
5.3.3 Estimation of extracellular flux ............................................. 108 
5.3.4 Estimation of intracellular TCA cycle flux ............................. 110 
5.4 Discussion ................................................................................. 117 
Chapter 6 Conclusion and Future Directions ......................................... 120 
6.1 Summary ................................................................................... 120 
6.2 Future work ................................................................................ 121 
Appendix A Additional Analyses for Chapter 2 ...................................... 125 
Appendix B Additional Analyses for Chapter 3 ...................................... 127 
Appendix C Additional Analyses and Model Details for Chapter 4 ......... 128 
C.1 Non-dimensionalization of the n = 3 network .......................... 128 
vi 
 
C.2 Mapping of dimensionless parameter values to dimensional 
parameter values for numeric simulation ............................................ 130 
C.3 Randomly selecting 50,000 parameter sets instead of 5000 
produced the same percentage of off-target effects ........................... 131 
C.4 Application of Xenopus MAPK Model Parameters ................. 134 
C.5 Additional analysis of the extended n = 3 network with 
amplification ....................................................................................... 134 




List of Tables  
Table 2.1.  Justifications for logic functions used in Figure 2.5, Model I. . 31 
Table 3.1.  Table of key interactions identified in the PI3K signaling 
pathway. .................................................................................................. 46 
Table 3.2.  PI3K pathway related mutations identified in four breast cell 
lines ......................................................................................................... 47 
Table 3.3.  Justifications for logic functions used in the PI3K/MAPK cross-
talk model in Figure 3.5. ........................................................................... 63 
Table 3.4.  Oncogenic perturbations to the PI3K/MAPK cross-talk model.  .
 ................................................................................................................. 65 
Table 4.1.  The parameter space of each network consisted of a set of 
non-dimensional parameters, each with a minimum and maximum allowed 
value. ....................................................................................................... 70 
Table 4.2.  Parameter sets used in stimulus response curves.. ............... 83 
Table 4.3. The percentage of off-target effects decreased as the network 
size increased.. ........................................................................................ 84 
Table 4.4.   Off-target effects can amplify downstream of cycle 2. ........... 84 
Table 5.1.  Carbon atom transitions used in metabolic flux analysis model 
of the TCA cycle. ................................................................................... 115 
Table 5.2.  Estimated TCA cycle flux.. ................................................... 116 
Table B.1. Oncogenic perturbations to the PI3K/MAPK cross-talk model 





List of Figures 
Figure 1.1. Breast cancer progression. ...................................................... 7 
Figure 2.1.  Logic models approximate molecular interactions. ............... 12 
Figure 2.2.  A hypothetical network example with 12 nodes... ................. 14 
Figure 2.3.  The hypothetical network example reduced to 4 nodes. ....... 19 
Figure 2.4.  Logic Functions.. ................................................................... 25 
Figure 2.5. A Model of Normal Cell Proliferation and Apoptosis: OR NOT 
vs. AND NOT.. ......................................................................................... 28 
Figure 2.6.  Regulatory feedback and oscillations in logic models ........... 32 
Figure 2.7.  An Expanded Model of Normal Cell Proliferation and 
Apoptosis ................................................................................................. 34 
Figure 3.1. Links between the PI3K/AKT pathway and glucose 
metabolism.. ............................................................................................ 43 
Figure 3.2.  Logic network of PI3K signaling.  26 inhibition of MEK, and 
EGF stimulation of EGFR are indicated. .................................................. 49 
Figure 3.3.  Western blot analysis.. .......................................................... 50 
Figure 3.4.  Results of PI3K logic model simulations under normal-like 
conditions.. ............................................................................................... 52 
Figure 3.5.  Logic network of PI3K/MAPK cross-talk. .............................. 53 
Figure 3.6. Results of PI3K/MAPK cross-talk logic model simulations 
under normal-like conditions.. .................................................................. 56 
Figure 3.7.  Results of PI3K/MAPK cross-talk logic model simulations 
under non-normal conditions with PTEN OFF and RAS constitutively ON.
 ................................................................................................................. 57 
Figure 4.1.  Retroactivity arises from enzyme sequestration in covalently 
modified cascades.. ................................................................................. 67 
Figure 4.2.  Topology of signaling networks studied. ............................... 69 
ix 
 
Figure 4.3.  A numerical perturbation analysis revealed parameter value 
ranges that promote off-target effects in the n = 3 network. ..................... 77 
Figure 4.4.  Distribution of the size of off-target effects in the n = 3 
network. ................................................................................................... 81 
Figure 4.5.  Varying a single parameter value can produce a large change 
in the off-target response. ........................................................................ 82 
Figure 4.6.  A summary of conditions that favor off-target in the n = 3 and 
the extended n = 3 networks.. .................................................................... 91 
Figure 5.1.  Central carbon metabolism. .................................................. 94 
Figure 5.2.  Evidence of isotopic steady state. ......................................... 97 
Figure 5.3.  Carbon atom transitions ........................................................ 97 
Figure 5.4.  Enrichment of 13C in M2 Acetyl-CoA.. ................................... 99 
Figure 5.5.  Evidence of oxidative and non-oxidative flux in the pentose 
phosphate pathway. ............................................................................... 100 
Figure 5.6.  Enrichment of glycolytic intermediates. ............................... 102 
Figure 5.7.  Enrichment of 13C in M5 Citrate in SUM-149 cells. ............. 106 
Figure 5.8.  Enrichment of 13C in M3 Malate and M3 Aspartate in SUM-149 
cells........................................................................................................ 107 
Figure 5.9.  Evidence of glutamine derived 13C enrichment in N-
acetylasparate in SUM-149 cells.. ......................................................... 108 
Figure 5.10.  Estimation of extracellular flux. ......................................... 109 
Figure 5.11.  Metabolic model of TCA cycle used in metabolic flux 
analysis. ................................................................................................. 112 
Figure 5.12.  Larger model of central carbon metabolism. ..................... 119 
Figure A.1.  Network reduction example with linear regulations ............ 125 
Figure A.2.  Qualitative comparison of output from the full and reduced 
hypothetical network examples with 12 nodes and 4 nodes.. ................ 126 
x 
 
Figure C.1.   Determination of the number of parameter sets to sample.  
 ............................................................................................................... 132 
Figure C.2  Histograms of parameter values in 50,000 randomly sampled 
parameter sets in the n =  3 network ...................................................... 133 
Figure C.3.  A numerical perturbation analysis revealed parameter value 
ranges that promote off-target effects when the n = 3 network’s parameter 
space was restricted .............................................................................. 135 
Figure C.4. A numerical perturbation analysis revealed parameter value 
ranges that promote off-target effects with amplification in extended n = 3 





List of Appendices  
Appendix A   Additional Analyses for Chapter 2 .................................... 125 
Appendix B   Additional Analyses for Chapter 3 .................................... 127 







List of Abbreviations  
 
2/3PG - 2-phosphoglycerate and 3-phosphoglycerate pool 
AKG - alpha-ketoglutarate  
ASP - aspartate 
BAD - bcl-2-associated death promoter 
DCIS - ductal carcinoma in situ  
E4P - erythrose 4-phosphate 
EGF - epidermal growth factor  
ERK - extracellular signal-regulated kinases 
F6P - fructose 6-phosphate  
FAS - fatty acid synthesis 
FBP - fructose 1,6-bisphosphate  
G6P - glucose 6-phosphate 
GAP - or glyceraldehyde 3-phosphate  
GL-OH3P - Glycerol 3-phosphate 
GLU - glutamate 
GLUT - glucose transporter proteins  
GLY - glycine 
GPG - 6-phosphogluconate  
GSK3ß - Glycogen synthase kinase 3 beta 
IBC - inflammatory breast cancer  
IDH - isocitrate dehydrogenase  
IRS1 - insulin receptor substrate 1 
KRAS - v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (isoform of RAS) 
LY - LY294002, a PI3K inhibitor 
MAPK - Mitogen-activated protein kinase 
xiii 
 
MEETHF - methylenetetrahydrofolate  
MM - Michaelis-Menten 
mTOR - mammalian target of rapamycin 
NAA - N-acetylaspartate  
NAAG - N-acetyl-aspartylglutamate  
NTS - nucleotide synthesis 
OAA - oxaloacetate  
PEP - phosphoenolpyruvate 
PFK1 - phosphofructokinase-1 
PFK2 - phosphofructokinase-2  
PI3K - phosphatidylinositol 3-kinase 
PIK3CA - gene that encodes the catalytic subunit of PI3K 
PIP3 - hosphatidylinositol (3,4,5)-triphosphate  
PPP - pentose phosphate pathway 
PTEN - phosphatase and tensin homolog 
R5P - ribulose 5-phosphate  
S7P - sedoheptulose 7-phosphate  
TCA - tricarboxylic acid cycle 
TGS - triglyceride synthesis  





Almost all cancer cells exhibit a metabolic phenotype characterized by 
high rates of glucose uptake known as the Warburg effect.  Metabolic changes 
that are representative of distinct stages of breast cancer may suggest 
dependence by cancer cells on certain metabolic processes that are not relevant 
to normal cells.  Importantly, these differences may help identify therapeutic 
targets that are non-lethal to normal cells.  In this thesis, I present a set of 
models and methodologies developed using both experimental and theoretical 
approaches to investigate the complex intracellular signaling and metabolic 
networks associated with distinct stages of breast cancer.  First, a detailed 
literature search was used to construct a logic network model of the PI3K 
signaling pathway, which is known to play an important regulatory role in glucose 
metabolism.  Comparisons of experimental and simulated results suggest that 
the network model is well constructed but some regulatory crosstalk with MAPK 
requires additional refinement.   Targeted therapeutic inhibitors frequently induce 
off-target effects.  This thesis also explored the role of retroactivity in generating 
off-target effects in signaling networks using a computational model.  The 
simulation results suggest that the kinetics governing covalently modified cycles 
in a cascade are more important for propagating an upstream off-target effect via 
retroactivity than the binding affinity of a drug to a targeted protein, which is a 
commonly optimized property in drug development.  Finally, 13C tracer 
experiments were used to infer relative glucose and glutamine derived flux in cell 
lines representing distinct stages of breast cancer.  Steady state metabolic flux 
analysis was also used to computationally fit the absolute TCA cycle flux in these 
cell lines.  Variations in acetyl-CoA, citrate, pyruvate, and alpha-ketoglutarate flux 
were identified.  A particularly important finding was a large reductive 
carboxylation flux from alpha-ketoglutarate to citrate in SUM-149 cells.  Together, 
xv 
 
the models presented in this thesis provide a framework for identifying 
mechanistic drivers of the Warburg effect, which may represent important 
therapeutic targets for modulating cancer proliferation and progression. 
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Chapter 1  
Background and Introduction 
 
Portions of this chapter were previously published by the author in Advances in 
Experimental Medicine and Biology [1]. 
1.1 Background and significance 
Despite the enormous genetic diversity found within a single tumor and 
across different cancers, the same signaling pathways are routinely altered in 
cancer cells [2].   A net result of this dysregulation is almost always the 
deregulation of apoptotic programs and the upregulation of survival and 
proliferation programs.  As these interconnected programs are altered, a cancer 
cell’s metabolic processes also undergo changes and adaptations to manage 
energy and nutrient needs.  A critical component of a cancer cell’s survival 
program is an altered metabolic phenotype characterized by high rates of 
glucose uptake and glycolysis, even under aerobic conditions. This altered 
metabolism, first described by Otto Warburg [3], is referred to as the Warburg 
effect or “aerobic glycolysis” [4-7] and is so pervasive among cancers that it is 
routinely leveraged in the clinic with fluorodeoxyglucose-positron emission 
tomography (FDG-PET).  In general, high tumor glucose uptake observed by an 
FDG-PET scan correlates with the number of metabolically active tumor cells and 
their proliferation rates, both of which are robust prognostic indicators of adverse 
outcomes [5, 8].   
The Warburg effect is considered paradoxical because, despite the high 
energy demands needed for rapid proliferation, this form of non-oxidative 
metabolism generates only 2 molecules of ATP per molecule of glucose. In 
contrast, under normal oxidative metabolism, cells generate approximately 36 
molecules of ATP.  While a tumor’s reliance on an inefficient form of energy 
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metabolism may appear paradoxical, evidence suggests that the use of non-
oxidative metabolism to fuel proliferation is evolutionarily conserved across 
unicellular and multicellular organisms [6].  There is also evidence that cancer 
cells divert a significant amount of carbon from glucose to nucleotide and fatty 
acid synthesis [5], suggesting that the dependence on glycolysis exhibited by 
cancer cells likely sustains the high biosynthetic requirements of rapid 
proliferation.  Moreover, aggressive cancer cells appear to be increasingly 
dependent on glutamine metabolism [5], and some cancer cells appear unable to 
proliferate in vitro without sufficient extracellular glutamine [4, 5, 7].  It should be 
noted that there is debate about whether increased glucose uptake translates 
into net glycolytic ATP gain in cancer [9].  It is possible that a significant amount 
of the glucose uptake in cancer cells is shunted to pathways other than glycolysis 
(e.g., to the pentose phosphate pathway).  Nonetheless, metabolic 
transformation is increasingly recognized as an essential hallmark of cancer [5, 
10].  
While the Warburg effect appears to be intrinsic to most cancers, a 
precise etiology remains elusive.  Both oncogenic signaling [6, 11] and 
interactions with the tumor microenvironment [12] are likely involved in the 
induction and maintenance of the malignant metabolic phenotype.   
1.2 Targeted cancer therapies  
Targeted molecular inhibition is now a leading anti-cancer strategy [13, 
14].  A number of targeted therapies are in wide clinical use and many more are 
in clinical trials.  The phosphatidylinositol 3-kinase (PI3K)  pathway is one the 
most commonly altered signaling pathways in human cancers [15] and AKT, a 
key component of this pathway, is known to play a critical role in stimulating 
glycolysis as well as inhibiting apoptosis [16, 17]. As a result, the PI3K pathway 
is viewed as a promising anti-cancer therapeutic target and a number of drugs 
targeting this pathway are in clinical trials [18-20].    
In practice, only a small percentage of targeted therapies are approved for 
clinical use, however, because of harmful off-target effects or lower than 
expected efficacy, despite promising pre-clinical data [14].  For targeted 
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therapies approved for clinical use, the emergence of drug resistant clones is 
common [13].  The large number of off-target effects associated with targeted 
cancer inhibitors was recently termed the “whack a mole problem” [13] because 
the inhibition of a target molecule often results in the unexpected activation of 
one or more non-targeted molecules. In the cancer research community, off-
target effects are generally attributed to non-specific drug interactions or non-
linear regulatory feedback within an intracellular network, sometimes without 
explicit evidence.  In Chapter 4, it is demonstrated that off-target effects may 
also arise via a process termed retroactivity [21], where a downstream 
perturbation in a signaling network induces an upstream response without any 
direct regulatory feedback connections.  This non-linear behavior may be an 
important but overlooked source of off-target effects.   
It is increasingly likely that the inability of many targeted cancer therapies 
to successfully control the disease when administered as monotherapy is related 
to the complexity of non-linear intracellular networks as well as the complexity 
associated with a tumor as a whole.  Tumors exhibit a variety of non-linear, 
emergent, and adaptive behaviors and consist of many layers of spatial 
complexity.  Given the extreme complexity of intracellular signaling networks and 
the regulatory feedback connections between component pathways and 
modules, the use of experimental intuition alone will not be enough to make 
robust predictions about where off-target effects are likely to occur in a network.  
The development of computational or mathematical models that can simulate a 
non-linear response in a complex signaling network as a consequence of a 
molecular perturbation (such as treatment with one or more targeted inhibitors) is 
needed. 
1.3 Cancer systems biology 
Systems biology is the integration of theoretical and experimental methods 
to build predictive models of complex biological phenomena.  The objective of 
cancer systems biology is to understand the interactions that occur across 
microscopic and macroscopic scales in a tumor and, critically, to exploit these 
interactions in a predictive way.  Ideally, models built using cancer systems 
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biology methods will have translational significance and can be used to predict 
candidate therapeutic targets as well as their likelihood to induce an off-target 
effect or therapeutic resistance. 
Several important studies have identified molecular differences between 
normal and malignant metabolism [17, 22-27]. Genomic and proteomic 
approaches are increasingly used to identify differences in expression levels 
between normal and malignant phenotypes [23, 28]. The current statistical 
methods associated with high-throughput approaches cannot always distinguish 
small fold changes from experimental noise [29], however.  Because an 
expression change in a metabolic enzyme or metabolite of only 1 or 2 fold is 
often sufficient to substantially alter the rate of a metabolic reaction, high-
throughput methods should ideally be complemented with methods that can 
detect smaller changes in metabolic reaction rates [29].  
Modeling intracellular biochemical processes 
It is never practical to create a model that is an exact replica of a complex 
system, and trade-offs must be made between the scope and level of detail 
included in a model [30].   Complex cellular processes are commonly modeled 
with systems of continuous ordinary (ODE) or partial (PDE) differential equations. 
ODE and PDE models are built from underlying biophysical principles and, as a 
consequence, are inherently predictive.  The use of continuous ODE based 
approximations is justified when the system is assumed to be well mixed and the 
number of molecules of a given reactant ranges from 100 to 1000 [31].  ODE 
based systems, which are commonly employed to build models of protein signal 
transduction and metabolism, are generally based on mass action and Michaelis-
Menten (MM) kinetics [30, 32-34].  MM kinetics depends on the quasi-steady-
state approximation that assumes the formation of the complex occurs on a 
much faster timescale than the other reactants involved in the reaction.  When 
building theoretical models of biochemical processes, it is important to recognize 
that these assumptions may be invalid under physiological conditions [35, 36].   
An alternative to ODE based kinetic models are stoichiometric models 
where the known structure of a chemical pathway is used to understand the state 
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of the system under a set of specific conditions.  The methods assume an 
optimization function (e.g., the goal of bacteria is continual production of 
biomass) and have demonstrated predictive power in prokaryotes.  Because 
these methods do not include any regulatory or kinetic information in the model 
formulation [37], they lack predictive power for multifunctional mammalian cells 
[38], however.  It would be extremely difficult to define an optimization function 
that adequately captures the complexity of a mammalian cell.  Kinetic ODE 
models, therefore, tend to be more predictive than stoichiometric models 
because they can predict temporal dynamics.  Kinetic ODE models require more 
knowledge a priori [37] than stoichiometric models, however, and this information 
is not always readily available.   
Modeling signal transduction 
A large number of ODE based models of signal transduction can be found 
in the literature [33, 34, 39-46].  In contrast to central carbon metabolism, 
however, significant information about the structure of signal transduction 
networks is often not known a priori, making ODE models of large scale signaling 
networks difficult to accurately construct.  In addition, large scale ODE models 
are limited by extremely large and poorly defined parameter spaces.  Alternative 
methods for modeling signal transduction networks include Bayesian network 
analysis, structural network analysis, Markov models, and discrete logic based 
models [47].   A number of logic-based network models of gene regulation and 
signal transduction have generated experimentally valid predictions [47-51].  
Logic models are a parameter free method that can be used in the absence of 
detailed kinetic and mechanistic information.  The theoretical underpinnings and 
limits of logic modeling are explored in Chapter 2. 
Modeling cellular metabolism 
Many ODE based models of metabolism exist in the literature [38, 52-54].  
In general, metabolism is the set of enzyme catalyzed reactions that break down 
or synthesize molecules in a cell [32].  Enzymes regulate metabolism by 
catalyzing these reactions [55].  Specifically, an enzyme reacts selectively with a 
substrate and transforms it into a product.  In experimental studies of 
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metabolism, enzyme concentrations are generally assumed to be constant during 
the catalyzed transformation of substrates into products [56, 57].   
The most widely used theories of metabolic regulation are biochemical 
systems theory [58-60], metabolic control theory [61-63], and flux-oriented theory 
[64-66].  All three of these theories are applications of sensitivity analysis applied 
to biochemical reaction models. The models consist of coupled ODEs based on 
the law of mass action.  Sensitivity analysis is used to investigate the effects of 
parameter value changes on model behavior [67]. It is not surprising, then, that 
the primary difference between these theories is the choice of which parameters 
to vary when evaluating model sensitivity [67, 68].   Another common attribute of 
these theories is the assumption of constant enzyme concentration [68, 69].  The 
assumption of constant enzyme concentration has been questioned for some 
time, however [70].  Enzymes are not indefinitely stable; they too are metabolites 
like their substrates and products [32]. The synthesis of enzymes is an essential 
part of metabolism and is catalyzed by other enzymes.  A theory to investigate 
metabolic regulation in cancer cells that takes into account enzyme production 
and depletion is needed in system biology.   
1.4 Modeling breast cancer complexity 
In the United States, breast cancer is a leading cause of cancer deaths 
among women, second only to lung cancer [71].  Mammary ductal carcinoma in 
situ (DCIS) is an early form of breast cancer that occurs when luminal epithelial 
cells in a mammary duct begin to proliferate abnormally and disturb the ductal 
architecture.  DCIS advances to invasive breast cancer when proliferating cells 
breach the basement membrane and begin the process of metastasis [72] 
(Figure 1.1), the most lethal stage of cancer.  The 5-year survival rate after 
diagnosis with metastatic breast cancer is 23%, while the 5-year survival rate for 
other stages of breast cancer is greater than 80% [71].   A distinct breast cancer 
phenotype known as inflammatory breast cancer (IBC) represents the most 
deadly form of the disease  [73, 74], with more than 90% of patients exhibiting 
metastases within 1 year of diagnosis  [75].  New treatment strategies for IBC 





Figure 1.1. Breast cancer progression. (A) Normal adult mammary glands are hollow tube-like structures 
surrounded by polarized luminal epithelial cells (grey).  (B) In ductal carcinoma development, aberrant 
luminal cell proliferation ensues, which may be followed by (C) invasion if the basement membrane 
surrounding the myopethelium is breached (black). (D-G) Representative images of 3-dimensional breast 
cell culture performed by the Merajver lab and imaged with fluorescent confocal microscopy. (D) The MCF-
10A normal-like mammary epithelial cells form well-organized acini with empty central lumen resembling 
normal mammary ducts; compare to (A). In contrast, the tumorigenic (E) MCF-7 cancer cells form defined 
acini with filled lumen resembling ductal carcinoma in situ; compare to (B).  (F) SUM -149 and (G) MDA-MB-
231 are metastatic cell lines that exhibit forms of invasion and loss of organization; compare to (C). 
 
The Warburg effect in cancer is similar to proliferative metabolism in 
normal cells but molecular and kinetic differences have been discovered.  I 
hypothesize that there are key drivers of the Warburg effect that can be exploited 
to target breast cancer proliferation without substantial negative effects on 
normal tissue growth.  Because the intracellular networks involved in regulating 
cancer metabolism are highly complex and interconnected, identifying these 
drivers will require systems biology approaches.    
The challenges associated with cancer’s complexity are well recognized 
within the cancer systems biology community [76-84].  While a number of models 
of cancer complexity have been developed [51, 82, 85-88], few have included 
proliferative metabolism, or its regulation, in detail.   [89, 90].  In this thesis, I 
present a set of models and methodologies developed using principles of cancer 
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systems biology to investigate the complex intracellular networks in distinct 
stages of breast cancer, including metabolic networks. The models in Chapter 3 
and Chapter 5 rely on an in vitro model of breast cancer progression, where 
normal tissue is modeled using data from normal-like MCF-10A mammary 
epithelial cells lines and malignant tissue is modeled using data from three 
tumorigenic cell lines: MCF-7 (non-metastatic breast cancer), MDA-MB-231 
(highly metastatic, triple negative breast cancer), and SUM-149 (highly 
aggressive metastatic IBC) (Figure 1.1D-G). The objective of all models 
presented is the elucidation of system level properties that would be difficult to 
discern by experimental methods alone.  The models presented also provide a 
framework for identifying mechanistic drivers of the Warburg effect, which I 
hypothesize may be important potential therapeutic targets. 
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Chapter 2  
Logic-based models: a predictive and parameter-
free network analysis method 
 
The content of this chapter was previously published by the author as a critical 
review in Integrative Biology [91]. 
2.1 Introduction 
The emergence of molecular biology has produced a vast literature on the 
cellular function of individual genes and their protein products.  It has also 
generated massive amounts of molecular interaction data derived from high-
throughput methods as well as more classical low-throughput methods, such as 
immunoprecipitation, immunoblotting, and yeast two-hybrid systems.  From this 
accumulation of interaction data, researchers can now attempt to reconstruct and 
analyze the highly complex molecular networks involved in cellular function. 
The objective of systems biology is to integrate experimental data with 
theoretical methods to build predictive models of complex biological processes 
across a variety of spatial and temporal scales.  Two very different paradigms of 
system biology are frequently used to construct and analyze network models of 
molecular interactions inferred from experimental data: structural network 
analysis methods and mathematical models based on differential equations.  A 
third increasingly important network analysis paradigm in systems biology is the 
application of logic-based methods to generate predictive output [92, 93].  
Although qualitative in nature, logic-based methods have the capacity to provide 
insights into the dynamics of highly complex gene regulatory and signal 
transduction networks without the burden of large parameter spaces.    
Understanding the networks associated with cancer offers especially 
difficult challenges.  Fundamental problems in understanding the transition from 
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the normal to near normal to dysplastic to neoplastic to metastatic states of 
cancer progression can theoretically be modeled by longitudinal comparisons of 
networks in which, as progression occurs, certain molecular interactions are 
rendered stronger (for instance through gene amplification) or lost (through 
mutation, deletion, down-regulation, or methylation).  Logic models provide a 
framework in which these types of network comparisons are possible.  Multi-state 
logic models can simulate signal amplification, and random order asynchronous 
logic models can simulate the heterogeneous response in a population of cells to 
diverse stimuli.  Logic-models are also well suited for performing in silico 
molecular perturbations, which could be used to predict a population level 
response to a targeted therapy or a combination of therapies.  In this review, we 
provide a tutorial on the use of logic-based methods as well as a discussion of 
their limitations, using biologically motivated examples.   
Modeling intracellular networks 
Typically, knowledge of molecular interactions is summarized in diagrams 
of varying complexity, commonly known as interaction networks [94].  In an 
interaction network diagram, each node represents a molecule and a line drawn 
between two nodes represents a molecular interaction, also referred to as an 
edge in graph theory.  If the nature of an interaction between two nodes is known 
(e.g., which molecule is the regulator that activates or inhibits the other 
molecule), the edge is said to have directionality.  If a correlation between the 
activities or expression levels of two nodes is known but the causal relationship 
underlying their interaction is not, the edge is said to lack directionality.  
Structural network methods 
Structural network analysis provides a picture of the correlations between 
molecules in very large networks.  In structural network models, which are 
usually derived from high-throughput genomic or proteomic experimental 
methods, the directionality of interactions in the network is generally not known 
and it is the static correlations in expression patterns that are important.  The 
primary objective of these methods is to infer functional patterns in large 
networks using statistical methods [95].  These methods are also used to 
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construct species specific interactomes [94].  A limitation of these methods, 
however, is that they generally provide only a static view of molecular 
interactions in a network at single point in a time.  Additionally, the current 
experimental methods used to generate data for structural network models are 
extremely noisy [96], which further limits the predictive power of this method. 
Differential equation methods 
As discussed in Chapter 1, systems of ordinary differential equations 
(ODEs) are frequently used to model biochemical reactions involved in gene and 
protein regulation.  In these models, information about the mechanistic nature of 
the interaction is essential and edges between species must be directional.  ODE 
models are built from underlying biophysical principles, such as biochemical rate 
laws and the conservation of mass and energy.  Consequently, ODE models 
have the capacity to be highly predictive [97-99].  This predictive power 
translates into the ability to generate a dynamic view of the concentration of each 
interacting species in the network over time as well as the ability to identify 
biologically realistic steady states [98].  The predictive power of ODE systems is 
dependent, however, on large numbers of kinetic parameters that are rarely 
known with any degree of certainty.  These powerful methods are, therefore, 
limited both by the enormous parameter spaces involved in even a relatively 
simple network and by their need for detailed mechanistic knowledge a priori. 
Logic-based methods 
Logic-based network models were pioneered in the biomedical sciences by 
Kauffman [100, 101] and represent a compromise between structural analysis 
and ODE methods in terms of  precision and complexity [97].  While logic models 
do not require mechanistic knowledge of interactions, they do require knowledge 
of edge directionality.  In their simplest form, logic-based models permit each 
biochemical species (represented as nodes in a network) to be in one of two 
discrete states: ON or OFF. The state of a logic network evolves in a dynamic 
fashion as nodes in the network are switched ON and OFF according to the state 
of other nodes in the network, until the network settles into an unchanging state, 
often referred to as an attractor [93].  Logic-based models with only two binary 
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states are generally known as Boolean models.  While there is no explicit notion 
of time in a logic model, each round of updating can be considered an arbitrary 
time unit. 
 
Figure 2.1.  Logic models approximate molecular interactions.  Logic models approximate molecular 
interactions.  The motivation behind logic models comes from the sigmoidal relationship observed between 
regulatory molecules and their target molecules. This relationship approximates a Boolean switch and can 
be thought of as having two states: saturated (ON) and un-saturated (OFF). (A) An inhibitor regulates a 
target molecule in a logic model: the target remains ON until the inhibitor’s activity surpasses a threshold of 
activation. (B) An activator regulates a target molecule in a logic model: the target remains OFF until the 
activator’s activity surpasses a threshold of activation. In these models, ON means the molecule has 
reached a threshold of functional activation that is high enough to affect the state of other molecule(s) it 
directly regulates, while OFF means the molecule is not present at a high enough level to affect the 
molecules it directly regulates.  Critically, OFF does not necessarily mean the molecule has a zero 
concentration. (C) A standard hyperbolic saturation curve measuring reaction velocity, v, as substrate 
concentration, S, increases.  K0.5 is the substrate concentration needed to reach half the maximum velocity, 
Vmax. (D) A plot of v/Vmax vs. S/K0.5 (the specific substrate concentration) takes the form of a sigmoidal 
saturation curve approximating a Boolean-like switch. When S/K0.5 << 1, the reaction is effectively OFF.  
When S/K0.5 >>1, the reaction is effectively ON. 
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2.2 Logic-based models approximate biochemical regulation 
The assumption that a molecule can have only two possible states is a 
simplification of biological complexity. It is a reasonable regulatory 
approximation, however, given the switch-like sigmoidal relationship often 
observed between an affector molecule and its target molecule (Figure 2.1A-B) 
[49, 93, 102, 103].  It is important to emphasize that when a molecule’s node is 
OFF in a discrete logic model, it does not imply that the molecule has zero 
concentration in the system.  Instead, it implies that the molecule is not present 
at a high enough level to induce a change in the molecules it directly regulates 
[103].  When a molecule’s node is ON in a logic model, it means the molecule 
has reached a threshold of functional activation that is high enough to affect the 
state of the molecules it directly regulates.  More specifically, a target molecule 
will remain OFF in a logic model until its activator reaches a specific threshold of 
activity (Figure 2.1B).  Likewise, a target molecule will remain ON in a logic 
model until its inhibitor reaches a specific threshold of activity (Figure 2.1A) 
[103]. As a consequence, logic models can only provide qualitative 
approximations of molecular regulation. While this represents a limitation of the 
methodology, in reality, the majority of experimental data available on molecular 
regulations are also qualitative in nature [104]. 
More complex logic-based methods have been developed, such as multi-
state and fuzzy logic methods, which permit nodes to be in more than two 
discrete states.  In addition, logic models that allow node states to vary 
continuously between states (e.g., from 0 to 1) have also been developed [47, 
49, 51, 97].  Although theoretically able to more precisely simulate biochemical 
regulation [47], these more complicated approaches require parameter value 
estimates that are rarely known and, in some cases, are difficult to correlate with 
biophysical chemistry theory.  Thus, discrete two-state logic models (Boolean 
models) are an intuitive and predictive method for describing biochemical 
interactions without requiring prior knowledge of complex mechanistic details of 
reaction kinetics (needed for ODE systems) or degrees of membership (needed 
for multi-state fuzzy logic systems). 
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Figure 2.2.  A hypothetical network example with 12 nodes. (A) An interaction network diagram 
summarizing a hypothetical network with 12 nodes where input is the only input node, output is the only 
output node, and A–J are internally regulated nodes.  (B) A logic network diagram explicitly identifying how 
multiple signals (edges in the diagram) will be integrated to produce a response in nodes B and output, the 
only nodes with more than one regulator.  (C) A table explicitly listing the logic functions used in the 
hypothetical logic model. The information in this table is equivalent to the information available in (B), and 
both (B) and (C) contain more information than (A).  (D) Each unique network state in a logic network can be 
identified in a number of ways: a graphical table where white = OFF and black = ON, a binary representation 
where 0 = OFF and 1 = ON, or a decimal value that is equivalent to the binary representation.  Each of these 
states will give rise to another state based on the logic functions (B–C) that control signal transfer in the 
network.  (E) Eventually, all states will settle into an attractor, a state from which it is not possible to escape 
without an external perturbation to the system.  In the graphs, attractor states are colored red and non-
attractor states are colored grey.  An example of a limit cycle and a point attractor are highlighted.  In this 
model, there are a total of 212 (4096) possible states that settle into 1 of 10 attractors.  Blue circles indicate 
AND interactions. 
15 
Moreover, Boolean models can produce the same qualitative output as 
more quantitatively precise ODE models when well-constructed. For example, 
Albert and Othmer [48] used a Boolean model of the genetic regulation of 
segmentation patterns in Drosophila to produce results that were in close 
agreement with an earlier ODE model of the same system [105].  Fauré et al. 
[104] analyzed a simple Boolean model of cell cycle regulation and found 
qualitative steady state agreement with a complex ODE model [42].  More 
recently, Akman et al.[106] demonstrated that a series of Boolean models 
produce the same qualitative output as a series of ODE models of circadian clock 
regulation.  In addition, Boolean models are well suited for the testing of 
hypothesized regulatory mechanisms [48, 107] and for helping to direct future 
experiments [50, 108-110]. They are also useful for performing a preliminary 
network analysis [110] prior to developing more detailed experimental or 
theoretical models.  For all these reasons, the development and analysis of two-
state Boolean models will be the primary focus of this review. 
2.2.1 A basis for the Boolean approximation is also found in chemical 
reaction kinetics 
In addition to the switch-like regulatory dependence described above, 
another switch-like behavior in biochemical systems is related to the substrate 
concentration (S) needed to reach half the maximum velocity (Vmax) of a reaction, 
commonly represented by K0.5.  Enzymologists routinely use saturation curves 
depicting how reaction velocity (v) varies with S (Figure 2.1C) to estimate the 
K0.5 of a reaction.  In reality, v is not dependent on S but is, instead, dependent 
on the specific substrate concentration, defined as the ratio of S to K0.5 (S/K0.5).  
The well-known constant Km is the substrate concentration needed to reach K0.5 
under Michaelis-Menten (MM) kinetics [32].  While K0.5 is sometimes called the 
“apparent Km”, K0.5 is not restricted to kinetic mechanisms that follow the MM 
approximation.   
The standard MM expression for the velocity (vMM) of a non-reversible 
enzyme catalyzed reaction is presented in equation (1).  This expression is 
similar to the generalized expression for the velocity (v) of any enzyme catalyzed 
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reaction presented in equation (2), where S is converted to a product.  Here, n 
refers to the Hill coefficient describing the degree of cooperativity in the reaction 
(i.e., positive, negative, or no cooperativity).  Dividing both sides of equation (2) 
by Vmax and factoring K0.5 out of the right-hand side, gives equation (3), which is 
now in the form commonly used to normalize reaction velocities (v’).  Equation 
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In equation (3), when S/K0.5 = 1, then v’  = 1/2.  Consequently, there are 
two distinct regions where the normalized reaction velocity responds in a 
characteristic way to S/K0.5 (Figure 2.1D).  When S/K0.5 << 1, then S < (0.01 x 
K0.5), meaning the enzyme is not saturated and the reaction rate is linear with 
respect to the substrate concentration.  In contrast, when S/K0.5 >> 1, then S > 
(100 x K0.5), meaning the enzyme is saturated, the reaction rate is independent of 
the substrate concentration, and the reaction has reached (or is very near to) its 
maximum velocity.  Thus, the specific substrate concentration serves as the on-
off switch of a reaction.  In logical terms, when the node representing S is OFF 
(or 0), then the specific substrate concentration will be less than 1 and the 
reaction cannot not proceed.  Likewise, when the node representing S is ON (or 
1), then the specific substrate concentration will be greater than 1 and the 
reaction will proceed at a rate near Vmax (Figure 2.1D).   
The use of logic to describe chemical change is not limited to the rate of 
biochemical reactions.  Molecular substrates have been described as 
computational devices that process physical and chemical inputs into outputs 
according to Boolean logic [111].  Molecular logical operations are achieved by 
leveraging observable chemical changes to create a computational device.  
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These devices, for example, can be used to solve arithmetic or logical operations 
by exploiting changes in the conformations of chemical components.  In the 
laboratory, molecular logic functions have been developed that rely on charge 
transfer, which affects the fluorescent state of a molecule [112, 113].  Logical 
functions have also been created to exploit charge transfers in cascades of 
coupled enzymes [114, 115].  In fact, molecular logic operations serve as the 
basis for many nanosensors currently used in the basic sciences, industry, and 
medicine [111]. 
2.2.2 Predictive logic-based models in the literature 
Although the theoretical underpinnings of logic models provide qualitative 
approximations of molecular and biochemical regulation, in reality these models 
can only generate predictive output when the logic model is well constructed.  
Several examples of well-constructed logic models providing good agreement 
with experimental data exist in the literature [47, 48, 50, 51, 116-119]. 
For example, Li et al. [117] constructed a Boolean model of the genetic 
network controlling the cell cycle in Saccharomyces cerevisiae.  The authors 
found that 86% of the 2048 possible states in the network settled into a steady 
state (also known as a stable attractor) that corresponded to the G1 stationary 
phase of the cell cycle.  Their analysis suggested that the regulatory network 
controlling the yeast cell cycle is resistant to stochastic perturbations. The 
authors interpreted these findings to mean that robustness in the underlying 
network is advantageous for the organism because, under normal conditions 
there is a high probability that the regulatory network dynamics will settle into the 
G1 state regardless of the current state of the network.  Once in the G1 state, the 
network will remain in that state until a significant external signal perturbs the 
network and initiates another round of cellular division.  Subsequent work by 
Davidich and Bornholdt [120] used a similar Boolean approach to study the cell 
cycle regulation in Schizosaccharomyces pombe.  These authors found that the 
majority of S. pombe network states settle into a steady state corresponding to 
the G1 stationary phase, which is in agreement with the results of the S. 
cerevisiae model.  However, they also found significant differences in the 
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regulatory network of S. pombe compared to S. cerevisiae, which yielded very 
different network dynamics.   
Using a somewhat different logic-based approach, Bolouri and colleagues 
[110, 121] constructed an a priori gene regulatory network of endomesoderm 
specification control in sea urchin embryos.  The network was logic-based and 
generated a series of testable predictions.  Using computational methodologies 
and large-scale perturbation analyses, the authors iteratively tested and revised 
their model by comparing model output to biological readouts.  Their use of a 
regulatory network to logically map inputs and outputs for cis-regulatory elements 
identified system level properties that would not otherwise have been observable.  
From this information, the authors were able to draw important conclusions about 
the developmental features of endomesoderm specification.  
In addition to gene regulatory networks, logic models can also be used to 
model signal transduction networks.  Li, Assmann, and Albert [50] developed a 
Boolean model of the signal transduction network controlling abscisic acid 
regulation of stomatal closure in plants.  The authors employed a network 
construction approach that inferred indirect molecular relationships from data to 
build the sparsest logic network possible that was compatible with available 
experimental data.  A random order asynchronous Boolean approach was then 
used to simulate the heterogeneity in a population of cells.  The model results 
were in good agreement with previous experimental findings and generated 
novel predictions about the conditions likely to have the strongest effect on 
stomatal closure.  In a subsequent manuscript, which also serves as an excellent 
tutorial, Albert et al. [49] contrasted the asynchronous approach used in the Li, 
Assmann, and Albert [50] model with a continuous piecewise Boolean model of 
the same system that allowed node states to vary between 0 and 1.  They 
reported that the asynchronous discrete Boolean model produced the same 
qualitative results as the continuous piecewise Boolean model. 
For additional examples of predictive logic-based models in the literature, 
we direct the reader to comprehensive reviews by Morris et al. [97] and Albert et 
al. [49].  Both reviews provide detailed case studies of logic model 
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implementations and demonstrate the variety of ways logic-based models can be 
applied to answer biological questions.   
 
 
Figure 2.3.  The hypothetical network example reduced to 4 nodes.  (A) An interaction network diagram 
summarizing an alternate form of the network in Figure 2.2A where all linear regulations have been 
collapsed into single regulations.  (B) A logic network identifying how multiple signals (edges in the diagram) 
will be integrated to produce a response in B and output, the only nodes with more than one regulator.  (C) 
A table listing logic functions used in the reduced model.  The information in this table is equivalent to the 
information available in (B), and both (B) and (C) contain more information than (A).  (D) Eventually, all 
states will settle into an attractor.  In the graphs, attractor states are colored red and non-attractor states are 
colored grey.  In this model, there are 24 (16) possible states that settle into one of two attractors, which, 
because of their small size, can be easily visualized.  The binary numbers on the nodes represent the state 
of each node in the network in the following order input, B, E, and output.  Blue circles indicate AND 
interactions. 
2.3 Time in a Logic Model 
Each time a network is updated in a standard two-state Boolean model, 
signals are transferred according to logic functions in a synchronous and 
deterministic manner.  In these models, all nodes are updated instantaneously in 
the same time step so that the state of the network is always fully determined by 
the state of all nodes in the previous time step.  Thus, the underlying assumption 
is that all molecular interactions in the network take the same arbitrary amount of 
time to complete. In reality, the time it takes for molecular interactions to 
complete varies widely.   
An alternate updating method involves asynchronous updating where one 
node is selected at random and instantly updated according to the current state 
of the network.  In these models, the next state of the network is non-
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deterministic.  The random and instantaneous updating of a node is repeated 
many times with each random update representing a time step in the model.  
This non-deterministic updating scheme is thought to more closely resemble 
biological variation by eliminating temporal uniformity in the model [49, 92, 103, 
122, 123].  Typically, implementation of this type of scheme involves running a 
large number of model simulations to calculate a probability that any given node 
will end up ON or OFF for any set of initial conditions [49, 50]. Synchronous and 
asynchronous updating methods are discussed in more detail in later sections of 
this chapter.      
2.4 Building predictive logic-based models 
Creating a logic model is relatively straight-forward.  Building a logic model 
that can generate predictive output that can be leveraged by experimentalists, 
however, requires considerably more effort.  Specifically, building predictive 
logic-based models entails two primary steps: building a detailed interaction 
network and translating the interaction network into a logic network. The 
development of a logic network includes the careful derivation of the logic 
functions that will drive the network’s dynamics. 
Build an interaction network by surveying the literature 
The first step in developing a logic model is to construct an interaction 
network of the system to be modeled (see, for example, Figure 2.2A).  To do so 
will typically require a thorough literature or database search.  This is a critical 
step and should be performed by, or in close collaboration with, someone who is 
well acquainted with the biology of the system.  Once the interactions involved in 
the network have been identified, it is often desirable to perform a node reduction 
to reduce network complexity, especially for very large networks.  The 
formulation of any theoretical model requires sound judgments about which 
approximations are appropriate for simplifying model complexity without losing 
essential elements of the underlying mechanism(s) [124].  This is certainly true of 
logic models where decisions must be made about whether some complex 
interactions can be lumped into a smaller subset of nodes and interactions 
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(Appendix A).  In general, the objective is to use the simplest network possible 
that still agrees with known experimental data.  This may be done manually or 
with the assistance of computational algorithms [50, 125, 126].  If automated 
tools are used, it is useful to validate that the reduced network generated 
includes a suitable amount of complexity for the system and problem considered.    
A common manual approach is to eliminate redundant linear regulations.  
For example, in Figure 2.2A, nodes B and C are both activators of E because an 
even number of inhibitions produces an activating regulation.  In contrast, E is an 
inhibitor of B because there is one inhibitory regulation between E and B.  A 
reduced version of this network is presented in Figure 2.3.  As shown in 
Appendix A both forms of the network produce the same qualitative output.    
Translate the interaction network into a logic network 
Ultimately, the interaction network must be translated into a set of logic 
functions (also referred to as transfer functions or logic gates) that will be used to 
transfer information (or signals) between nodes each time the model is updated.  
Logic functions often contain one or more Boolean operators.  The AND and OR 
operators are used to define how distinct signals acting on the same node (which 
may be stimulatory and/or inhibitory) will be processed.  The NOT operator is 
used to negate the state of the node it precedes. The derivation of logic functions 
is discussed in detail in the next section. 
A justification from the literature (or evidence from experimental data) 
should be provided to support each logic function.  When individual logic 
functions qualitatively agree with experimental data, it is more likely that the 
model, as a whole, will be predictive.  Ideally, a table or appendix summarizing 
each logic function’s rationale will be included with all published models (see  
Table 2.1 for an example) [48, 50, 51, 104]. 
From an interaction network diagram alone, it is not possible to infer how 
multiple signals acting on the same node should be processed.  Therefore, the 
use of descriptive logic network diagrams is recommended to graphically depict a 
logic model.  The information contained in the full set of logic functions should be 
equivalent to the information contained in a logic network diagram (compare 
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Figure 2.2B to Figure 2.2C and Figure 2.3B to Figure 2.3C).   The use of 
descriptive diagrams to represent a biological network is not a novel concept [92, 
127].  Albert and colleagues [48] proposed the use of “pseudo-nodes” and 
“complementary pseudo-nodes” to clarify the functional nature of edge 
interactions in a logic network diagram.  In a large-scale Boolean model of EGFR 
and ERB2 signaling, Samaga et al. [119] used a graphical representation where 
AND interactions were depicted as small blue circles and all other interactions 
were assumed to be OR interactions.  More recently, Morris et al. [97] presented 
logic network diagrams that used “logic gate” notation similar to that used in an 
engineering diagram.   
Throughout this review, we have adopted a modified version of the 
notation used by Morris et al. [97]  Our notation graphically illustrates how 
multiple edges regulating the same node will be integrated by explicitly identifying 
where AND and OR operators are used in the network.  In addition, all activating 
interactions in our logic network diagrams are indicated with a black arrow and all 
inhibiting interactions are indicated with a red line and a blunt edge.  Regardless 
of the graphical method used, the use of diagrammatic logic networks is strongly 
encouraged to remove ambiguity from interaction networks.  
Deriving logic functions: the importance of characterizing each interaction 
When translating a set of interactions into a logic model, the implicit 
assumptions underlying all logic functions must be carefully considered.  We 
recommend the construction of truth tables for each logic function to confirm the 
logical output of each function is in agreement with experimental data (or that of 
a hypothesized regulatory mechanism).  A truth table provides the logical output 
of all possible combinations of input values a logic function may receive.  In 
Boolean models with only two discrete states, there are 2r possible combinations 
of regulatory inputs in a truth table, where r is the number of regulators (or 
edges) leading into the regulated node.   
For nodes with one regulator, derivation of the logic function is 
straightforward: the next state of the regulated node is fully determined by the 
current state of its only regulator (Figure 2.4A).  An example of the two ways a 
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single molecule can regulate another molecule in a Boolean model is presented 
in Figure 2.4A, along with corresponding truth tables.  In the case where C is 
activated by A, the logic rule is represented as Ct+1 = At, which means the value 
of C in the next arbitrary time step (t+1) will be the current value of A.  In the case 
where C is inhibited by B, the rule is represented as Ct+1 = NOT Bt, which means 
the value of C in the next arbitrary time step (t+1) will be the inverse of the 
current value of B.  Importantly, because C will always be ON whenever B is 
OFF in this inhibition example, the implicit meaning of this function is that of 
constitutive activation of C in the absence of B.  If this turned out to be an 
inappropriate assumption for the of regulation of C, then additional activators of C 
would need to be added to the model in order to generate a more complex and 
accurate regulatory logic function for C. 
For nodes that have multiple regulators, the development of a logic 
function can be more challenging.  In a logic model, there are three possible 
mechanisms by which two nodes can regulate another node: regulation by two 
activators (Figure 2.4B), regulation by an activator and an inhibitor (Figure 
2.4C), or regulation by two inhibitors (Figure 2.4D).  The simple 3 node 
interaction networks presented in the first column of Figure 2.4B-D clearly 
indicate that 2 nodes regulate another node but do not provide precise 
information about how the signals will be integrated to produce a response in the 
regulated node.  In contrast, the second and third columns of Figure 2.4B-D 
provide logic network diagrams and truth tables illustrating the logical output 
produced when an AND or OR operator is used, respectively.  In general, the 
use of an AND operator with two regulators results in the regulated node turning 
ON in one of the four possible input conditions.  In contrast, the use of an OR 
operator with two regulators results in the regulated node turning ON in three of 
the four possible input conditions.  Although the examples provided are simple, 
there are important underlying assumptions that should be emphasized. 
AND NOT: inhibitor wins 
When an activator and an inhibitor are joined by an AND operator (Figure 
2.4C: AND column), the function is referred to as an AND NOT function.  In the 
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logic function Ct+1 = At AND NOT Bt, the inhibitor is dominant because the state 
of C is OFF in three of the four possible input conditions.  The presence of the 
inhibitor also trumps the presence of the activator when both are ON (refer to the 
last row in the truth table). 
OR NOT: activator wins 
Similarly, when an activator and an inhibitor are joined with an OR 
operator (Figure 2.4C: OR column), the function is referred to as an OR NOT 
function.  In this case, the activator is dominant because the state of C is ON in 
three of the four input conditions.  The presence of the activator trumps the 
presence of the inhibitor when both are ON (refer to the last row in the truth 
table).  Importantly, when both the activator and inhibitor are OFF, C will turn ON 
(refer to the first row in the truth table).  The implicit meaning of Ct+1 = At OR 
NOT Bt, therefore, is that C becomes activated when both regulators are absent 
or below their functional threshold, even if C was OFF in the previous time step.  
At first glance this may seem counter intuitive and biologically implausible. 
However, what the OR NOT function actually simulates is the condition where 
the regulated node is ubiquitously expressed at a functionally active level such 
that it can only be deactivated by the presence of a direct inhibitor and, 
importantly, this direct inhibitor can be overridden by an activator (refer to the 
truth table).  Later, we will consider a biological example where OR NOT is the 
correct function to model a biological interaction. 
To be OR NOT to be? 
As illustrated in Figure 2.4 and described above, when more than one 
node regulates the same target node, the AND and OR logical operators produce 
very different outcomes.  It is important to understand the underlying 
assumptions of all logic function included in a logic model to ensure they provide 
a reasonable biological approximation [123].  Of course, the exact nature of an 
interaction may not be known (e.g., what is necessary and what is sufficient for a 
molecular activation).  In these cases, logic models can also be used to test 
hypothetical interactions and compare if results match experimental data.  
25 
 
Figure 2.4.  Logic Functions.  Each node in a logic model has a corresponding logic function that controls 
its regulation each time the model is updated.  (A) Derivation of logic functions for nodes regulated by only 
one node: the next state of the regulated node (at time t + 1) is fully determined by the current state of the 
regulating node (at time t). Ct+1 indicates the value of C at the next time step.  (B–D) When multiple nodes 
regulate the same node, derivation of logic functions is more complex.  Three node networks are presented 
where C is regulated by two nodes: A and/or B.  In the left hand column, typical representations of 
interaction diagrams are presented with regulation by (B) two activators, (C) an activator and an inhibitor, or 
(D) two inhibitors.  The corresponding logic functions when an AND or an OR relationship is used, 
respectively, are presented in the next two columns.  In each example, a more precise logic network is 
depicted that clearly indicates how the two nodes will be integrated to produce a response in C.  A truth 
table is provided that illustrates the output Ct+1 generated  for all possible input conditions.  0 indicates OFF 
and 1 indicates ON.  For clarity, activating nodes are colored green and inhibiting nodes are colored red. 
Blue circles indicate AND interactions and yellow circles indicate OR interactions. 
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2.5 Logic models have one or more fixed states known as attractors 
The network state of a logic model can be uniquely represented in a 
variety ways, including by binary or decimal notation (Figure 2.2D).  In 
synchronously updated Boolean logic models (where all nodes are updated at 
the same instant each time step), each state deterministically gives rise to 
another state according to the model’s logic functions.  Eventually, all states will 
settle into one or more stable states known as attractors.  If an attractor consists 
of a series of states that oscillate in a cycle, the attractor is called a cycle 
attractor or a limit cycle.  If an attractor consists of a single fixed state (which will 
be the case when a state always gives rise to itself), the attractor is called a fixed 
point attractor [93, 128].  Examples of each type of attractor are presented in 
Figure 2.2E and Figure 2.3D.  In asynchronously updated Boolean logic models 
(where a single node is selected randomly and updated instantly), the next state 
of the network is non-deterministic.  Nevertheless, the network will eventually 
settle into an attractor regardless of the initial state of the network [92, 103, 123]. 
In small to moderate sized network models that have been well 
constructed, attractors often empirically agree with biological phenotypes [93, 
117]. In the model previously discussed of yeast cell cycle regulation developed 
by Li et al. [117], for example, there were 11 nodes which generated 2048 
possible network states and 7 attractors.  The vast majority of all possible states 
(1764 out of 2048) settled into a fixed point attractor that represented the 
stationary phase of the cell cycle. The authors found that the trajectory of states 
(also referred to as a basin of attraction [128]) leading to this point attractor 
followed expected molecular changes observed during cell cycle progression.   
In any binary Boolean logic model consisting of n nodes, there are 2n 
possible network states.  In the hypothetical 12 node network presented in 
Figure 2.2 there are 4096 possible states, and in the synchronous form of this 
model there are 10 attractors (Figure 2.2E).  In a 21 node model we recently 
developed, there were 2,097,152 possible states that settled into 1 of 52 possible 
attractors (data not shown).  Clearly, as the network size increases, it becomes 
difficult to draw biological inferences from the full attractor space.  In addition, for 
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large-scale networks, the enumeration of all attractors quickly becomes 
computationally intractable owing to the exponential relationship between the 
number of nodes in the network and the number of possible network states [129].  
One approach for analyzing large attractor spaces is to measure the robustness 
of each attractor [130-132].  Unfortunately, these methods are generally more 
useful to a theoretician than a biologist.  Another approach for analyzing large 
state spaces with many attractors is to use asynchronous updating methods [49, 
50].  These methods can generate a probability that a given network node will be 
ON or OFF under a particular set of conditions.  Because asynchronous methods 
represent a repeated sampling of many different timescales [103, 123, 133], they 
are also useful for modeling the heterogeneity of a population of cells [50, 134]. 
Asynchronous methods can also facilitate in silico molecular perturbations (such 
as knock-downs or constitutive activations) to generate output that is readily 
comparable to biological data [50]. 
Finally, not all stable attractors in a deterministic synchronous logic model 
remain stable under non-deterministic asynchronous update conditions.  The 
random perturbations associated with an asynchronously updated model result in 
the disappearance of some synchronous attractors when the assumption of 
timescale uniformity is removed [93, 103, 128].  Thus, the asynchronous method 
is more likely to identify attractors that are robust to the typical stochastic 
variations observed in molecular interactions [135, 136] under physiological 




Figure 2.5. A Model of Normal Cell Proliferation and Apoptosis: OR NOT vs. AND NOT.  (A) An 
interaction network diagram depicting regulation of cellular proliferation and apoptosis based on a model 
published by Ribba et al. [87].  Overpopulation, Growth Factor, Hypoxia, and DNA Damage are the input 
nodes and proliferation and apoptosis are the output nodes.  The four internally regulated nodes are 
colored white.  (B) Logic network describing the logic functions used in Model I (see also Table 2.1).  (C) 
The 10 nodes in this network produce a total of 210 (1024) possible states, each of which settles into 1 of 16 
possible attractors (identified as steady state output in the table), under a synchronous updating scheme.  
The 16 possible input conditions are displayed in the center table.  On the left, Model I output is presented 
(with P27 regulated by OR NOT) and, on the right, Model II output is presented (with P27 regulated by AND 
NOT).  (D) Comparison between asynchronous attractors produced by Model I and Model II when all input 
nodes are OFF.  This input condition corresponds to the first row in the synchronous scheme’s table.  An 
asynchronous random order update was repeated 200 times for 15 time steps.  Each curve shows the 
average value of a node after 200 simulations for each time point.  Blue circles indicate AND interactions 
and yellow circles indicate OR interactions. 
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2.6 Biologically motivated examples 
A model of normal cell proliferation and apoptosis 
In Figure 2.5, we present a 10 node network of the regulation of cellular 
proliferation and apoptosis.  This model is adapted from the Boolean model used 
by Ribba et al. to control cell division and cell death in a multiscale model of 
colorectal cancer [87].  For simplicity, our version of the model eliminates linear 
regulations.  In the original Ribba model, for example, P53 activated BAX and 
BAX, in turn, activated apoptosis.  BAX was eliminated in our model so that P53 
is a direct activator of apoptosis.  In this example, the linear node reduction 
results in the same qualitative network behavior and output.  The interaction 
network for this model is presented in Figure 2.5A, and the logic network is 
depicted in Figure 2.5B.  There are 4 input nodes representing the signals a cell 
may respond to in the model: Growth Factor, Over-population, Hypoxia, and 
DNA Damage. The output nodes are proliferation and apoptosis.  The 4 
internally regulated nodes are MYC, P27, Cyc-CDK, and P53.  The logic 
functions used in this model are listed in Table 2.1 along with a biological 
justification for each function and a statement of any relevant assumptions.
 In this model there are 1024 (210) possible network states and 16 (24) 
possible input conditions (Figure 2.5C). For the logic network referred to as 
Model I (Figure 2.5B), under synchronous updating each of the 1024 possible 
states eventually settle into one of 16 fixed point attractors corresponding to one 
of three biological states (Figure 2.5C, left).  In Model I, when all input signals 
are OFF, apoptosis and proliferation are also OFF in the attractor, indicating 
cellular homeostasis.  When all four input signals are ON, the combination of 
these signals leads to apoptosis ON and cell death (first row in the table).  The 
only input condition leading to proliferation ON in Model I is Growth Factor ON 
and all other inputs OFF.   
In another version of this model referred to as Model II, the logical 
operator controlling the regulation of P27 by MYC inhibition and Hypoxia 
activation is changed to AND NOT from OR NOT (Figure 2.5C, right).  This 
seemingly small change produces very different output.  In Model II, under 
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synchronous updating when all input signals are OFF, all states settle into an 
attractor that leads to proliferation ON and population growth, which is not the 
behavior expected from a normal cell. Moreover, there are now 4 input conditions 
that give rise to proliferation ON, including the state where all input signals are 
OFF.  In this network example, the use of OR NOT for the regulation of P27, 
rather than AND NOT, is essential for obtaining the expected readout.   
Under asynchronous updating, Model I and II settle into the same 
attractors each model produced under synchronous updating (Figure 2.5D). 
Empirically, this will be the case when only point attractors are possible under 
synchronous updating because no regulatory feedback loops are included in the 
network.  For more complex networks with multiple feedback loops, the attractor 
space produced by synchronous and asynchronous updating methods will not 
always be identical.   
Oscillations in Boolean models 
Logic models have been used to model oscillations in a number of 
biological systems [48, 106, 109].  Oscillations play important roles in many 
biological processes including the cell cycle, circadian rhythms, developmental 
processes, and the cellular response to stress [137].  It is easy to generate 
sustained oscillations (which are, by definition, a cycle attractor) with a 
synchronous logic model. All that is required is the presence of a negative 
feedback between one or more nodes.  Even a single node can generate 
oscillations (Figure 2.6A) [138].  In contrast, generating sustained oscillations in 
chemical systems with an ODE model requires at least three distinct species 
represented by two or more ODEs [139, 140]. Physically realistic sustained 
oscillations are possible with only two chemical species when delay differential 
equations are used because these equations introduce an explicit time delay into 
the system [43, 141].  It must be emphasized that simply generating oscillations 
in a mathematical model of any type does not imply the underlying mechanism 
driving the oscillations in the model is equivalent to that driving the 
experimentally observed oscillations. 
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Given the ease with which oscillations can be generated with a logic 
model, it is essential to ensure that the implicit assumptions underlying the logic 
functions in a model are appropriate for the oscillatory system modeled.  The 
protein P53 has been dubbed the “guardian of the genome” for its role in 
maintaining genome integrity and tumor suppression in normal cells [142].  P53 
plays critical regulatory roles in both cell cycle progression and apoptosis.  In 
response to stress, such as DNA damage from ionizing radiation, P53 protein is 
known to mediate the transcription of MDM2, which targets P53 for degradation 
via ubiquitination [45, 137, 143, 144].  In response to DNA damage, this 
antagonistic relationship induces important cellular oscillations in P53 and MDM2 
expression, which have been described as a digital behavior [137] 
. 
Table 2.1.  Justifications for logic functions used in Figure 2.5, Model I.  







Both overpopulation and hypoxia inhibit MYC expression. Hypoxia initiates 
the TGF-Beta pathway and promotes phosphorylation of SMAD’s MH2 
domain, which inhibits MYC expression. Overpopulation activates the Wnt 
signaling pathway, releasing the APC destruction complex and promoting 
degradation of β -catenin, a transcriptional activator of MYC.  In contrast, 
growth factors activate MYC transcription via RAS signaling.  Our logic rule 
assumes that MYC activation (via growth factor induced signaling) is only 
possible when neither inhibitor (Overpopulation and Hypoxia) is active. 
[145-148] 
P27t+1 = Hypoxia 
OR NOT MYCt 
Hypoxia activates P27, a potent cell cycle inhibitor, by initiating the TGF-β 
pathway and promoting phosphorylation of SMAD’s MH2 domain, which 
plays a role in maintaining P27 expression. MYC, when active, inhibits 
transcription of P27 by binding to its promoter.  We assume there are 
endogenous levels of active P27 present in the absence of hypoxia. The OR 
NOT logic rule ensures that when present, Hypoxia's activation of P27 




NOT P27t AND 
NOT P53t 
Cyclin dependent kinases (Cyc-Cdk) are inhibited by both P27 and P21.  
P21 is activated by P53 in response to DNA damage signals.  For simplicity 
we have excluded P21 from this regulation. 
[150, 151] 
P53t+1 = DNA 
Damage P53 is transcriptionally activated in the presence of DNA Damage. [137] 
Proliferationt+1 = 
Cyc-Cdkt 
Cyclin dependent kinases (Cyc-Cdk) are required for cell progression in the 
G1 phase.  They act to inhibit the Rb protein by phosphorylation, which is an 









Figure 2.6.  Regulatory feedback and oscillations in logic models. (A) A single node will produce an 
oscillating attractor if a negative auto-feedback is present.  (B) Two nodes will produce an oscillating 
attractor if a negative feedback is present. In this example P53 activates MDM2, which inhibits P53.  (C) A 
more realistic representation of the P53/MDM2 circuit includes activation of P53 by DNA Damage.  This 
representation of the network does not identify whether an AND NOT or an OR NOT should be used.  (D) 
When P53 is regulated by an AND NOT function, two synchronous attractors are possible.  (E) When P53 is 
regulated by an OR NOT function, two synchronous attractors are possible.  (F) Based on biological data, 
the AND NOT appears to be the correct regulation because the presence of DNA Damage induces 
functional levels of P53 that give rise to oscillations in the attractor.  In the absence of DNA Damage, all 
nodes in the attractor are below their functional activation threshold (OFF).  In the plots, a synchronous 
update scheme and an asynchronous update scheme (with 200 simulations) are compared for the logic 
model presented in (D) when DNA Damage is ON and the other 2 nodes are OFF at the start of the 
simulation.  Blue circles indicate AND interactions and yellow circles indicate OR interactions. 
If we first consider the simple 2 node network in Figure 2.6B consisting of 
only P53 and MDM2 nodes, we can see that, because only one edge leads into 
each node, the interaction network is equivalent to its representation as a logic 
network (using the logic network notation described previously). In this simple 
network, all four possible states make up the limit cycle attractor.  Thus, if no 
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other inputs are added to this network, it will perpetually oscillate between these 
four states.  A slightly more realistic model includes adding a DNA Damage node 
as the input signal (Figure 2.6C).  Because two nodes now regulate P53 (an 
activator and an inhibitor), we must decide whether AND NOT or OR NOT 
(Figure 2.6E) is appropriate for the regulation of P53.  In the AND NOT case, 
four of the eight possible network states settle into a fixed point attractor where 
everything is OFF.  The remaining four states settle into a limit cycle where P53 
and MDM2 oscillate and DNA Damage is fixed to ON (Figure 2.6D).  In contrast, 
in the OR NOT case, four of the eight possible states settle into a point attractor 
where everything is ON and the remaining four states settle into a limit cycle 
where P53 and MDM2 oscillate and DNA Damage is fixed to OFF (Figure 2.6D).  
Because there is nothing in the network to regulate DNA Damage, it will never 
oscillate in either version of model.    
P53 and MDM2 proteins are known to exist at low endogenous levels in 
the absence of DNA damage [137].  We, therefore, consider them to be at levels 
below their functional threshold in the absence of DNA damage.  However, when 
DNA damage is present, P53 becomes functionally activated [137], which 
triggers functional MDM2 expression levels and oscillations.  Thus, we conclude 
that the AND NOT function is appropriate for this regulation (Figure 2.6D).  All 
model results presented in Figure 2.6D-E relied on a synchronous updating 
scheme.  In Figure 2.6F, the synchronous and asynchronous updating schemes 
are compared for the AND NOT form of the model using the following initial 
conditions: P53 OFF, MDM2 OFF, and DNA Damage ON.  In the synchronous 
approach, it can clearly be seen that DNA Damage stays constant, while P53 
and MDM2 oscillate out of phase between 0 and 1 (or OFF and ON).  In the 
asynchronous model, which represents and average of 200 simulations using a 
random update order, over time both P53 and MDM2 are roughly 50% likely to 
be ON.  This is the expected probability when all 200 simulations settle into a 
limit cycle attractor where P53 and MDM2 oscillate, which is also suggestive of 




Figure 2.7.  An Expanded Model of Normal Cell Proliferation and Apoptosis.  (A) A logic model diagram 
of a more detailed version of Model I in Figure 2.5.  Specifically, growth factor activation of MAPK and PI3K 
signaling pathway is incorporated via RAS and AKT, respectively. In addition, PTEN’s downstream inhibition 
of AKT is included as is AKT’s influence on cell cycle progression and apoptosis. (B) Control and in silico 
perturbations of this model were performed using asynchronous simulations. Comparison between 
asynchronous attractors with and without P27 knock down (KD) for the initial condition: DNA Damage ON 
and all other nodes randomized.  (C) Comparison between asynchronous attractors with and without P27 
KD for the initial condition: Growth Factor (GF) ON, PTEN ON, and all other nodes randomized. All 
simulations with P27 KD began with P27 OFF and kept it fixed to this state for the duration of the simulation. 
All asynchronous simulations were performed 200 times to get the probability each node would be ON under 
the test conditions. Blue circles indicate AND interactions and yellow circles indicate OR interactions. 
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Expanding the model of normal cell proliferation and apoptosis 
In the previous model of cellular proliferation and apoptosis (Figure 2.5) 
only fixed point attractors were possible because no regulatory feedback loops 
were present in the network model.  If the feedback loop in Figure 6D is added to 
the network in Figure 5, then the 8 fixed point attractors with DNA Damage ON 
become cycle attractors with P53 and MDM2 oscillations (data not shown).  In 
addition to adding an MDM2 node, we expanded Model I (Figure 2.5) to include 
5 additional nodes (Figure 2.7A).  An AKT node was included because AKT 
related signaling plays an important role in activating cellular growth and 
inhibiting apoptosis.  In addition, PTEN, a powerful tumor suppressor and 
upstream inhibitor of AKT activation was included [153].  RAS, FOXO, BAD, and 
BAX were also added.  In Figure 2.7B, we performed asynchronous simulations 
using two distinct conditions: (1) DNA Damage ON and all other inputs OFF and 
(2) Growth Factor ON, PTEN ON, and all other inputs OFF.  We also perturbed 
each of these conditions by preventing P27 from turning ON in the simulations, 
which effectively served as an in silico knock down (KD) of this node.  In the DNA 
Damage ON condition, the result is as expected: all states settle into attractors 
where there is 0% probability for population growth (proliferation) and 
approximately 50% probability for cell death (apoptosis).  This intermediate cell 
death probability, which results from the fact that P53, MDM2, and apoptosis 
nodes are oscillating in the attractor, is representative of an average between the 
oscillating states.  A very different outcome is found, however, when the DNA 
Damage ON condition is tested with the P27 KD.  In this case, proliferation also 
has approximately 50% probability to be ON (Figure 2.7B). 
When both Growth Factor (which should trigger proliferative signals) and 
PTEN (which should suppress proliferative signals) are ON, then cellular 
homeostasis (or quiescence) occurs because all states end up in an attractor 
where both population growth (proliferation) and cell death (apoptosis) have a 
0% probability to be ON.  When the same conditions are tested with the P27 KD, 
however, population growth is 100% likely to be ON in the attractor (Figure 
2.7C).  While these results are not surprising given the importance of P27 in 
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regulating cell cycle progression and proliferation, they do demonstrate how 
models of this type may be used to make predictions related to network 
dynamics that can then be verified experimentally.   
2.7 The use of Boolean models in dynamical systems 
We have seen how Boolean models can be used to simulate network 
dynamics and have also discussed that Boolean models are capable of 
qualitative agreement with more mechanistically precise ODE models.  It must be 
stressed, however, that a Boolean model will not always be appropriate for 
modelling network dynamics.  In complex biochemical pathways, the time 
evolution of the concentration of interacting species is governed by nonlinear 
equations representing feedback loops in which the output of a pathway is not 
proportional to its input [154].  Examples of network behavior that a two-state 
Boolean model cannot approximate include retroactive signalling [21, 41], load-
induced modulation [155], and bifurcations associated with nonlinear equations 
[156].  In the case of retroactivity and load-induced modulation, which involve 
upstream signal propagation in covalently modified signalling cascades and are 
discussed in Chapter 4, a two-state Boolean model is too qualitative to predict 
this behavior because these signalling processes arise from enzyme 
sequestration mechanisms that are out of reach of two-state Boolean models.  In 
the case of bifurcations, which occur when the qualitative behavior of the solution 
of a nonlinear system changes as a parameter changes, two-state Boolean 
models are unable to predict bifurcations because they lack parameters.  It is 
possible that multistate or continuous piecewise logic models (which are 
parameter driven) are capable of predicting bifurcations.  To our knowledge, 
however, this has not yet been explored systematically. 
In a recent paper by Batchelor et al [157], the mechanisms regulating P53 
response to different perturbations were investigated.  The authors employed 
ODE models as part of an analysis into the amplitude, duration, and frequency of 
individual p53 pulses in response to varying amounts of ultra violet radiation.   
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While a synchronous Boolean model would not be able to elucidate 
mechanisms driving the degrees of response in a system like this, multistate 
fuzzy logic [47] and continuous piecewise logic models [49] have been used for 
similar purposes in other systems.  In addition, asynchronous Boolean models 
may be used for these types of responses.  In the model of guard cell aperture 
closure previously discussed [50], the authors chose to use an asynchronous 
Boolean model to generate a probability of stomate closure because stomate 
aperture responses are known to be graded and cannot be represented as 
simply open or closed.  While the predictive power of an ODE model is preferred 
for a dose dependent response, an ODE model may not be practical for 
modelling such responses in large networks for computational and parameter 
space reasons.  In such cases when a binary response is not sufficient, the use 
of more complex logic-based methods, such as asynchronous, multistate, fuzzy, 
or piecewise models, may be a reasonable alternative. 
2.8 Concluding theoretical remarks 
Logic-based models are predictive tools that can be leveraged in the 
absence of reliable parameter information or mechanistic details needed for more 
quantitatively precise methods, such as ODE models.  Importantly, the predictive 
power of logic methods is dependent on the nature of the logic network model 
constructed.  In this review, we have pointed out important factors to consider 
when building predictive logic-based models.  We have emphasized the 
importance of using descriptive logic network diagrams and provided biologically 
motivated example networks.  Most significantly, we have emphasized the need 
to properly characterize the nature of all interactions in the network and to 
understand the implicit meaning of logic functions used to integrate multiple input 
signals.   
As we have seen, the use of AND and OR logical operators produce very 
different results for the same input conditions (Figure 2.4B-D, Figure 2.5C-D 
and Figure 2.6D-E).  We strongly encourage the creation of truth tables to verify 
that the output of each logic function is reasonable and in qualitative agreement 
with experimental data, if available.  When the nature of the interaction modeled 
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by a logic function is not known (e.g., whether an activator will trump an inhibitor, 
if both are active, or vice versa), then the logic model can be used to test 
hypothesized mechanisms for the uncertain interaction. The use of “incomplete 
truth tables”, a computational approach for analyzing the effect of logical 
uncertainty in a logic network, has also been proposed for these cases [158].  
Despite their advantages, resistance to the use of logic-based models in 
biology exists.  Some resistance is related to the idea that a molecule’s state can 
be reduced to discrete ON and OFF values.  In actuality, experimental molecular 
states are often qualitatively described in binary terms.  Genes may be 
characterized as up-regulated or down-regulated in microarray experiments and 
proteins are often referred to as activated or inactivated to indicate their 
functional state.  Given the stochastic variation in gene and protein expression 
across cells, biological molecular networks are remarkably robust [159].  The 
presence of growth factors in the local environment, for example, will almost 
invariably result in the induction of proliferative pathways within a population of 
cells, despite the heterogeneity in the molecular expression across individual 
cells in the population.  This deterministic output from a given cellular input has 
been compared to cellular digital computation [160].  Fundamentally, the basis of 
digital readouts are 0’s and 1’s – at least at the computational level.  Another 
point of concern with logic-based Boolean models is that time is unrelated to 
physiological time and can provide only a qualitative chronology of molecular 
activations [93].  While this is true, Boolean models can provide qualitative 
predictive values, which allow biomedical scientists to gain unique insights in 
molecular network dynamics that may otherwise be out of reach. 
For those interested in using logic models to study large networks, the use 
of asynchronous updating is generally recommended [92, 128].  A variety of 
algorithms exist for introducing asynchronous updates in a logic model [128].  For 
most purposes, the repeated random order asynchronous [128] update method 
(which is similar to a statistical Monte Carlo simulation) will be sufficient.  This is 
the algorithm used for the asynchronous simulations in this review. Some 
attractors found with the simpler synchronous updating scheme may be artifacts 
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of uniform timescales.  In contrast, an asynchronous scheme introduces 
stochastic variation in timescales.  Moreover, asynchronous methods can 
produce qualitative readouts that are more representative of biological readouts 
(Figure 2.5D and Figure 2.7B-C) and can easily facilitate in silico perturbations, 
such as knock downs and constitutive activations.    
We view logic models as complementary to other network analysis 
methods in systems biology and consider them to be an important tool for making 
biological inferences about the dynamics of intracellular networks.  A number of 
software tools for logic-based network analysis are available [49, 126, 158, 161].  
The appropriate software tool to use will depend on the nature of the network 
model and objectives of the analysis [97].  For asynchronous simulations and in 
silico molecular perturbation studies, we recommend BooleanNet [49] which is a 
relatively easy to use open source tool developed in Python.  Needless to say, 
the implementation of logic-based models requires computational and 
mathematical proficiency.  As a consequence, collaboration between integrative 
biologists and computational scientists will play a pivotal role in the successful 
development, analysis, and interpretation of logic-based models.  
Importantly, logic-based models are also a powerful approach for 
constructing models of biological networks that can ultimately be integrated into 
multiscale models — models that consider the integration between different 
scales and phenomena in a biological system or process — to provide an 
integrative view of biological systems [1].  In the literature, multiscale models of 
cancer growth have been developed that account for the cellular, genetic, and 
environmental factors regulating tumor growth [87, 162].  These models have 
implemented genetic and signaling networks as Boolean models to regulate cell 
cycle progression where the response to signals from the intracellular gene 
network determines whether a cell will proliferate or die and, therefore, directly 
influences the cellular and the extracellular tissue level of the model.   
In conclusion, it is never feasible to create a model that is an exact replica 
of a complex system and, as a consequence, compromises must be made 
between the predictive power of a model and the complexity of the model.  The 
40 
discrete nature of a Boolean model sacrifices quantitative dynamics for 
qualitative dynamics.  In exchange, a parameter-free modeling framework can be 
used to investigate complex intracellular networks.    
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Chapter 3  
A Discrete Logic Model of the PI3K Signaling 
Pathway 
 
Portions of the discussion section of this chapter were previously published by 
the author in Advances in Experimental Medicine and Biology [1]. 
3.1 Background 
The phosphatidylinositol 3-kinase (PI3K) pathway is highly dysregulated in 
human cancers and plays important regulatory roles in glucose metabolism [163].  
AKT, a protein kinase that plays a central role in the pathway, is a master 
regulator of cellular growth and survival.  AKT (also known as PKB) promotes 
survival by suppressing apoptosis via inhibition of BAD [164], by stimulating 
glucose metabolism in several direct and indirect ways, and by controlling cell 
cycle progression via MYC regulation [165].  AKT’s regulation of glucose 
metabolism includes the direct phosphorylation of phosphofructokinase-2 
(PFK2), an enzyme that promotes fructose-2,6-bisphosphate’s allosteric 
regulation of the glycolytic enzyme phosphofructokinase-1 (PFK1) [166].  ATP 
citrate lyase is both a direct target [167] and downstream target of AKT [168].  In 
addition, AKT promotes the expression of glucose transporter proteins (GLUT),  
lactate dehydrogenase, and hexokinase [153] (Figure 3.1).  
PI3K is a lipid phosphatase consisting of regulatory p85 and catalytic p110 
subunits when fully active.  PI3K acts as a key upstream regulator of AKT 
because of its tight regulation of the activity of mammalian target of rapamycin 
complex 2 (mTORc2) and phosphatidylinositol (3,4,5)-triphosphate (PIP3), which 
phosphorylate AKT at ser473 and thr308, respectively.  PI3K is required for 
mTORc2 activation via ribosomal binding [169, 170] and PI3K activates PIP3, 
which recruits AKT to the cellular membrane where it is phosphorylated at thr308 
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by PDPK1 [163].  In addition to activation by PI3K, PIP3 is strongly inhibited by 
the tumor suppressor phosphatase and tensin homolog (PTEN) [153, 171, 172].  
Given the importance of the PI3K pathway in promoting cell survival and 
inhibiting cell death, the PI3K pathway is viewed as an extremely promising 
target for anti-cancer interventions [18-20], and a number of clinical trials 
featuring PI3K inhibitors are underway [173, 174].  Despite promising pre-clinical 
data, off-target effects and the induction of drug resistance remain common 
problems associated with targeted molecular inhibitors [13, 14].  As discussed in 
Chapter 1, it is increasingly likely that the high-incidence of off-target effects and 
the emergence of therapeutic resistance from molecular inhibitors are related to 
the complexity of intracellular molecular networks.  New approaches for studying 
complex intracellular networks and generating testable predictions related to off-
target effects are needed.  In order to build models of this type, the underlying 
networks they are based upon must be validated with experimental data.  
In this chapter, I present a logic network model that links growth factor 
signaling to the PI3K pathway and glucose metabolism. The objective of the 
model is to elucidate the non-linear regulation between PI3K/AKT signaling and 
glucose metabolism.  A logic network representing a canonical view of normal 
PI3K signaling was built. This model was validated by comparing experimental 
data from the MCF10A cell line to model output under six experimental 
conditions, including treatment with pathway specific inhibitors and stimulation 
with epidermal growth factor (EGF).  To help understand the nature of PI3K 
pathway dysregulation as breast cancer progresses, in silico oncogenic 
perturbations were made to the normal network model and the generated output 
was compared to experimental data from the three cancer cell lines under the 
same six experimental conditions.    
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Figure 3.1. Links between the PI3K/AKT pathway and glucose metabolism.  Black arrows in the signal 
transduction interaction network represent activation and red lines with blunt edges represent inhibitions.  
Black arrows in glucose metabolism represent enzyme catalyzed conversions from substrate to product.  
Bold dashed lines represent feedback to metabolism originating from the PI3K pathway.  Thin dashed lines 
represent feedback originating from glycolysis.  
3.2 Methods  
Western blot analysis 
Cells were serum starved overnight then incubated for 1 h with or without 
50 µM of LY294002 inhibitor (Cell Signaling) or 25 µM of U0126 inhibitor (Cell 
Signaling).  After 1 h, cells were treated with or without 10 ng/mL EGF stimulation 
for 10 minutes.  Proteins were immediately harvested from cell cultures.  Anti-
bodies against phospho-AKT (ser473), phospho-AKT (thr308), AKT (pan), 
phospho-GSK3β, GSK3β, phospho-PTEN (Ser380), and PTEN were obtained 
from Cell Signaling.  
Logic network development and analysis  
A detailed literature search was performed to identify the important 
regulatory components of the PI3K pathway as well as their interacting partners.  
Table 3.1 summarizes some key interactions identified, which represent edges in 
an interaction network (Figure 3.1).  The nature of each interaction was carefully 
considered before deriving a set of logic rules.  In Chapter 2, an overview of the 
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general methodology used to curate the network as well as an introduction to the 
theory of logic based models is presented. A random order asynchronous update 
scheme, which is similar to a Monte Carlo simulation, was used for all 
simulations (see Chapter 2).  All nodes not explicitly assigned a value at the start 
of a simulation were assigned random values in each of the 100 network 
simulations performed for any set of initial conditions.  Each simulation of 100 
networks ran for a pre-defined number of time steps (long enough for a logical 
steady state, also known as an attractor [93], to be reached).  The output of a set 
of asynchronous simulations was the probability that a node stabilized to ON in 
the attractor for a given set of initial conditions. The control condition was 
simulated by fixing the Growth Factor to OFF.  EGF stimulation was simulated 
by fixing Growth Factor to ON.  Inhibition by LY was simulated by fixing PI3K to 
OFF and inhibition of U0 was simulated by fixing MEK to OFF.   
Model validation and cost function penalties 
To compare model readout with experimental data, it was necessary to 
first discretize the experimental western blot data.  Values of ON, OFF, or partial 
were assigned to indicate the degree of AKT thr308, AKT ser473, ERK, GSK3β, 
and PTEN activation. A qualitative scoring system was devised to penalize 
differences between in silico read outs and in vitro readouts of AKT and ERK.  If 
the in silico experimental readout qualitatively matched the in vitro readout for a 
given treatment condition, then no penalty was imposed.  Otherwise, a cost 
penalty function was applied. It is important to note that logic modeling 
represents a qualitative methodology and attempts at precise quantitation can be 
misleading.    As a consequence, a simulated response of 100% likely to be ON 
for an expected partial experimental response was treated as more correct than 
a simulated response of 100% likely to be OFF for an expected partial 
experimental response.   
Discretized western blot data were assigned numeric values of 1.0 for ON, 
0.0 for OFF, and 0.5 for partial and are referred to as expected values (EV).  
Simulated values (SV) refer to the probability that a node will be ON in the logic 
model attractor.  Briefly, if the EV was 0.0 or 1.0 (i.e., 100% likely to OFF or ON, 
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respectively), then the cost penalty imposed was the absolute difference between 
EV and SV.  If the EV was 0.5 (i.e., partial), then SVs between .2 and .8 were 
not penalized because they were considered to be qualitative partial responses.  
If the EV was 0.5 and the SV < 0.2, then a penalty of 0.5 was imposed.    If the 
EV was 0.5 and the SV > 0.8, however, a smaller penalty of 0.25 was imposed. 
3.3 Results  
A detailed literature survey of molecular interactions associated with the 
PI3K pathway was completed (Table 3.1) from which an interaction network was 
constructed that summarized the regulatory links between glucose metabolism 
and PI3K signaling (Figure 3.1).  The information provided in Table 3.1 and 
Figure 3.1 is not sufficient to infer logic functions, however. As discussed in 
Chapter 2, it is essential to carefully derive each logic function before 
constructing a logic network.  After further analysis, logic functions were derived 
and a first iteration logic network was constructed to represent a canonical view 
of normal PI3K signaling (Figure 3.2).  Generally, when constructing a logic 
network, the objective is to build the simplest network possible that still agrees 
with experimental data [50, 91].  
The logic network model was validated by comparing in silico and in vitro 
readouts of AKT and ERK phosphorylation in the presence or absence of 
pathway inhibitors.  Western blots were performed on four cell lines used in an in 
vitro model of breast cancer progression (Figure 3.3).   For in vitro analysis, cells 
were treated with pharmacological inhibitor U0126 (U0), a direct inhibitor of MEK 
[175], or LY294002 (LY), a direct inhibitor of PI3K [176].   Six conditions (5 
treatments and 1 control) were performed in vitro (Figure 3.3) and in silico: (1) 
control (no LY, no U0, and no EGF) (2) EGF alone, (3) LY alone, (4) EGF + LY, 
(5) U0 alone, and (6) EGF + U0.    For in silico analysis, control conditions were 
simulated by fixing the Growth Factor input node to OFF.  The presence of EGF 
was simulated by fixing Growth Factor to ON.  The presence of LY was 
simulated by fixing PI3K to OFF for the duration of the simulation.  Likewise, the 
presence of U0 was simulated by fixing MEK to OFF for the duration of the 
simulation.   
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Table 3.1.  Table of key interactions identified in the PI3K signaling pathway. 
Affector Interaction Target Source 
AKT (-) phosphorylation TSC-1/2 [153, 171, 177, 178] 
AKT (+) phosphorylation MDM2 [45, 144, 179] 
AKT (-) via ATP/ADP levels AMPK [153, 166] 
AKT (+) via cytochrome c levels and apoptotic signals HK [166, 180] 
AKT (+) phosphorylation PFK-2 [166] 
AKT (-) serine phosphorylation, 14-3-3 binding Raf [181, 182] 
AMPK (+) direct phosphorylation TSC-1/2 [153, 171, 177, 183, 184] 
Cell Stress (+) mRNA expression p53 [45, 144, 185] 
cMyc (+) mRNA expression LDH-A [186, 187] 
EGFR (+) recruits to membrane and phosphorylation GAB1 [188-190] 
EGFR (+) binding and phosphorylation SHC [44, 188, 191] 
EGFR (+) direct binding GRB2/SOS [44] 
ERK (-) phosphorylation TSC-1/2 [177, 192, 193] 
ERK (-) via. serine phosphorylation of GAB1 Pi3K [194] 
ERK (-) phosphorylation SOS [195-197] 
F-1,6-BP (+) via FBPase-1 F-6-P [198] 
F-2,6-BP (-) allosteric inhibitor FBPase-1 [166, 185, 198] 
F-2,6-BP (+) potent allosteric activator PFK-1 [185, 198] 
F-2,6-BP (+) via FBPase-2 F-6-P [185] 
F-6-P (+) via PFK-1 F-1,6-BP [198] 
F-6-P (+) via PFK-2 F-2,6-BP [166] 
GAB (+) amplifier Ras-GTP [199] 
GAB1 (+) membrane relocation GAP [188] 
GAB1 (+) phosphorylation (p85) PI3K [189] 
GAB1 (+) recruitment and phosphorylation SHP2 [188] 
GAP (-) phosphatase for GTP Ras-GTP [177, 200] 
GRB2/SOS (+) catalyzes the GDP->GTP reaction Ras-GTP [196, 201] 
GrowthF1 (+) direct PI3K [45, 144] 
IR (+) phosphorylation of Tyr895 IRS1 [202] 
IR (+) read another paper to find out… GAB1 [203] 
IR (+) phosphorylation Shc [204] 
iRS1 (+) physically associated with Pi3K Pi3K [171] 
IRS1 (+) binding via SH2 domain of GRB2 GRB2/SOS [44, 201, 202, 205] 
IRS1 (+) phosphorylates (tyrosine) Shc [201] 
IRS1 (+) binding via. SH2 domain of SHP2 SHP2 [205] 
MDM2 (-) delayed degradation via ubiquinations p53 [45, 144] 
MEK (+) phosphorylation ERK [191] 
mTORc1 (-) via S6K, inverse inhibitor iRS1 [153, 171, 177, 180] 
mTORc1 (-) inhibits assembly of other mTOR mTORc2 [153] 
mTORc1 (+) via HIF1-a LDHA [166, 187] 
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Affector Interaction Target Source 
mTORc2 (+) phosphorylation (Ser473) AKT [153, 171, 206, 207] 
p53 (+) mRNA expression AMPK [177] 
p53 (+) mRNA expression MDM2 [45, 144] 
p53 (-) via PTEN, which dephosphorylates PIP3 [45, 144] 
p53 (+) mRNA expression TIGAR [5, 185] 
p53 (-) mRNA expression PGM [5] 
PDK1 (+) phosphorylation (Thr308) AKT [192] 
Pi3K (+) via ribosomes mTORc2 [153, 170, 171, 177, 206] 
Pi3K (+) induces phosphorylation PIP3 [45, 144, 200] 
PIP3 (+) direct AKT [45, 144, 153, 200] 
PIP3 (+) binding of PH domain GAB1 [44, 189, 190] 
PIP3 (+) recruits to membrane PDK1 [192] 
Raf (+) phosphorylation MEK [191] 
Ras-GTP (+) via Raf, MEK, MAPK pathway ERK [177, 200] 
Ras-GTP (+) physically associated with Pi3K PI3K [180, 191, 200] 
Ras-GTP (+) membrane recruitment and phosphorylation Raf [191] 
SHC (+) creates docking site for SH2 domain of Grb2 GRB2/SOS [191] 
SHP2 (-) dephosphorylation GAB1/PI3K [188, 189, 208] 
SHP2 (+) dephosphorylation GAB1/GAP [188] 
SHP2 (-) via. IRS1 PI3K [203] 
TIGAR (-) phosphatase activity F-2,6-BP [5, 185, 186] 
TSC-1/2 (-) inverse inhibitor mTORc1 [153, 171, 177, 180] 
 
 
Table 3.2. PI3K pathway related mutations identified in three breast cancer cell lines.  Genes with 
mutations are indicated by “Y”. 
Gene MCF7 MDA-MB-231 SUM-149 Source 
BRAF  Y  [209] 
P53  Y Y [210-212] 
PIK3CA Y Y Y [209, 213, 214] 
PTEN   Y [209, 215] 





3.3.1 Western blot analysis of each cell line 
Based on phospho-western blot analysis (Figure 3.3), the activation state 
of AKT, ERK, PTEN, and GSK3β (a downstream target of AKT) was assessed in 
each cell line.  The activation state of each protein was assigned one of three 
possible values based on the western blot analysis:  ON, OFF, or partial 
activation. The status of PTEN was probed because of its role as a potent tumor 
suppressor that modulates AKT signaling by directly inhibiting PIP3, which 
mediates the phosphorylation of AKT at thr308 [153].  In Figure 3.3C, SUM-149 
cells clearly lack PTEN protein expression, which is in agreement with other 
studies [209, 215] as well as our own qPCR analysis (data not shown).  The 
remaining three cell lines, however, express phosphorylated PTEN under all six 
experimental conditions, and none of these cells exhibit phosphorylation of AKT 
on the thr308 residue (Figure 3.3A-B,D).  In contrast, SUM-149 cells exhibit 
some phosphorylation on this residue under all experimental conditions except 
when EGF and LY are applied together (Figure 3.3C).   
The status of GSK3β was probed because GSK3β inhibition has been 
linked to AKT activation [216].  Our data suggest that GSK3β is a robust indicator 
of EGF stimulation and not necessarily AKT activation, however (Figure 3.3).  In 
our experiments GSK3β was always ON in conditions where EGF stimulation 
occurred, regardless of AKT status or the presence of a pathway inhibitor.    
3.3.2 PI3K pathway mutations in each cell line 
To help identify differences in the PI3K pathway across the four cell lines, 
the existence of mutations in genes involved in PI3K signaling was investigated 
in the four cell lines (Table 3.2).  In addition to lacking PTEN gene expression 
[209, 215], SUM-149 cells have a known P53 mutation (M237I) that appears to 
disrupt normal conformation and induces loss of functional activity [211, 212].  
SUM-149 cells also have a known synonymous single nucleotide polymorphism 
(SNP) mutation (81T>C) in HRAS, an isoform of RAS [209].  While synonymous 
mutations are generally not thought to induce disease, this particular mutation 
was identified as an indicator of bladder cancer risk in patient samples [217].  In 
addition, there is some evidence in the literature that mutations which do not 
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change the amino acid sequence are still capable of inducing aberrant behavior 
[218, 219].  For this reason, the SNP mutation was included in Table 3.2 as a 
potential source of differential signaling across the cell lines.   
  Both MDA-MB-231 and SUM-149 cells have the same SNP (1173A>G; 
(I391M) in PIK3CA [209], which encodes the p110 catalytic subunit of PI3K.  No 
data has been reported to suggest this mutation is activating or disease inducing 
in breast cancer, however [209, 213, 214].   MDA-MB-231 cells also have a 
known mutation in BRAF (1391G>T) and KRAS (38G>A), which are considered 
oncogenic mutations [209].  MDA-MB-231 cells have a mutation in P53 (R280K) 
that severely effects P53 localization and promotes its rapid degradation by 
MDM2 [210, 211].  Finally, the only PI3K pathway related mutation identified in 
non-metastatic MCF-7 cells is a mutation in PIK3CA (E545K), which is 
considered an oncogenic mutation [209].   
 
 
Figure 3.2.  Logic network of PI3K signaling.  Yellow circles indicate OR logic functions and blue circles 
indicate AND logic functions.  LY294002 inhibition of PI3K, U0126 inhibition of MEK, and EGF stimulation of 




Figure 3.3.  Western blot analysis.  Results of western blot analysis of AKT, ERK1/2, PTEN, and GSK3β 
under different experimental conditions are presented for (A) MCF10A, (B) MCF7, (C) SUM-149, and (D) 
MDA-MB-231 cells.  All cells were grown in serum free media overnight then treated with or without U0126 
(U0) or LY294002  (LY) for 1 h, followed by 10 m with or without EGF stimulation under the following 
conditions (1) control (--); (2) EGF alone; (3) LY alone; (4) EGF + LY;  (5) U0 alone;  (6) EGF + U0.   The 
data was then discretized to one of three states (ON, partial, or OFF) which is summarized in table form for 
each cell line.  For AKT, which is activated via phosphorylation at two distinct residues, the discretized state 
of AKT was inferred based on the phospho-western blot of both residues.   
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3.3.3 PI3K logic model 
For logic model analysis, the activation state of AKT and ERK under each 
experimental condition was compared to the in silico probability that AKT and 
ERK were ON in the logic attractor after 100 simulations using a random update 
order (refer to Chapter 2 for a detailed explanation of this approach) for each 
experimental condition.   AKT and ERK were chosen as the primary in silico and 
in vitro readouts for three main reasons.  First, AKT activation is tightly controlled 
by PI3K and ERK activation is tightly controlled by MEK activation.  In normal 
cells, inhibiting PI3K with LY is expected to inhibit AKT, and inhibiting MEK with 
U0 is expected to inhibit ERK.  Second, AKT and ERK signaling are known to be 
important for promoting proliferation and survival.  Finally, AKT and ERK are 
frequently used as readouts of PI3K and mitogen-activated protein kinase 
(MAPK) pathway activation in the literature, which allows for comparison of our 
results to other studies in the literature [194, 220, 221].   
After a round of simulations was completed, the simulated activation 
states of AKT and ERK were compared to their experimentally determined states 
for each treatment condition.  A cost function was applied that evaluated how the 
simulated results compared to experimental results under each of the six 
treatment conditions.  The cost function assessed a penalty score based on how 
different the simulated AKT and ERK values were to the expected experimental 
values (see Methods for more details).   
To test the PI3K pathway logic model in Figure 3.2, simulations were run 
to mimic a normal (non-cancerous) network with PTEN ON under all six 
experimental conditions.  The states of all other nodes were randomized at the 
start of each simulation but were not otherwise directly perturbed.  This 
effectively meant that all other nodes had a 50% probability to be ON at the start 
of each of the 100 simulations run under these conditions.  The MCF10A normal-
like cell line compared reasonably well to this network (Figure 3.4C) generating a 
relatively low cost penalty of 1.5.  The non-metastatic cancer cell line, MCF7, 
also performed well compared to this “normal-like” model, generating a penalty of 
only 0.5.  Given that only one oncogenic mutation involved in PI3K signaling was 
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found for this cell line in the literature (Table 3.2), this result is not surprising.  
Compared to the normal-like network conditions, however, the metastatic cell 
lines fared much worse, with SUM-149 and MDA-MB-231 cells generating cost 
penalties of 4.0 and 2.5, respectively (Figure 3.3C). 
 
Figure 3.4.  Results of PI3K logic model simulations under normal-like conditions. The six 
experimental conditions were simulated in a normal-like network model where PTEN was set to ON.  For 
each experimental condition, the network was perturbed to match the in vitro experimental conditions as 
described in the Methods.  (A)  The simulated results of each condition via asynchronous update are 
presented along with (B) a summary of the simulated results for AKT and ERK under each condition.  (C)  A 
summary of the difference in in silico simulated results and the experimental results for each condition are 
presented as cost penalties.  A penalty of 0.00 indicates that the simulation and experimental results were 
qualitatively identical.   
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I next perturbed the network with two different oncogenic in silico mutation 
states:  (1) PTEN OFF and (2) PTEN ON and P53 OFF.  Surprisingly, the 
simulated results for both of these network perturbations were qualitatively the 
same as that of the normal PTEN ON state presented in Figure 3.4 (data not 
shown).  Suppressing the activity of PTEN, which is a potent tumor suppressor 
and upstream regulator of AKT, is expected to significantly affect the activity of 
AKT as well as ERK.  As a consequence, the observation that both oncogenic 
perturbations produced results that were qualitatively the same as the results 
produced by the normal-like network for all six treatment conditions indicates that 
the logic network in the current form (Figure 3.2) is highly robust to molecular 
perturbations.   
 
 
Figure 3.5.  Logic network of PI3K/MAPK cross-talk.  Yellow circles indicate OR logic functions and blue 
circles indicate AND logic functions.  LY294002 inhibition of PI3K, U0126 inhibition of MEK, and EGF 
stimulation of EGFR are indicated. 
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3.3.4 PI3K and MAPK cross-talk logic model 
Based on the initial simulations results, it was hypothesized that some 
regulatory feedback connections between the PI3K and MAPK pathways that 
were not included in the first iteration of the model may be essential for the 
regulation of both AKT and ERK.  The cross-talk between MAPK and PI3K 
signaling is complex and a number of regulatory feedback connections between 
the MAPK and PI3K pathways have been proposed to explain experimental 
evidence of cross-talk between these two pathways.  The most significant 
examples of cross-talk between these pathways cited in the literature involve the 
activation of AKT after MEK or ERK inhibition [222-224] and the activation of 
ERK after AKT knockdown [220] or inhibition [225].    After careful review of the 
literature, more direct regulatory feedback related to cross-talk with MAPK was 
included in an expanded logic network model (Figure 3.5).  This network is 
referred to as the PI3K/MAPK cross-talk model.  The full set of logic rules used 
for this model, along with a justification of each rule, is summarized in Table 3.3. 
First, the normal-like network condition with PTEN ON and all other nodes 
randomized at the start of the simulation was tested with the expanded 
PI3K/MAPK cross-talk model.  The MCF10A normal-like cell line again compared 
reasonably well to this network (Figure 3.6C), generating a relatively low cost 
penalty of 1.7, while the cancer cell lines did not compare as well.  The time 
scale of this network model is also observed to be much different than the 
previous network model.  In the previous iteration of the logic network model, all 
attractors were reached in approximately 5 arbitrary time steps in all treatment 
conditions (Figure 3.4A).  In the expanded PI3K/MAPK cross-talk network 
model, however, the arbitrary time to reach an attractor took much longer when 
no inhibitor was used in the network (Figure 3.6A,D).   When either the presence 
of LY or U0 were simulated, the network reached a steady state attractor in 
approximately 5 – 10 time steps.  In the two conditions without an inhibitor 
(Control and EGF), however, the time for AKT and ERK to reach a stable value 
was around 200 time steps, which is referred to as the late response in Figure 
3.6D.  The fact that the larger network would take significantly longer to reach a 
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steady state under some conditions is not surprising given the addition of several 
non-linear feedback loops to the network. The observation that the inhibition of 
PI3K or MEK rapidly induced a steady state attractor (see all conditions other 
than Control and EGF in Figure 3.6A), suggests the extreme importance of PI3K 
and MEK to the non-linear cross-talk between these two pathways.    
Next, the network was tested with the malignant condition of PTEN OFF 
and RAS constitutively ON (Figure 3.7).  Now (unlike in the first iteration of the 
model), very different results were obtained compared to the normal-like network 
conditions. As expected, the PTEN null SUM-149 cells compared best to this 
network condition.  A series of additional oncogenic in silico perturbations were 
performed and are summarized in Table 3.4   In the table, the conditions that 
generated the lowest cost penalty for each cell line are indicated in green.  Of the 
tested perturbations, the normal-like MCF10A cells compared most favorably to 
the network conditions with PTEN ON and all other nodes randomized, which is 
representative of normal-like conditions.  MCF7 cells compared most favorably to 
network conditions with PTEN ON and insulin receptor OFF.  This result 
suggests that IRS1, or a downstream target of IRS1, could be deactivated or 
otherwise modulated in MCF7 cells.  As presented in Figure 3.7, SUM-149 cells 
compared most favorably to network conditions with PTEN OFF and RAS ON.   
Surprisingly, metastatic MDA-MB-231 cells compared most favorably to the 
normal-like conditions (PTEN ON and all other nodes randomized).  This finding 
may suggest that our current logic model is not sufficiently detailed to account for 
this cell line’s dysregulation.  Alternatively, it may suggest that the limited number 
of perturbations tested (Table 3.4) do not fully account for the extreme 
dysregulation of this cell line.   
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Figure 3.6. Results of PI3K/MAPK cross-talk logic model simulations under normal-like conditions. 
The six experimental conditions were simulated in a normal-like network model where PTEN was set to ON.  
For each of experimental condition, the network was perturbed to match the in vitro experimental conditions 
as described in the Methods.  (A) The simulated results of each condition via asynchronous update are 
presented along with (B) a summary of the simulated results for AKT and ERK under each condition.  (C)  A 
summary of the difference in in silico simulated results and the experimental results for each condition are 
presented as cost penalties.  A penalty of 0.00 indicates that the simulation and experimental results were 




Figure 3.7.  Results of PI3K/MAPK cross-talk logic model simulations under non-normal conditions 
with PTEN OFF and RAS constitutively ON. The six experimental conditions were simulated in a normal-
like network model where PTEN was set to ON.  For each of experimental condition, the network was 
perturbed to match the in vitro experimental conditions as described in the Methods.  (A) The simulated 
results of each condition via asynchronous update are presented along with (B) a summary of the simulated 
results for AKT and ERK under each condition.  (C)  A summary of the difference in in silico simulated 
results and the experimental results for each condition are presented as cost penalties.  A penalty of 0.00 
indicates that the simulation and experimental results were qualitatively identical.   
3.4 Discussion 
The objective of the logic network developed in this work was to construct 
and validate a predictive network model that can be used to investigate the 
regulatory relationships between PI3K signaling and glucose metabolism.  Before 
the model can be used to make robust predictions about which signaling 
molecules exert the greatest degree of control over various components of 
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glucose metabolism, however, the model must be validated with experimental 
data.  The iterative network construction generated a model that was able to 
partially recapitulate experimental data in the four cell lines investigated.  In 
general, the network did better at estimating AKT activation state than it did ERK 
activation.  In Table 3.4, the numbers shaded green identify the network 
perturbation condition that most closely match each cell line (i.e., generated the 
lowest cost penalty).  For MCF10A, MCF7, MDA-MB-231, and SUM-149 cells, 
the total cost penalties for AKT activation were 0.20, 0.10, 0.70, and 0.75, 
respectively, for each network condition that produced the lowest total cost 
penalty for each cell line.  In contrast, the total cost penalties for ERK activation 
were 1.50, 1.80, 2.40, and 2.0, respectively, for the same conditions.  These 
results suggest that some direct and indirect regulations of ERK are not correct in 
the current model.   
Both the PI3K and MAPK pathways are highly dysregulated in cancer. 
Thus far, therapeutic targeting of the MAPK pathway has not been very effective 
because of so called “de novo” resistance and acquired therapeutic resistance 
[223].  It has been suggested that RAS to ERK signaling in the MAPK pathway 
represents an important “escape mechanism” when PI3K is inhibited [224].  
Several regulatory cross-talk mechanisms have been suggested to explain the 
apparent cross-talk between these two pathways.  Future work will include a 
detailed sensitivity analysis of each node in the logic network.  Systematically 
perturbing each node and measuring the change from a baseline network 
response will allow for the ranking of the relative importance of each node to the 
overall robustness of the network as well as to any specific functional response 
(e.g., to ERK activation).  A few examples of similar analyses can be found in the 
literature [226].   
Another type of sensitivity analysis that will be important for models of this 
type is the systematic perturbation of each logic rule as well as each edge in 
logic network.  This latter type of analysis will be particularly important for 
evaluating the relative importance of proposed feedback regulation between 
MAPK and PI3K signaling in the literature.  In the course of my literature review 
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of MAPK and PI3K signaling, many proposed feedback mechanisms driving the 
cross-talk between these two pathways were found.  In general, only those that I 
had a high confidence in, based on available data, were included in the current 
iteration of the logic model (Figure 3.5).  Nonetheless, I am skeptical that all 
feedback loops included in the current model are valid based on a preliminary 
sensitivity analysis (data not shown).  A systematic evaluation of each feedback 
regulation according to its ability to reproduce experimental data will be important 
for validating the likelihood that all feedback loops in the current model represent 
a valid regulatory mechanism.  
Glycolytic oscillations 
An interesting feature in some of the simulations performed was the 
presence of glycolytic oscillations (red dashed line in Figure 3.4A and Figure 
3.6A).  I am not aware of any studies that have directly reported glycolytic 
oscillations in cancer cells.  The switch from tetrameric to dimeric forms of PKM2 
[22, 23, 227], which appears to be regulated by cellular serine and FBP levels, 
has been proposed as a potential source of oscillations, however [228].  Future 
experimental validation of this prediction would open up important therapeutic 
avenues for cancer treatment.   
 OR regulation of AKT  
As discussed in Chapter 2, the output of a logic model is very sensitive to 
the nature of the logic rules constructed.  Determining whether to use an AND or 
OR logic rule can have profound effects on the network output (Figure 2.5).  In 
Table 3.3, I have provided justification for all logic rules used in our network 
simulations.  The activation of AKT was particularly important to understand in 
order to construct an appropriate logic function for its regulation in the model.  
PIP3 and mTORc2 both play important roles in activating ATK at thr308 and 
ser473, respectively.   AKT requires phosphorylation of both of these residues for 
full activation, suggesting that the AKT rule could be written as AKTt+1 = PIP3 
AND mTORc2. However, it is possible that AKT retains important downstream 
function when only one residue is phosphorylated.  If this is the case, then the 
appropriate rule would be AKTt+1 = PIP3 OR mTORc2.  PTEN is a powerful 
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tumor suppressor that inhibits PIP3, preventing the activation of AKT at thr308.  
There is evidence that PTEN expressing cells retain some PI3K dependent AKT 
function, suggesting that phosphorylation at ser473 alone may be enough for 
downstream function [183, 229].   Evidence also suggests that PDPK1 and 
PDPK2 are required for activation of each residue, respectively. For simplicity we 
assume that PDPK1 and PDPK2 are both available in the system and that the 
presence of PIP3, PTEN, and mTORc2 are the rate limiting steps in the 
activation of AKT.  For these reasons, the regulation of AKT is controlled by an 
OR logical operator so that either active PIP3 or active mTORc2 can activate 
AKT in our model.  In Appendix B, a table that summarizes the cost penalties for 
molecular perturbations when the logic operator regulating AKT was an AND 
instead of an OR is provided for comparison with Table 3.4. 
Limitations 
A limitation of the model is the lack of isoform level regulation.  
Experimentally we found differences in AKT1, AKT2, and AKT3 expression in 
some of cell lines used in this study (data not shown).  Characterizing the exact 
function of these AKT isoforms in the literature is difficult, however.  Some 
important functional differences have been discovered about AKT1 and AKT2 but 
less is known about AKT3, and little is known about how each isoform affects 
metabolic regulation.  The future inclusion of AKT isoform specific detail is 
expected to improve the predictive power of the model.   
Another limitation of the model is the assumption that PI3K inhibition by 
LY is absolute.  In reality PI3K may still retain a low level of function after 
inhibition with LY.   The use of wortmannin, which has been shown to be a more 
complete and irreversible inhibitor of PI3K, as an additional control may be 
helpful [221].   U0126, the MEK inhibitor used in this study, is a very potent 
inhibitor of MEK [230].  It has also been shown to severely disrupt the 
mitochondrial membrane, and this effect appears to be independent of its 
inhibition of MEK [231].  My own experimental work demonstrated that U0126 
significantly increased glycolysis and lactate production in the cancer cell lines 
used in this work (data not shown).  PD325901, another potent MEK inhibitor, did 
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not have the same effect, however.  U0126, which is widely used in the literature, 
is likely still appropriate for studies that only consider molecular changes at the 
protein level because induced mitochondrial effects appear to be downstream of 
MEK activity.  It is possible, however, that the mitochondrial membrane disruption 
induced from U0126 generates feedback from metabolism that is ultimately 
manifested in signaling dynamics.  The use of U0126 in future studies that rely 
explicitly on metabolic readouts (e.g., glucose uptake rates, lactate production 
rates, or flux analysis) is not appropriate, however. 
In addition, it would be instructive to know the P53 activation state for 
each cell line under the different treatment conditions used in this study.  The 
phospho-western blot experiments were performed under serum starvation and 
there are data to suggest that, under such conditions, P53 mediates mTORC1 
sensitivity to an mTOR/raptor inhibitor.  Under nutrient rich conditions, however, 
the effect of P53 was abrogated along with the sensitivity to the inhibitor [232].  
Therefore, it is possible that P53 cell stress responses may be induced in the cell 
lines studied because of serum deprivation.   If that is the case, refining the 
model to adequately account for the effects of such a response will be important.  
3.4.1 Future directions 
In the future, the objective is to improve the model presented here so that 
it can be used to make predictions about the regulatory control of PI3K signaling 
over glucose metabolism at distinct stages of breast cancer.  To effectively build 
such a model will most likely require the development of a hybrid discreet 
continuum model. Hybrid models link discrete and continuous models across 
timescales and are widely used in the engineering and computational sciences.  
In models of tumor growth, cells can be modeled as discrete entities that respond 
to continuous models of intracellular and extracellular signals [87, 233-236].   For 
example, Ribba et al. [87] developed a multiscale model that linked a set of 
discrete models with continuous models of colorectal cancer growth. The model 
accounted for the cellular, genetic, and environmental factors regulating tumor 
growth.  It integrated key oncogenes involved in colorectal cancer evolution with 
a Boolean gene network that was regulated by a discrete cell cycle model.  The 
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response to signals from the intracellular gene network determined whether each 
cell proliferated or died in the discrete model and, therefore, directly influenced 
the cellular and the extracellular tissue levels.  The combination of discrete and 
continuous modeling was used to predict the qualitative effect of therapeutic 
protocols on colorectal cancer and demonstrated that the efficacy of irradiation 
protocols depend on the type of anti-growth signals to which the tumors are 
exposed.  In another model developed by Singhania et al. [237], a continuous 
model of the cell cycle was linked to a logic model of genetic pathways regulating 
critical substrates during cell cycle progression.  By combining a continuous ODE 
model with a discrete Boolean model, the authors obtained a piecewise ODE 
model system.   
In a similar manner, I propose it is possible to combine ODE based 
models of metabolism with discrete logic-based signaling models, such as the 
model presented here.  While discrete and continuous hybrid models have been 
used in cancer research for more than 10 years, I am not aware of any that have 
directly linked metabolism and signal transduction.  To successfully implement 
such a model, timescale separation will need to be carefully considered.   As 
noted in Chapter 1, the general paradigm for modeling metabolism assumes that 
enzyme concentrations do not change during the progression of enzyme-
catalyzed reactions.  While the assumption may be reasonable for many 
metabolic models, it will likely not be appropriate to truly understand the complex 
feedback and control between PI3K signaling and glucose metabolism in cancer.   
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Table 3.3.  Justifications for logic functions used in the PI3K/MAPK cross-talk model in Figure 3.5.   
Logic Rule Rule Justification  Source(s) 
AKTt + 1 =  
PIP3 OR mTORc2 
PIP3 recruits AKT to the cell membrane where AKT is activated by 
PDK1. In addition, there is evidence that mTORc2 is essential for full 
AKT activation (by directly phosphorylating AKT, likely due to PDK2 
activity).  While AKT requires both PIP3 and mTORc2 for full 
activation, we assume that partial activation is possible when only 
one is present.  In support of this is data indicating that cells 
expressing PTEN were still able to activate AKT.  We also assume 
PDK1 and PDK2 are present in the system but do not include them in 
the model for simplicity. 
[153, 172, 
183, 229] 
AMPK t + 1  =  
p53 AND NOT ATP 
AMPK is regulated by both P53 and the ATP/AMP ratio.  Declining 
levels of ATP and rising levels of AMP active AMPK, which is 
considered a conserved sensor of the energy state within a cell.  In 
addition, expression levels of AMPK have been shown to increase 
after P53 activation. 
[238, 239] 
Apoptosis t + 1  =  
p53 AND NOT AKT 
P53 transcriptionally activates BAX, which is an upstream activator of 
apoptosis. AKT also regulated BAD.  Both BAD and P53 are positive 
regulators of BAX, which is a direct regulator of apoptosis in this 
network.  It is assumed that the activation of BAD (via AKT inhibition) 
and the activation of P53 are required to induce apoptosis in the 
model.    
[152, 164] 
ATP t + 1  = Glycolysis A net gain of 2 ATP per molecule of glucose is produce in glycolysis when glucose is metabolized to pyruvate 
[166, 186, 
198] 
ERK t + 1  = MEK ERK1/2 is directly activated by MEK in the MAPK pathway [175] 
Fru26P2 t + 1  = PFK2 
AND NOT TIGAR 
Fru26P2 is the product of PFK2, while TIGAR is potent inhibitor of 
Fru26P2 levels. We assume that TIGAR is dominant relative to PFK2 
in the regulation of Fru26P2 expression (Li et al) 
[166, 240] 
GAB1 t + 1  = EGFR 
OR PIP3 
EGFR alone can activate GAB1 and the Ras/MAPK pathway.  PI3K 
can also bind to the PH domain of GAB1.  PIP3 can enhance 
activation of GAB1.  The rule is written as EGFR or PIP3 because 
loss of Gab1's PH domain was not found to not eliminate tyrosine 
phosphorylation of Gab1 in response to EGF.  Therefore PIP3 
enhances activation of GAB1, but is not required for activation. 
[188-190] 
Glut/HK t + 1  = 
mTORc1 OR AKT 
Data suggest that AKT up regulates Glucose receptors (GLUT) as 
well as hexokinase (HK).  In addition, data suggest mTORc1 can up 
regulate GLUT and HK a via HIF1(alpha) regulation.  Therefore, 
either mTORc1 or AKT may induce GLUT and HK in the model, 
which is treated as a single node for simplicity.  
[166] 
Glycolysis t + 1  = 
Glut/HK AND PFK1 
Data suggests that AKT upregulates Glut receptors and that mTORc1 
can also upregulate GLUT receptors a via HIF1(alpha) regulation. 
Therefore either mTORc1 or AKT may induce GLUT receptors in the 
model. 
[166, 186] 
Grb2/SOS t + 1  = 
(Shc OR IRS1) AND 
NOT  ERK 
Activation of Shc recruits the Grb2/SOS complex via SH2 domain 
binding. IRS1 can also bind to and activate the Grb2/SOS complex 
via SH2 domain binding.  Either Shc or IRS1 are needed to recruit 
the Grb2/SOS complex, however, which is why that part of the rule is 
written as an OR.  ERK has the ability to dephosphorylate SOS 
directly, resulting in disassociation of the Gbr2/SOS complex and a 
decrease in Ras-GTP.  Thus, we assume that ERK inhibition is 






Logic Rule Rule Justification  Source(s) 
IRS1 t + 1  = IR AND 
NOT S6K1 
mTORc1 inhibits IRS1 via S6K1.  IRS1 binds to and is activated by 
insulin receptors (IR).  We assume that inhibition is dominant relative 
to activation. 
[197] 
MDM2t + 1 = p53  P53 mediates the transcription of MDM2. [179] 
MEK t + 1  = Raf RAF is upstream activator of MEK. [175, 241] 
mTORc1 t + 1 =  
NOT TSC1/2 
TSC1 and TSC2 form a heterodimer that inhibits the activity of Rheb.  
Rheb is a small GTPase required for activation of mTORc1.  Thus, in 
the model we assume that mTORc1 is inactivated by TSC1/2 activity. 
[153] 
mTORc2 t + 1  = PI3K 
AND Ribosomes 
Evidence strongly suggests that PI3K is both necessary and sufficient 
for mTORc2 activation to occur via mTORc2 ribosomal binding. Thus, 
we assume both PI3K and ribosomes are necessary for mTORc2 
activation. 
[169, 170] 
p53 t + 1 = DNA 
Damage AND NOT 
MDM2 
P53 is transcriptionally activated  in the presence of DNA Damage 
and is targeted for degradation by MDM2 ubiquitination (Refer to 
Chapter 2, Figure 2.6 for additional explanation of this rule) 
[137] 
PFK1 t + 1  = Fru26P2 
OR NOT ATP 
Fru26P2 is activated PFK1 by allosteric regulation and inhibited by 
high cellular ATP levels.  We assume this regulation is an OR NOT 
regulation because we assume that activator is domination because 
of evidence part of Fru26P2 allosteric regulation includes decreasing 
PFK1 affinity for AKT. 
[242, 243] 
PFK2 t + 1  = AKT AKT directly activates PFK2 by phosphorylation [166] 
PI3K t + 1  =  
((IRS1 OR (GAB1 
AND NOT Erk)) 
AND NOT SHP2) 
OR RasGTP 
This is a particularly complicated regulation.  GAB1 activates PI3K by 
recruiting the p85 subunit and ERK negatively regulates PI3K by 
phosphorylating GAB1 and rendering it unable to recruit p85. This 
portion of the rule is written as: GAB1 and not ERK.  In addition, IRS1 
activates PI3K but both GAB1 and IRS1 activation can be regulated 
by SHP2; therefore, this portion of the rule is written as: [(GAB1 and 
not ERK) or IRS1] and not SHP2.  Finally, Ras-GTP can also activate 
PI3K, but its activation is not affected by SHP2 or ERK levels, thus 








PIP3t + 1 = PI3K and 
not PTEN 
PI3K activates PIP3 at the cell membrane and PTEN 
dephosphorylates PIP3.  We assume the inhibitor is dominant. [153] 
Raft + 1 = Ras-GTP 
AND NOT AKT 
RAS-GTP directly activates RAF and RAF must be phosphorylated 
and dephosphorylated on specific sites to remain active.  Regardless 
of the activation state of RAF, AKT appears able to phosphorylate 
RAF and reduce activation levels. Therefore, the rule is written as 
Ras-GTP and not AKT. 
[181, 182] 
[191] 
RasGAP t + 1   = 
GAB1 AND NOT 
SHP2 
GAB1 recruits RasGAP to the membrane and SHP2 down regulates 
this interaction. Without SHP2, GAB1 is able to recruit RasGAP to the 
membrane.  In the presence of SHP2, GAB1 is not able to recruit 
RasGAP to the membrane and RasGTP becomes activated.  If GAB1 
and SHP2 are both absent, then RasGAP is not recruited to the 
membrane, which is the primary justification for the AND NOT 
function. 
[188, 205] 
Ras-GTP t + 1   = 
Grb2/SOS AND 
NOT RasGAP 
This rule is based on the observation that RasGAP binds to Ras and 
does not allow the exchange of GDP to GTP, therefore RasGAP 
must be removed AND the Grb2/SOS complex must be present to 
catalyze the exchange of GDP to GTP, hence the rule is Grb2/SOS 
and not RasGAP. 
[188, 191] 
Ribosomes t + 1   = 
S6K1 Phosphorylation of S6K1 by MTORc1 induces ribosomal biogenesis.  [238] 
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Logic Rule Rule Justification  Source(s) 
S6K1 t + 1   
 = mTORc1 Phosphorylation of S6K1 is induced by mTORc1. [238] 
Shc t + 1   
 = EGFR OR IR 
Either activated EGFR or activated IR can stimulate RAS.  Because 
Shc activates the downstream Grb/SOS complex, which is essential 
for RAS activation, we assume that Shc is intermediary between this 




SHP2 t + 1 = GAB1 
OR IRS1 
SHP2 is crucial for Ras activation in insulin and EGF signaling.  
Activation of the RAS/MAPK pathway has been observed under 
insulin/IRS1 activation as well as under EGF/GAB1 activation. Thus, 
the rule is written as GAB1 or IRS1. 
[188, 205] 
TIGAR t + 1  = p53 TIGAR is induced by P53. [143] 
TSC1/2 t + 1  = NOT 
AKT AND NOT ERK 
AND NOT AMPK 
AKT inhibits TSC1/2 and ERK inhibits TSC1/2 through the activation 
of RSK1.  Phosphorylation (ser1798) of RSK1 inhibits TCS1/2 and 
results in increased mTORc1 expression.  We assume that TSC12 is 
only on when its activator is present and both its inhibitors are 
absent. While there are a number of negative regulators of the 
TSC12 dimer, our model only considers ERK inhibition and AKT 





Table 3.4.  Oncogenic perturbations to the PI3K/MAPK cross-talk model.  The table summarizes the 
difference in in silico simulated results and the experimental in vitro results by displaying the total AKT, total 
ERK and total combined cost penalty for each cell line and each condition.   The conditions that generated 
the lowest total cost penalty are displayed in green and the conditions that generated the highest total cost 
penalty are displayed in red for each cell line. A penalty of 0.00 indicates that the simulation and 





Chapter 4  
Targeted inhibitors can produce off-target effects 
and activate linked pathways by retroactivity
The content of this chapter was previously published by the author in  
BMC Systems Biology [21]. 
4.1 Background  
Chapters 2 and 3 explored the use of logic based network models as a 
qualitative and parameter-free network modeling method. As discussed at the 
end of Chapter 2, however, some forms of network behavior cannot be 
adequately modeled used logic-based methods.  In this chapter, an ordinary 
differential equation (ODE) system is used to explore whether off-target effects 
can be induced by phenomenon driven by enzyme sequestration, a mechanistic 
detail that is out of reach of parameter-free logic methods. 
Cells propagate information through protein signaling pathways that are 
part of complex signal transduction networks [34].  The simplest view of cellular 
signaling entails a cascade of molecular events initiated by the recognition of a 
stimulus and culminating in the chemical alteration of an effector molecule.   In 
the case of covalent modification by the addition or removal of a phosphate 
group, a reaction commonly found in signaling cascades, each phosphorylated 
protein serves as the kinase that activates the next cycle’s unphosphorylated 
protein.  
Targeted therapies are used to modulate disease progression by inhibiting 
a specific protein within a dysregulated signaling pathway [246].  Kinase 
inhibitors are a class of targeted therapies designed to interfere with a specific 
kinase molecule.  While extremely promising as anti-cancer agents, kinase 
inhibitors can produce off-target effects by inducing changes in molecules other 
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than the one specifically targeted.  Such off-target effects are generally attributed 
to non-specific binding or to cross-talk [247].     
 
Figure 4.1.  Retroactivity arises from enzyme sequestration in covalently modified cascades. A 
simple signaling cascade is depicted where each sequential cycle represents the activation (denoted by *) 
and inactivation of a protein Yi.  Y1* serves as the activating enzyme of Y2 and Y2* serves as the activating 
enzyme of Y3. The cycles can be thought of as modules where each module’s substrate sequesters a key 
competent of the previous module, limiting the component’s ability to participate in the previous module. This 
sequestration induces a natural change in the preceding module, which may propagate upstream through 
one or more preceding modules.  In this example, a perturbation in the deactivation reaction of cycle 3 
induces an effect in cycle 2.  If the perturbation takes the form of an increase in the concentration or activity 
of the enzyme catalyzing the conversion of Y3* to Y3, more Y3 will be available to react with and sequester 
Y2*, resulting in less Y2 substrate availability for the reaction with Y1*. Thus, a reverse response can 
propagate upstream to a preceding cycle or cycles. In the schematic, black arrows represent the cell surface 
to nucleus direction of cellular signaling and red arrows represent the direction of retroactive signaling. 
 
Recent theoretical and experimental studies have demonstrated that 
covalently modified cascades also exhibit bidirectional signal propagation via a 
phenomenon termed retroactivity [248-253].  This phenomenon arises because 
cycles in a cascade are coupled, not only to the next cycle, but also to the 
previous cycle (Figure 4.1). The cycles can be thought of as modules where 
each module’s substrate sequesters a key component of the previous module, 
limiting the component’s ability to participate in the previous module and inducing 
a natural change in the preceding module. This change may then propagate 
upstream through one or more preceding modules.    
While retroactivity is naturally present in covalently modified cascades, 
signaling pathways likely have evolved to propagate signals in an optimized 
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downstream manner.  An important consequence of retroactivity, however, is that 
a downstream perturbation in a signaling cascade can produce an upstream 
effect without the need for explicit negative feedback connections [248].  
Retroactivity may, therefore, play important roles in the dysregulated signaling 
networks of diseased cells as well as the cellular response to targeted therapies 
applied to dysregulated signaling networks.  
Ventura, Sepulchre, and Merajver [248] demonstrated that increasing the 
concentration of the inactivating enzyme (e.g., a phosphatase) in the terminal 
cycle of a cascade can decrease the concentration of the activated protein in the 
previous cycle [248].   This finding led us to hypothesize that a targeted inhibitor 
can produce upstream off-target effects via retroactivity that can propagate 
elsewhere in the signaling network.   
Off-target effects associated with targeted therapies are often attributed to 
cross-talk, which refers to inter-pathway molecular interactions arising because 
of explicit regulatory feedback connections between two pathways or because 
two pathways share one or more molecular components.  It is well accepted that 
two pathways sharing one or more components can exhibit cross-talk with 
respect to a stimulation or perturbation above the shared component(s).  If an 
upstream perturbation occurs in one of the pathways, the perturbation may affect 
the other pathway via the shared downstream component(s).  Such a scenario 
could lead to specificity problems [254].  Here we propose that perturbations 
(e.g., from an inhibitor) that occur downstream of a shared component can also 
induce cross-talk effects without any explicit feedback connections via the 
following mechanism: the information travels upstream from the site of the 
perturbation through retroactivity, reaches the common component and then is 
delivered to the parallel pathway.   
To test our hypothesis, we created a computational model that tested the 
application of a kinase inhibitor in a series of simple signaling networks.  The 
objective of the model was to probe the effect of a targeted inhibitor on 
retroactive signaling and to test whether retroactivity is likely to contribute to 
measurable off-target effects under physiological conditions.   Specifically, the 
69 
model simulated the targeted inhibition of a specific kinase in a series of multi-
cycle networks. In all networks, at least two cascades were activated by the 
same upstream cycle with no explicit feedback connections between them.  Our 
results indicate that within physiologically and therapeutically relevant ranges for 
all parameters, a targeted inhibitor can naturally induce a steady state off-target 
effect via retroactivity.  Our results also reveal the surprising and crucial result 
that a downstream kinase inhibitor has the capacity to turn “on” an otherwise “off” 
parallel cascade when two cascades share an upstream activator. 
 
Figure 4.2.  Topology of signaling networks studied.  Two general types of network motifs consisting of 
covalently modified cycles were studied: (A) the vertical case where the n-th cycle in the right hand cascade 
is inhibited and (B) the lateral case where the n-th single-cycle cascade is inhibited. Y1* served as the 
upstream activator for both cycle 2 and cycle 3, which were always in distinct cascades. No additional 
regulatory connections were included in any network. Off-target effects were monitored in the networks by 
measuring the steady state concentrations of Y2 and Y2* as the concentration of an inhibitory drug that 
specifically targeted Yn* was increased.  (C) The n = 3 network consisted of exactly 3 cycles and was the 
simplest form of both the vertical and lateral case. (D) An extended n = 3 network was also studied where a 




Table 4.1.  The parameter space of each network consisted of a set of non-dimensional parameters, 
each with a minimum and maximum allowed value. Each cycle i, consisted of 5 dimensionless 
parameters: Ei, E'i,Ki, K'i, and Pi.  A final parameter, KB, applied to the targeted inhibitor. Randomly selected 
parameter values could not exceed the default ranges listed for each parameter type. 
  default range   
parameter minimum maximum description 
Ei 0.01 100 total kinase to total substrate ratio 
E'i 0.01 100 total phosphatase to substrate ratio 
Ki 0.01 100 normalized Km of kinase reaction 
K'i 0.01 100 normalized Km of phosphatase reaction 
Pi 0.1 10 ratio of the kinase reaction Vmax to the phosphatase reaction Vmax 




We designed simple signaling networks to test whether a measurable off-
target effect in one cascade can occur when a protein in another cascade is 
selectively inhibited.  In each network studied, cycle i contained the active 
(phosphorylated) and inactive (unphosphorylated) forms of protein Yi, where the 
active form was denoted by Yi*.  For simplicity, we refer to activating and 
inactivating enzymes in a network as kinases and phosphatases, respectively.   
 Protein Y1* served as the activating kinase for all cascades. Cycle 2 and 
cycle n were always in distinct cascades (Figure 4.2).  To determine if an off-
target effect occurred due to perturbation by the inhibitor, the steady state 
concentration of the protein in cycle 2 was monitored as the concentration of the 
drug that specifically targeted Yn* was increased.   A competitive inhibitor was 
used that directly bound to Yn*, limiting its ability to participate in the phosphatase 
reaction of cycle n, but did not change the rate of the phosphatase reaction in 
cycle n.   
Two general network types were considered: a vertical and a lateral case 
(Figure 4.2).  The vertical case consisted of two cascades where the inhibited 
cascade length varied (Figure 4.2A). This motif is similar to the upstream 
activation of JUN and P53 by JNK1/2 in the mitogen-activated protein kinase 
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(MAPK) pathway [255].  The lateral case was equivalent to a fan-out network 
topology and consisted of n - 1 single cycle cascades that were all activated by 
Y1* (Figure 4.2B).   This motif is similar to the activation of multiple cascades by 
p38 [255].  The n = 3 network consisted of exactly 3 cycles and represented the 
simplest form of both network types studied (Figure 4.2C).    
The general reaction scheme used was:   
𝑌𝑖 + 𝐸𝑘𝑖   <
𝑎𝑖 
𝑑𝑖 
> 𝐶𝑖  
𝑘𝑖 >  𝑌𝑖∗  + 𝐸𝑘𝑖    







>   𝑌𝑖  + 𝐸𝑝𝑖 








𝑖 = 1, 𝐸𝑘1
𝑖 = 2, 𝑖 = 3, 𝑌1∗
𝑖 > 3 (vertical), 𝑌𝑖−1∗
𝑖 > 3 (lateral), 𝑌1∗
 
where 
𝑌𝑖∗ is the activated protein in the 𝑖th cycle      
𝑌𝑖 is the inactivated protein in the 𝑖th cycle 
𝐸𝑘𝑖  is the kinase enzyme in the 𝑖
th cycle 
𝐸𝑝𝑖  is the phosphatase enzyme in the 𝑖
th cycle 
𝐷 is the inhibitory drug 
𝐶𝑖 is the 𝑌𝑖 and 𝐸𝑘𝑖complex in the 𝑖
th cycle 
𝐶𝑖′ is the 𝑌𝑖∗and 𝐸𝑝𝑖complex in the 𝑖
th cycle 
𝐶𝐷 is the 𝑌𝑛∗ and D complex in the 𝑛th cycle 
         and values above and below arrows represent rate constants. 
Parameter definitions 
In order to reduce the complexity of each network studied, parameters 
were non-dimensionalized into 4 parameter types as described in Appendix C.  
The allowed value of each parameter type was restricted to the default ranges 
listed in Table 4.1.  A summary of the parameters types is provided below.  
Subscripts containing k or p indicate parameters associated with a kinase 
or phosphatase reaction, respectively, and subscripts containing T indicate the 
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total concentration of a species.   Vmax and Km are the standard Michaelis-Menten 
constants representing, respectively, the maximum velocity of a reaction (at a 
given enzyme concentration) and the substrate concentration necessary to 
achieve 1
2
 Vmax [32].   
(1) total enzyme to substrate ratio of the kinase and phosphatase reaction, 
respectively, in cycle i: 
Ei = 𝐸𝑘iT/𝑌𝑖T      E'i = 𝐸𝑝iT/𝑌𝑖T   
(2) normalized Km of the kinase and phosphataste reaction, respectively, 
in cycle i: 
Ki = Km𝑘𝑖/𝑌𝑖T    K'i = Km𝑝𝑖/𝑌𝑖T   
where Km𝑘𝑖 =  
𝑑𝑖+𝑘𝑖
𝑎𝑖






(3) Vmax ratio of the kinase and phosphatase reactions in cycle i: 
Pi = Vmax𝑘𝑖/Vmax𝑝𝑖 
where Vmax𝑘𝑖 =  𝑘𝑖𝐸𝑘iT  and  Vmax𝑝𝑖 =  𝑘𝑖
′𝐸𝑝𝑖T  





Ei and E'i values less than 1 indicate that the enzyme is less abundant 
than the substrate. Ki and K'i values less than 1 indicate that the total available 
substrate exceeds the concentration needed to reach Km and, consequently, the 
enzymatic reaction operates close to or in the zero order regime [33].  In 
contrast, Ki and K'i values greater than 1 indicate that an insufficient amount of 
substrate exists to reach  Km and the enzymatic reaction operates in the linear 
regime [33].  Pi values greater than 1 indicate that the Vmax of the kinase reaction 
exceeds the Vmax of the phosphatase reaction and, consequently, the cycle tends 
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toward the activation reaction.  Likewise, Pi values less than 1 indicate that the 
cycle tends toward the deactivation reaction. 
Determination of off-target effects 
The concentrations of species Yi, Yi*, and the inhibitory drug D were 
normalized as follows:   
𝑦𝑖 =  
[𝑌𝑖]
𝑌𝑖𝑇
    𝑦𝑖∗ =
[𝑌𝑖∗]
𝑌𝑖𝑇




To determine if a detectable off-target effect occurred for a specific set of 
parameters, changes in the steady values of 𝑦2 and 𝑦2∗ were monitored as the 
model parameters were held fixed but 𝑰 was varied from 10-4 to 104.  If a change 
in the steady state value of 𝑦2 or 𝑦2∗ occurred that was greater than or equal to a 
detection threshold of 0.10, an off-target effect in cycle 2 was reported.  For 
numeric reasons, the range used for 𝑰 was intentionally larger than needed.  For 
a given parameter set, it was numerically more efficient to simulate with a small 
(10-4) and a large (104) value for 𝑰 and then check for a change in the steady 
state values of 𝑦2 and 𝑦2∗ than it was to simulate with many values of 𝑰.  In fact, 
the majority of target-effects in our model were observed as 𝑰 was varied from 
0.1 to 10.    
When we tested the n = 3 network, we obtained the same results when we 
used either I = 0.0000 or I = 0.0001 (10-4) as the minimum drug concentration.  
For this reason (and because it would be experimentally challenging to 
distinguish 0.0000 from 0.0001 in vivo), we effectively considered I = 10-4 to 
represent the absence of the drug in the system. 
Numerical simulations 
For each network tested, a system of ODEs was used to model the rate of 
change of the reactants.  Because we were only interested in changes in steady 
state values as a function of I, we first solved the system by setting the ODEs 
equal to zero and generating a system of steady state equations. As described in 
Appendix C, the model in this form was the basis for the non-dimensionalization 
of model parameters.   
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For numerical reasons, it was more efficient to solve the ODEs over a very 
long time period rather than solving the system of steady state equations directly.  
After randomly selecting a set of non-dimensional parameters, the selected 
values were mapped to corresponding dimensional parameter values (as 
described in Appendix C) and the system of ODEs was solved using the Matlab 
R2009b ode15s stiff solver from 0 to a maximum of 100,000 arbitrary time units. 
The majority (~90%) of randomly selected parameter sets obtained steady state 
within 5,000 arbitrary time units.  The units are arbitrary because we began with 
dimensionless parameters lacking an explicit timescale.  Finally, to confirm the 
numerical steady state solution, the original dimensionless parameters and the 
final yi  and yi* variable values were substituted into the analytical steady state 
equations listed in Appendix C.  Matlab source code was compiled as a C 
program and run on Intel Nehalem/i7 Core processors.  
Random parameter space exploration 
Random parameter selection was performed via latin hypercube sampling 
(LHS) to provide an efficient and even sampling distribution across the range of 
allowed values in the parameter space [256-258].  Each parameter space 
exploration consisted of 5000 randomly selected parameter sets.   The number of 
parameter sets sampled was determined by calculating the percent of off-target 
effects in q randomly sampled parameter sets for the n = 3 network (Figure 
4.2C). The variation in the percent of off-target effects stabilized when q was 
greater than or equal to 5000 (Appendix C, Figure C.1).  The percentage of 
5000 randomly selected parameter sets that produced an off-target effect 
provided a probability that off-target effects would occur in a given network’s 
parameter space.   
Numeric perturbation analysis  
A modified perturbation method was used to probe which model 
parameters were most important for producing an off-target effect as a result of 
the inhibition of Yn*.  Traditional biochemical sensitivity analysis [259] with the 
dimensionless parameters was not possible because these parameters applied 
to the steady state equations and not the time dependent differential equations 
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(Appendix C).  Instead, we developed a numerical perturbation based method 
that allowed us to evaluate the parametric sensitivity of off-target effects in a 
network’s parameter space.  In the method, the value of a single parameter was 
randomly selected from a restricted range of values while all other parameter 
values were randomly selected from the full range permitted by the baseline 
parameter space.  If off-target effects are sensitive to a given parameter, we 
expect that when values for the parameter under test are randomly selected from 
a reduced range of values, the percentage of off-target effects produced will 
differ from the percentage produced when values for the parameter are instead 
selected from a fixed baseline range.  In both cases, all other parameter values 
are selected from a fixed baseline range so that the only change in the system is 
a perturbation in the allowed range of the parameter under test.   
The reduced ranges used to perturb each parameter were arrived at by 
partitioning the default range established for each parameter type in Table 4.1.  
The default ranges were divided into smaller perturbation sub-ranges such that 
the minimum and maximum of a sub-range was an order of magnitude larger 
than the minimum and maximum of the previous sub-range.  Because the Ei, E’i, 
Ki, K’i, and KB parameters had a default initial range of 0.01 – 100.0 (Table 4.1), 
the sub-ranges used to perturb these parameters were: (i) 0.01 – 0.10, (ii) 0.10 – 
1.0, (iii) 1.0 – 10.0, and (iv) 10.0 – 100.0.  Because the Pi parameters had a 
default range of 0.10 – 10.0, the sub-ranges used to perturb these parameters 
were: (i) 0.10 – 1.0 and (ii) 1.0 – 10.0.   
A complete numeric perturbation analysis of a parameter space consisted 
of determining the percentage of off-target effects in 5000 randomly selected 
parameter sets for each parameter’s sub-ranges.  In the n = 3 network (Figure 
4.2C) there were a total of 16 parameters (5 parameters per cycle and KB).  
Three of the parameters (P1, P2, and P3) had 2 perturbation sub-ranges each and 
the remaining 13 parameters had 4 perturbation sub-ranges each.  In this 
example, the analysis consisted of a total of 59 sets of 5000 simulations (58 sets 
for each parameter sub-range and 1 set to establish the baseline percentage of 
off-target effects in the parameter space prior to perturbation). 
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4.3 Results  
The question we wanted to answer with our models was whether a 
targeted inhibitor is likely to induce a measurable off-target effect due to 
retroactivity in a non-targeted cascade under physiological conditions.  In each 
network, cycle n, was perturbed by an inhibitor.  An off-target effect occurred in 
the model if, after increasing I (the normalized inhibitor concentration) from 10-4 
to 104, a change in the steady state concentration of Y2 and/or Y2* occurred that 
was at least 0.10 of the total Y2 protein pool.  For example, a change of 0.25 in Y2 
and 0.08 in Y2* would indicate that the steady state values of Y2 and Y2* changed 
by 25% and 8% of the total Y2 protein pool, respectively, and that a detectable 
off-target effect occurred in Y2.   
4.3.1 Parameter ranges promoting off-target effects in cycle 2 
First, we investigated the n = 3 network (Figure 4.2C) where Y3* is 
targeted by the inhibitor.  When the full parameter space (defined in Table 4.1 
and depicted in Figure 4.3H) was used, 1.6% of the 5000 randomly selected 
parameters sets produced an off-target effect in cycle 2.  This value was 
essentially unchanged (1.5%) when we randomly selected 50,000 parameter 
sets for comparison. To identify the model parameters that were most important 
for producing a cycle 2 off-target effect, a numerical perturbation analysis was 
performed (Figure 4.3A-F).  The results of the analysis suggest that the 
parameters controlling the activity of cycle 3 play a large role in inducing an off-
target effect in cycle 2.  Not surprisingly, K3 (the normalized Km of the kinase 
reaction in cycle 3) had the greatest effect on off-target effects in this network 
(Figure 4.3D).  K3 determines how much sequestration of Y1* by Y3 occurs and 
this is the key mechanism of retroactivity.  When K3 was restricted to values 
greater than 1, the off-target effects in the network were essentially eliminated.  
In contrast, when K3 was restricted to values between 0.01 and 0.10, the 
percentage of off-target effects increased to 4.6%.  Similarly, K’3 (the normalized 
Km of the phosphatase reaction in cycle 3) also affected the percentage of off-
target effects but to a lesser degree than K3 (Figure 4.3E).   
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Figure 4.3.  A numerical perturbation analysis revealed parameter value ranges that promote off-
target effects in the n = 3 network.  A perturbation analysis of the n = 3 network (G) was performed where 
a single parameter’s value was randomly selected from a small range of values, while all other parameters 
were selected from the larger ranges defined in Table 4.1  The baseline in each plot reflects the percent of 
off-target effects in cycle 2 in 5000 sampled parameter sets when all parameter values were randomly 
selected from the ranges defined in Table 4.1 and depicted in (H).  All other bars reflect the results of 
systematically perturbing each parameter (one at a time) using the given sub-ranges (A-F).  Based on this 
perturbation analysis, a restricted parameter space was generated (I) from which ~74% of the sampled 
parameter sets produced off-target effects in cycle 2.  In contrast, only ~1.6% of sampled parameter sets 
from the full parameter space (H) produced off-target effects in cycle 2. 
E3 and E’3 (the total kinase to substrate and the total phosphatase to 
substrate ratio, respectively, in cycle 3) also appeared to exert a large degree of 
control over off-target effects (Figure 4.3A-B).  These results indicate that off-
target effects were more likely when the kinase and phosphatase enzymes of 
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cycle 3 were saturated.  P3, the ratio of the Vmax of the kinase and phosphatase 
reactions in cycle 3, also affected the percentage of off-target effects (Figure 
4.3C).  When P3 was less than 1, cycle 3 tended toward the deactivation reaction 
and the percentage of off-target effects increased to 2.56% from 1.6%.  Similarly, 
when P3 was greater than 1, cycle 3 tended toward the activation reaction and 
the percentage of off-target effects was significantly reduced relative to the 
baseline (0.32%). 
The only parameter associated with cycle 2 that affected the percentage 
of off-target effects in this network was K2 (the normalized Km of the kinase 
reaction of cycle 2).  K2 values between 0.01 and 0.10 are expected to produce 
an efficient kinase reaction because Y2T >> Km2.  The results of the numerical 
perturbation analysis indicated that when K2 was restricted to values in this sub-
range, a small percentage of off-target effects was observed (Figure 4.3D).  In 
contrast, when K2 was restricted to values between 1.0 and 10.00, the 
percentage of off-target effects increased relative to the baseline.  These results 
suggest that an off-target effect in cycle 2 is more likely to occur in the n = 3 
network when the conversion of Y2 to Y2* operates in the linear regime because 
of substrate constraints.  This result is somewhat counter intuitive given the fact 
that we are interested in measuring a response that propagates from cycle 3 to 
cycle 1 and then down to cycle 2.  It is reasonable to expect that an efficient 
kinase reaction in cycle 2 would be important for recruiting Y1* to activate Y2 and 
generate an effect in cycle 2.  If the cycle 2 kinase reaction is less efficient than 
the cycle 3 kinase reaction, however, more Y1* will be available to convert Y3 to 
Y3*, ultimately contributing to the sequestration of more Y3* into a complex with D 
(Figure 4.2C).  Such a sequestration may give rise to a detectable upstream 
effect as a result of the reduced substrate availability in cycle 3.  
The cycle 1 parameters with the greatest impact on the percentage of off-
target effects were K1 and K’1 (the normalized Km of the kinase and phosphatase 
reaction, respectively, in cycle 1) (Figure 4.3D-E).  Larger values of K1 acted to 
suppress off-target effects, while smaller values produced an increase in off-
target effects relative to the baseline (Figure 4.3D).  The reverse was observed 
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for K’1, with higher values producing a higher percentage of off-target effects 
than smaller values (Figure 4.3E).  Together, the K1 and K’1 results suggest that 
off-target effects are favored when the cycle 1 phosphatase reaction tends 
toward inefficiency and the cycle 2 kinase reaction tends towards efficiency.  This 
result is not surprising given that the availability of Y1* is essential for the 
propagation of a signal from cycle 3 to cycle 2.  
The value of KB, the normalized drug disassociation constant, had a very 
slight effect on the percentage of off-target effects.  In general, KB values greater 
than 1 produced a slight decrease in the percentage of off-target effects relative 
to the baseline (Figure 4.3F).  This result suggests that weaker binding (and 
larger dissociation constants) promoted fewer off-target effects, as would be 
expected given the decreased sequestration of Y3* that would occur.  The change 
in the percentage of off-target effects induced by restricting KB values was fairly 
small compared to the change induced when other model parameter values were 
restricted (Figure 4.3). This result suggests that the activity and efficiency of 
component cycles in the network may be more important for propagating an off-
target effect than the actual kinetics of a targeted therapy.    
The results of the above analysis indicated that certain parameter value 
ranges are more likely to induce an off-target effect in cycle 2 as the drug 
concentration is increased (Figure 4.3).  When we restricted the n = 3 parameter 
space by reducing the ranges from which some key parameters were selected 
(Figure 4.3I), the percentage of off-target effects in 5000 randomly sampled 
parameter sets increased from 1.6% to 73.9%.   
A second numerical perturbation analysis was performed using this new 
restricted n = 3 parameter space as a baseline.   In general, many of the trends 
observed in the analysis of the original n = 3 parameter space (depicted in Figure 
4.3H) were observed in the analysis of the restricted n = 3 parameter space 
(Appendix C, Figure C.3).  For example, low K3 values remained important for 
producing off-target effects in both parameter spaces.  The effects of parameters 
associated with cycle 2, however, were different in the two parameter spaces.   
When the original parameter space was tested, K2 was the only cycle 2 
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parameter found to substantially affect the percentage of off-target effects 
(Figure 4.3D).  In the restricted parameter space, however, some ranges of E2, 
E’2, and K’2 produced off-target effect percentages that differed substantially from 
the baseline.  For example, E2 values between 10 and 100 produced off-target 
effects in 92.1% of sampled parameter sets, the largest percentage of off-target 
effects observed in any of our analyses (Figure C.3A).  Because E2 is the total 
enzyme to substrate ratio of the kinase reaction (Y1T/Y2T), this result suggests 
when more total protein exists in cycle 1 compared to cycle 2, off-target effects in 
cycle 2 are more likely in this network. 
While some parameters associated with cycle 2 were able to effect the 
percentage of off-target effects, the parameters associated with cycle 3 
continued to have the greatest effect on off-target effects in the restricted n = 3 
parameter space.  Only parameters in cycle 3 had the ability to effectively 
eliminate (or substantially reduce) the percentage of off-target effects within 
specific reduced ranges.  Values between 10 and 100 for E3, E’3, K3 and K’3 
produced off-target effect percentages of 0%, 3.24%, 0% and 3.20%, 
respectively.  In addition, P3 values greater than 1 produced off-target effects in 
18.24% of sampled parameter sets which, compared to the baseline of 73.9%, 
represents a large decrease in off-target effects (Figure C.3).   
4.3.2 Varying a single parameter can produce a large change in the size of 
the off-target effect  
The magnitude of off-target effects produced by parameter sets randomly 
sampled from the original n = 3 parameter space (Figure 4.3H) generally fell 
between .10 and .30 of the total Y2 protein pool (Figure 4.4A).  In contrast, the 
magnitude of off-target effects produced by parameter sets randomly sampled 
from the restricted n = 3 parameter space (Figure 4.3I) were more uniformly 
distributed across a range of values (Figure 4.4B).  These results suggest that 
when conditions in a network are favorable for off-target effects, the size of an 




Figure 4.4.  Distribution of the size of off-target effects in the n = 3 network.  Histograms of the size of 
off-target effects in n = 3 network (Figure 4.3D) are plotted for two different parameter spaces. The y-axis on 
each plot represents the proportion of all parameter sets that produced off-target effects in 5000 randomly 
selected parameter sets.  The x-axis on each plot represents the size of an off-target effect in cycle 2 as a 
proportion of Y2T such that each value indicates a response that was at least as big as the given value but 
less than the next sequential value. For example, a value of 0.30 indicates that the magnitude of the 
response was greater than or equal to 0.30 but less than 0.40.  (A) The majority of off-target effects in the 
original n = 3 parameter space (depicted in Figure 4.3H) were less than 0.30.  (B) In contrast, the 
distribution of the size of off-target effects in the restricted n = 3 parameter space (depicted in Figure 4.3I) 
was more uniform. 
We used stimulus response curves to examine how a change in a single 
parameter value may affect the size of an off-target effect in Y2* as a function of 
the normalized inhibitor concentration (Figure 4.5).  A randomly selected 
parameter set and a parameter set derived from a Xenopus MAPK model [260] 
(refer Appendix C for the derivation of the Xenopus parameter values) were 
used.  In each parameter set, either E2 or K3 was varied, while all other 
parameter values were fixed to the values listed in Table 4.2.   
The randomly selected parameter set produced a baseline off-target 
response of 0.19 in Y2* (Figure 4.5A-B) and of 0.40 in Y2 (data not shown).  In 
this parameter set the original E2 value was 32.56 and the original K3 value was 
0.04.  Increasing E2 to 326.61 substantially decreased the response in Y2* and 
decreasing E2 to 3.26 increased the response in Y2* from 0.19 to 0.27 (Figure 
4.5A).  Similarly, increasing K3 to 0.41 reduced the response in Y2 * to 0.07 
(below the detection threshold) and decreasing K3 to 0.004 increased the 
response in Y2 * to 0.26 (Figure 4.5B). 
The parameter set derived from the MAPK Xenopus model [260] produced 
a baseline response of 0.08 (below the detection threshold) in both Y2* (Figure 
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4.5C-D) and Y2 (data not shown).  In this parameter set the original E2 value was 
0.0025 and the original K3 value was 0.25.  While changing E2 did not alter the 
response (Figure 4.5C), increasing K3 to 2.5 completely eliminated the response 
in Y2* and decreasing K3 to 0.025 substantially increased the response in Y2* to 
0.60 (Figure 4.5D). These results suggest that when using physiologically 
realistic parameter values, changing one kinetic parameter or species 
concentration by an order of magnitude has the capacity to dramatically alter 
whether a targeted inhibitor induces an off-target effect.   
 
Figure 4.5.  Varying a single parameter value can produce a large change in the off-target response. 
Stimulus response curves were plotted for the n = 3 network using a randomly selected parameter set and a 
parameter set derived from a Xenopus model [39] (all parameters values are listed in Table 4.2).  For each 
parameter set, E2 and K3 were increased or decreased by 1 order of magnitude and the resulting stimulus 
response curves were plotted.  (A-B) The random parameter set produced an off-target effect in Y2 of 0.40 
(data not shown) and in Y2* of 0.19.  (A) Increasing E2 from 32.56 to 326.61 substantially decreased the off-
target effect in Y2 *, while decreasing E2 to 3.26 increased the off-target effect in Y2 * to 0.27. (B) Increasing 
K3 from 0.04 to 0.41 reduced the response in Y2 * below the detection threshold to 0.07, while decreasing K3 
to 0.004 increased the off-target response to 0.26.  (C-D) A second parameter set was derived from the 
literature using MAPK parameters from a Xenopus model.  This parameter set did not initially produce an 
off-target effect because the response in both Y2* and Y2 was 0.08, which is below the detection threshold.  
(C)  Increasing or decreasing E3 to 0.025 or 0.00025, respectively, from 0.0025 had no effect on the 
response to the targeted inhibitor.  (D) In contrast, increasing K3 from 0.25 to 2.5 eliminated the original 
response completely, while decreasing K3 from 0.25 to 0.025 produced a large off-target response of 0.60. 
Original parameter values prior to variation are indicated by ‡ on the plots (see also Table 4.2). 
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A few of the enzyme to substrate ratios in the Xenopus parameter set (E2 
= 0.0025, E’2 = 0.00025, and E3 = 0.0025) were outside the limits of parameter 
ranges allowed in our random parameter space explorations (Table 4.1 and 
Figure 4.3H), suggesting that off-target effects are possible for a larger range of 
parameter values than we specifically tested.  While we may have been too 
conservative in the estimation of the ranges defined in Table 4.1, this finding 
supports the position that a targeted inhibitor can naturally induce an off-target 
effect via retroactivity over a range of physiologically relevant conditions.   
 
Table 4.2.  Parameter sets used in stimulus response curves.  The two parameters sets used in Figure 
4.5 are summarized in the table. The Random set refers to a randomly selected parameter set and the 
Xenopus set refers to a parameter set derived from a Xenopus MAPK model.  Bolded values represent the 
original parameter values varied in Figure 4.5. 
 
Random set Xenopus set 
E1 4.87 0.1 
E2 32.56 0.0025 
E3 0.28 0.0025 
E'1 0.05 0.1 
E'2 1.26 0.00025 
E'3 0.29 0.1 
K1 5.07 100 
K2 28.18 0.25 
K3 0.04 0.25 
K'1 66.34 100 
K'2 9.33 0.25 
K'3 0.59 0.25 
P1 0.21 1.00 
P2 3.43 1.00 
P3 0.42 0.025 




Table 4.3. The percentage of off-target effects decreased as the network size increased. The n = 3 
network’s restricted parameter space (depicted in Figure 4.3I) produced off-target effects in 73.94% of 
sampled parameter sets.  The n = 5 and n = 7 vertical networks produced 27.92% and 13.50% off-target 
effects, respectively, using the same parameter space.  In the lateral case, the drop was more dramatic with 
the n = 5 and n = 7 networks producing 6% and 0% off-target effects, respectively.   Parameter values used 
in cycles 4, 5, 6 or 7 were homogenous with cycle 3.  All percentages are out of 5000 randomly selected 
parameter sets using the parameter space depicted in Figure 4.3I. 
n 
Cycle 2 
% Off Target Effects  
3 73.9 
 vertical lateral 
5 27.9 6.0 
7 13.5 0.0 
 
 
Table 4.4.   Off-target effects can amplify downstream of cycle 2. To test for downstream propagation of 
off-target effects from cycle 2, we created an extended n = 3 network by adding a 4th cycle activated by Y2*.  If 
an off-target effect occurred in cycle 4 and the size of the response in cycle 4 exceeded the size of the 
response in cycle 2, then an off-target effect with amplification was reported for cycle 4. First, we looked at 
off-target effects in cycle 4 using the n = 3 restricted parameter space (Figure 4.3I) for cycles 1 – 3 and the 
default parameter ranges from Table 4.1 for cycle 4 (this parameter space is depicted in Appendix C, Figure 
C.4H).   Next, we looked at off-target effects in a similar parameter space but with cycles 2 – 4 restricted to 
ranges found to favor propagation of off-target effects from cycle 2 to cycle 4 (this parameter space is 
depicted in Figure C.4I).  Values listed in the table are percentages out of 5000 randomly selected 
parameter sets. 
              
  Cycle 2 Cycle 4   
extended n = 3 network with cycle 4 default ranges 
% Off Target Effects 75.3 35.5   
% Off Target Effects with Amplification -- 23.4   
% Off Target Effects without Amplification -- 12.1   
extended n = 3 network with cycle 4 restricted ranges 
% Off Target Effects 45.3 67.4   
% Off Target Effects with Amplification -- 61.9   
% Off Target Effects without Amplification -- 5.5   
              
 
4.3.3 The percentage of off-target effects decreased as the size of the 
vertical and lateral networks increased  
 We next investigated networks with more than 3 cycles by 
randomly exploring the parameter spaces of the vertical (Figure 4.2A) and lateral 
(Figure 4.2B) cases using n = 5 and n = 7 cycles.  As before, we measured the 
steady state change in cycle 2 as the normalized concentration of the drug that 
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targeted cycle n was increased.  The restricted parameter space depicted in 
Figure 4.3I (from which 73.9% of sampled parameter sets produced off-target 
effects in cycle 2) was used for this analysis. Networks were analyzed using 
homogenous parameter values in cycles 4, 5, 6 and 7 that equaled the 
corresponding parameter values randomly selected for cycle 3 (e.g., in the n = 5 
case, E3 = E4 = E5).  This allowed us to keep the size of the parameter space 
fixed so that 5000 parameter sets remained a reasonable number to sample from 
each network’s parameter space.   
 In the vertical case, the percentage of off-target effects in the n = 5 and n = 
7 networks were 27.92% and 13.50%, respectively (Table 4.3).  The reduced 
probability of off-target effects as the cascade lengthened suggests that applying 
a targeted inhibitor near the bottom of a long cascade can produce a detectable 
off-target response but the signal may attenuate as it travels up the cascade.  
This conclusion is in agreement with a recent work that investigated retroactivity 
in long signaling cascades [253] and found retroactive signals are likely to 
attenuate as they travel up long cascades. 
In the lateral case, the drop in the percentage of off-target effects was 
more dramatic than in the vertical case, with the n = 5 and n = 7 networks 
producing 6% and 0% off-target effects, respectively (Table 4.3).  This result 
suggests applying a targeted inhibitor to a cycle that is activated by a signaling 
molecule involved in the simultaneous activation of many other cycles decreases 
the likelihood of off-target effects.  This conclusion is based on a limited 
exploration of the parameter space (due to the homogenous parameter selection 
used for cycles 3 and greater) but is in agreement with a model proposed by Kim 
et al. [252] that showed retroactivity (or what they referred to as subsrate-
dependent control) is attenuated by the number of substrates available.   
4.3.4 Off-target effects from retroactivity can propagate down a non-
targeted cascade  
Our results suggest that, under appropriate conditions, it is possible for a 
downstream perturbation from a targeted inhibitor to transmit up a cascade 
resulting in a detectable off-target effect near the top of another cascade. 
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Because signal amplification is an important cellular sensory mechanism [261], 
we next investigated whether upstream off-target effects from targeted inhibitors 
are likely to amplify down a non-targeted cascade.   
To test for downstream propagation of off-target effects from cycle 2, we 
created an extended n = 3 network by adding a 4th cycle activated by Y2* (Figure 
4.2D).  If a change in the steady state concentration of Y4 and/or Y4* occurred 
that was at least 0.10 of the total Y4 protein pool, then an off-target effect was 
considered to have occurred in cycle 4.  If an off-target effect occurred in cycle 4 
and the size of the response in cycle 4 exceeded the size of the response in 
cycle 2, then an off-target effect with amplification was considered to have 
occurred in cycle 4. 
When the default parameter ranges defined in Table 4.1 were used for all 
cycles in the extended n = 3 network, the percentage of off-targets in cycle 2 and 
cycle 4, respectively, was 1.78% and 0.03%.  We next tested the extended n = 3 
network using the restricted n = 3 parameter space (Figure 4.3I) for cycles 1 – 3 
and the default parameter ranges from Table 4.1 for cycle 4.  In this partially 
restricted parameter space (depicted in Appendix C, Figure C.4H), the 
percentage of off-target effects in cycle 2 and cycle 4 increased to 75.3% and 
35.5%, respectively, and amplification contributed to cycle 4 off-target effects in 
23.3% of the sampled parameter sets (representing more than half of the off-
target effects in the sampled parameter sets).  The remaining off-target effects in 
cycle 4 occurred in 12.2% of the sampled parameter and had a response size 
that was either attenuated relative to cycle 2 or equal to the cycle 2 response 
(Table 4.4).  
To identify the parameters that were most important for amplifying an off-
target effect from cycle 2 to cycle 4 in the extended n = 3 network, we performed a 
numeric perturbation analysis (as previously described) on the partially restricted 
parameter space depicted in Appendix C, Figure C.4H.   From these results, we 
generated a new parameter space (Appendix C, Figure C.4I) which produced 
off-target effects of 45.3% and 67.4% in cycle 2 and cycle 4, respectively.  
Amplification contributed to cycle 4 off-target effects in 61.9% of the sampled 
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parameter sets. The remaining off-target effects in cycle 4 occurred in 5.5% of 
the sampled parameter sets and had a response size that was either attenuated 
relative to cycle 2 or equal to the cycle 2 response (Table 4.4).   
4.4 Discussion  
We developed a computational model to test whether targeted therapies, 
such as kinase inhibitors, can produce off-target effects in upstream pathways as 
a consequence of retroactivity alone.   Using a numeric perturbation method, we 
identified specific conditions (Figure 4.6) for the promotion of steady state off-
target effects via retroactivity when a targeted inhibitor was applied to cycle n in a 
series of simple signaling networks (Figure 4.2).   
Our investigation considered only the effect of retroactivity and targeted 
inhibitors on the individual motifs we studied in the absence of genetic and/or 
other regulatory relationships.  This allowed us to investigate whether such motifs 
have the capacity to produce off-target effects without regulatory feedback 
connections.  In addition, the present study only considered the steady state 
response to a targeted therapy.  The primary reason we considered only steady 
state responses was because it provided us with an objective measure that could 
be used to compare the effect of a targeted inhibitor across many different 
parameter sets.  It is important to note that the dynamics of a retroactive 
signaling process are likely to induce transient changes in the levels of key 
signaling molecules.  These transient changes, which are not observable at 
steady state, may lead to important in vivo responses.   
It is also well known that the dynamics of signal transduction networks can 
be modulated by important oscillatory behavior, for example, from the P53/MDM2 
regulatory feedback loop [45, 137].  Because we have not considered transient 
dynamics, our approach cannot be assumed to apply to all signaling networks.  
Nevertheless, we expect conditions that favor the induction of off-target effects at 
steady state to also favor the induction of detectable transient changes 
associated with the steady state response.  In fact, this is what we observed 
when we plotted the time-course of the cycle 2 proteins with the parameter sets 
used in Figure 4.5 (data not shown). 
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This work has led to very interesting and somewhat surprising results. A 
major importance of this work is that it did not investigate off-target effects related 
to a specific therapeutic intervention and, instead, investigated whether off-target 
effects from retroactivity are possible in a set of common network motifs, making 
the work generalizable to a number of signaling pathways.  There are, however, 
examples of targeted inhibitors of great clinical interest that are involved in 
signaling motifs similar to the network motifs we examined.  The drug NSC 
74859 [262], for example, is a selective inhibitor that targets STAT3.  JAK is an 
upstream activator of both STAT3 and PI3K [263], thus when NSC 74859 inhibits 
STAT3, JAK could potentially facilitate the propagation off-target effects due to 
retroactive signaling from STAT3 to PI3K.  Moreover, the inhibitor GSK690693 
[264] targets AKT and could potentially give rise to a retroactive signal that 
propagates upstream to a common activator of either the MAPK or STAT3 
cascades, generating off-target effects in these pathways. 
The binding affinity of the inhibitor for its target did not play a substantial 
role in the promotion of off-target effects in our model.  Instead, the kinetics of the 
component cycles in the network were more important for increasing the 
likelihood of off-target effects (Figure 4.3, Figure C.3, and Figure C.4).  In 
general, off-target effects were more likely to occur in the networks studied when 
the targeted cycle n favored the deactivation reaction because the Vmax of the 
deactivation reaction was larger than the Vmax of the activation reaction and/or 
both enzymatic reactions in cycle n operated in or near the zero order regime.  
Off-target effects were also more likely when cycle 1 (the source of the shared 
activator in our models) favored the activation reaction and its kinase reaction 
operated in or near the zero order regime.  
If cycle 2’s cascade was extended to include cycle 4 (Figure 4.2D), which 
was activated by Y2*, off-target effects were more likely to propagate to cycle 4 
when cycle 2 favored deactivation and cycle 4 favored activation.  In cycle 2 this 
meant that the kinetics of the kinase reaction were generally inefficient and 
operating in or near the linear regime and that the Vmax of the deactivation 
reaction was generally larger than the Vmax of the activation reaction.  Thus, off-
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target effects were promoted when cycle 2 was “off” and not consuming 
significant amounts of the shared upstream activator, Y1*.  
The results also indicate that off-target effects were more likely when the 
total kinase to substrate and the total phosphatase to substrate ratios in the 
inhibited cycle (En and E’n, respectively) were less than 1.  In the n = 3 network, 
this meant that there was less total protein in cycle 1 than in cycle 3 because E3 
< 1 implies Y1T < Y3T.  The reason for this is that the smaller the Y1T/Y3T ratio, the 
stronger the sequestration of Y1* will be.  The impact of this ratio increases if 
cycle 3 favors the deactivation reaction such that a large fraction of Y3T is in the 
inactive Y3 form, promoting the binding of Y3 to Y1*. 
 The immediate experimental implications of this result is that, in the 
absence of kinetic information, the likelihood of off-target effects may potentially 
be estimated for a network configuration of this type (Figure 4.2A,C-D) based on 
the ratio of the concentrations of components in the inhibited cycle and the 
preceding cycle (using, for example, proteomic or gene expression data).   While 
this ratio would not be an absolute predictor, the presence of this condition would 
suggest an increased probability of off-target effects.  
In agreement with the work of other groups [252, 253], we found the 
probability of off-target effects attenuated when the targeted cycle was near the 
bottom of a long cascade or when there were many substrates competing for a 
common upstream activator (Table 4.3).  Our results also suggest that within 
physiologically realistic parameter ranges, changing a single kinetic parameter or 
species concentration by 1 order of magnitude has the capacity to dramatically 
alter whether an off-target effect occurs as a direct result of targeted inhibition.  It 
is also worth noting that, even though we varied the normalized drug 
concentration over a very large range, in general, the normalized inhibitor 
concentration needed to change by only 2 orders of magnitude to induce an off-
target effect (see, for example, Figure 4.5).   
4.4.1 Conclusions  
Off-target drug effects in vivo are typically attributed to cross-talk arising 
from a feedback connection in a signaling network or to non-specific interactions 
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with other proteins.  In this work we have demonstrated that off-target drug 
effects can also arise naturally from retroactivity in a covalently modified 
signaling network.  This view of signaling challenges the widespread notion that 
information in signaling cascades only flows from the cell surface to the nucleus 
and, consequently, this work has far reaching implications for targeted cancer 
therapies.  
A crucial finding of this work is that the kinetics governing the covalently 
modified cycles in a signaling network are likely to be far more important for 
propagating an off-target effect due to retroactive signaling than the binding 
affinity of the drug for the targeted protein, which is a commonly optimized 
property in drug development.  Another particularly paramount finding is that an 
off-target effect due to retroactive signaling is more likely when the first cycle in a 
non-inhibited cascade is “off” and essentially inactive. This suggests that, in the 
motifs we studied, a targeted therapy has the capacity to turn “on” an otherwise 
“off” tributary cascade.   
To emphasize, it is entirely probable for a branch of a signaling network 
that is “off” to become activated or “on” due to the inhibition of another protein in 
the network based on retroactivity alone, suggesting an inherent opportunity for 
negative therapeutic effects.  Our findings, therefore, have implications for 
somatic evolution in cancer and the onset of therapeutic resistance, which has 
been widely reported for many targeted cancer therapeutics [265], most notably 
for the targeted inhibition of BCR-ABL by imatinib [266].  Moreover, a single 
mutation could conceivably give rise to a spontaneous off-target effect without 
the need for any direct regulatory connections between the targeted protein and 
the effected protein.    
While our approach does not definitively establish that the predicted 
responses will occur in vivo, our results demonstrate that off-target effects are 
indeed possible in the absence of direct regulatory relationships and suggest that 
additional (and more specific) experimental and theoretical investigations are 
warranted.  A proper characterization of a pathway’s structure is important for 
identifying the optimal protein to target as well as what concentration of the 
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targeted therapy is required to modulate the pathway in a safe and effective 
manner.  We believe our results strongly support the position that such 
characterizations should consider retroactivity as a potential source of off-target 
effects induced by kinase inhibitors and other targeted therapies.  This work has 
also provided an initial roadmap for how to assess the likelihood of off-target 
effects in a signaling network.  
 
Figure 4.6.  A summary of conditions that favor off-target in the n = 3 and the extended n = 3 networks.   
The conditions that promoted off-target effects in our model are summarized for two network types.  Off-
target effects in (A) the n = 3 network and (B) the extended n = 3 network were favored when cycle 3 tended 
toward the deactivation reaction and cycle 1 tended toward the activation reaction. Off-target effects were 
favored in cycle 4 of (B) the extended n = 3 network when cycle 2 tended toward the deactivation reaction 
and cycle 4 tended toward the activation reaction.   Blue arrows in a cycle indicate which Vmax is larger when 
off-target effects are favored. (C) A summary of the specific conditions in each cycle found to favor off-target 
effects in the n = 3 network, in the extended n = 3 network, or in both networks.  
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Chapter 5  




Otto Warburg was the first to observe that cancer cells, unlike normal 
quiescent cells, rely on glycolysis for energy production and produce large 
amounts of lactate relative to surrounding tissue, even when sufficient oxygen is 
present [3]. This form of metabolism, now known as the Warburg effect or 
aerobic glycolysis [4-7], generates only 2 molecules of ATP per molecule of 
glucose on average, compared to approximately 36 molecules of ATP when 
glucose is fully oxidized via mitochondrial oxidative phosphorylation.  The 
Warburg effect is so pervasive across cancers that it is routinely leveraged in the 
clinic via fluorodeoxyglucose-positron emission tomography (FDG-PET) scans, 
where high glucose uptake correlates with tumor cell proliferation and poor 
prognostic outcome [5, 8].  There is evidence that cancer cells divert some 
glucose derived  carbon to nucleotide and fatty acid synthesis [5], suggesting that 
the dependence on glycolysis exhibited by cancer may help sustain the high 
biosynthetic requirements of proliferation.  In addition to glucose, glutamine is 
also an important metabolic substrate consumed by cancer cells (Figure 5.1) [5]. 
The Warburg effect in cancer is similar to proliferative metabolism in 
normal cells but some molecular and kinetic differences have been discovered.  I 
hypothesize that there are key drivers of the Warburg effect that can be exploited 
to target cancer proliferation without substantial negative effects on normal tissue 
growth.  As a consequence of the highly complex and interconnected nature of 
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intracellular networks, identifying these drivers requires systems biology 
approaches. The objective of the work presented in this chapter is to identify 
some of the system level metabolic differences that occur at distinct stages of 
breast cancer and to provide a framework for identifying the key drivers of the 
Warburg effect.  The four breast cell lines used in this study represent normal-like 
breast tissue (MCF-10A), a primary tumor (MCF-7), and metastatic breast cancer 
(MDA-MB-231 and SUM-149) (Figure 1.1D-G).   
Understanding which mechanisms give rise to the Warburg effect is an 
active area of research. Most current approaches focus on the elucidation of 
gene and protein differences between normal and malignant metabolism.  
Another increasingly important approach for the study of cancer metabolism is 
the use of stable isotopes, such as 13C  [267].  The primary goal of isotope 
experiments is to quantify the enrichment in a molecule resulting from the 
addition of an isotopically labeled tracer.  Stable isotopes are not radioactive and 
differ in the number of neutrons in the nucleus, which alters the mass but not the 
chemical behavior of the atom.  The use of stable isotopes in metabolic research, 
predates the use of radioactive isotopes [268].   
Metabolic fluxes, which are time-dependent reaction rates involved in 
cellular metabolism, cannot be directly observed but can be inferred from isotope 
experiments. Relative fluxes between pathways can be inferred from mass 
isotopomer analysis, while absolute fluxes can be determined using metabolic 
flux analysis [267, 269]. Differences in molecular weight that occur as a 
consequence of enrichment from an isotopically labeled tracer are usually 
represented as a mass isotopomer distribution (MID).  A MID of a metabolite, 
which is measured with mass spectrometry, represents the relative abundance of 
isotopomers that differ only by one or more atomic mass units [269].  The MID of 
a 6 carbon metabolite exposed to 13C will have up to 7 mass isotopomers: M0, 
M1, M2, M3, M4, M5, and M6, where the number following the M indicates the 
atomic mass shift from the base mass of M0.  It is important to note that a mass 
isotopomer does not provide positional information about which atoms are 
labeled.  For example, the M2 abundance of a metabolite labeled with 13C 
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reflects only the relative abundance of all isotopomers where 13C is found in any 




Figure 5.1.  Central carbon metabolism.  (A) Central carbon metabolism involves glycolysis, the pentose 
phosphate pathway (PPP), and the TCA cycle, which are linked by shared intermediates and play critical 
roles in biosynthesis, proliferation, as well as the production of energy and reducing equivalents. Glucose 
and glutamine are taken up from the extracellular environment and lactate, the primary product of glycolysis, 




For isotope labeling experiments, cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) containing uniformly labeled glutamine.  Some cells 
also received positionally labeled glucose.  Two forms of labeled media were 
prepared and are identified as M* and M** to indicate the number of labeled 
substrates.  The M* medium contained 2.5 mM [U13C] glutamine and 10 mM 
unlabeled glucose.  The M** medium contained 2.5 mM [U13C] glutamine and 10 
mM [1,213C] glucose.  Variations of each labeled media were prepared to support 
the normal growth conditions of each cell line.   For MCF10A cells, the media 
was supplemented with 5% horse serum, 1% insulin and 0.05% hydrocortisone.  
For MCF7 and MDA-MB-231 cells, the media was supplemented with 5% fetal 
bovine serum (FBS).  For SUM-149 cells, the media was supplemented with 5% 
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FBS, 0.5% insulin, and 0.1% hydrocortisone.  SUM-149 cells were grown in 10% 
CO2 and the remaining cells were grown in 5% CO2.  For each cell line specific 
media formulation, the M* and M** form of the media were chemically identical. 
Each cell line was grown to approximately 60 – 80% confluence in twelve 
6-cm dishes in unlabeled media.  For 1 h, cells were incubated in fresh media 
chemically identical (except for the tracer) to the labeled media to allow cells to 
stabilize from effects related to metabolic waste in the spent media.  After 1 h, 
four of the plates from each cell line were changed to 5 mL M* media and four of 
the plates from each cell line were changed to 5 mL M** media.  The remaining 
four plates from each cell line were saved for total protein analysis.  The cells 
were incubated for 5 h to achieve isotopic steady state.  A total of nine 6-cm 
plates of media only with no cells were simultaneously incubated as controls for 5 
h (three for each cell line media type).  After 5 h, all media were collected for 
extracellular flux determination.  Cells were washed and quenched with liquid 
nitrogen and immediately stored at -80 C for subsequent LC-MS analysis.   
Measuring Extracellular flux 
The concentration of glucose, lactate, glutamine, and glutamate were 
measured in fresh media and spent media (after 5 h of incubation) with a YSI 
2900D.  The rate of glucose and glutamine uptake and the rate of lactate 
production in each cell line were estimated from these data.  Metabolite 
concentrations in the 6 cm dishes that contained only media were used to correct 
for evaporation as well as degradation of glutamine, both of which were observed 
in pilot studies.   
In the 5 h control experiment, the effect of glutamine degradation was not 
found to be significant, but an increase in both glucose and glutamine 
concentration was observed in the control media (Figure 5.10A-B).  The lactate 
control media did not show a change between the 0 h and 5 h control 
concentrations, most likely because the starting lactate concentration was too 
low to be measurably effected by evaporative loss after only 5 h.  It is worth 
noting that the 0 h starting concentration of both glucose and lactate were 
measured higher than expected.  This difference was confirmed to be a 
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consequence of glucose and lactate in horse serum and fetal bovine serum (data 
not shown).   
Computational Simulation 
For metabolic flux analysis, OpenFlux [270] was used, which is an open 
source implementation of the elementary metabolite unit framework [271]. 
Confidence intervals were determined based on the non-linear method 
developed by Antoniewicz et al. for MFA [272] .  
5.3 Results 
Each of the four cell lines were grown in 13C labeled media for 5 h to 
achieve isotopic steady state (Figure 5.2).  All cells were grown in one of two 
forms of labeled media containing 2.5 mM glutamine and 10 mM glucose. The 
first contained [U13C] glutamine, and the second contained both [U13C] glutamine 
and ([1,213C]) glucose.  This first medium is represented as M* to indicate the 
presence of one labeled substrate, and the second medium is represented as 
M** to indicate the presence of two labeled substrates.  This tracer combination 
was chosen because previous studies have shown that [U13C] glutamine is best 
for resolving flux within the TCA cycle and [1,213C] glucose is the optimal glucose 
tracer for elucidating flux in glycolysis and the pentose phosphate pathway (PPP) 
[273].  
Most studies of mammalian cells indicate that isotopic steady state of 
central carbon metabolism occurs within 3 - 6 h [273-275].  A pilot study was 
performed to identify when isotopic steady state was reached in the cells used in 
this work. In agreement with other studies, glycolytic intermediates were near 
isotopic steady state in approximately 15 min, while TCA cycle intermediates 





Figure 5.2.  Evidence of isotopic steady state.  A time course of 13C enrichment after exposing cells to 
[U13C] glucose for 6 h is presented for 3 metabolites. Bars represent the mass isotopomer distribution (MID) 
of fructose-1,6-bisphosphate (FBP), citrate and malate measured at each time point.  Representative plots 
from MDA-MB-231 cells are shown.  Isotopic steady state assumes a quasi-metabolic steady state where 




Figure 5.3.  Carbon atom transitions.    When [1,213C] glucose is used as a tracer substrate, the 
conversion of (A) FBP to DHAP and GAP results in labeling of the 2nd and 3rd carbon positions of DHAP 
and no labeling in GAP.  (B) If the isomerization reaction between DHAP and GAP proceeds, then the 2nd 
and 3rd carbons of GAP become labeled. Thus, significant enrichment of 13C in GAP is only possible when 
DHAP isomerizes to GAP.  If a significant portion of DHAP is diverted to phospholipid synthesis, however, 
limited GAP labeling will result.   (B) GAP labeled on the 2nd and 3rd carbons will generate pyruvate labeled 
on the 2nd and 3rd carbon and, ultimately, fully labeled Acetyl-CoA (ACOA).  The carbons of CoA have 
been neglected because only the two carbons in the acetyl group of ACOA participate directly in central 
carbon metabolism.  Red circles indicate 13C and blue circles indicates 12C. 
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5.3.1 Natural abundance of stable isotopes 
13C is a stable isotope that naturally occurs at a non-negligible abundance 
of approximately 1.11% [276].  To accurately quantify enrichment for a 13C based 
tracer, the MIDs of each metabolite measured after exposure to 13C must be 
corrected for natural abundance of carbon as well as other atoms.  The 
probability that any given carbon atom position is naturally labeled by 13C follows 
a binomial distribution.  As a result, simply subtracting 1.11% of the mass from 
each isotopomer in a MID will neglect the non-linear labeling distribution inherent 
to natural 13C abundance and can lead to an underestimation of the experimental 
enrichment of 13C at higher masses [276, 277]. While it is especially important to 
correct MIDs measured by gas chromatography mass spectrometry (GC-MS) 
because the derivatizing agents generate fragments with very high masses, it is 
also necessary to correct MIDs measured by liquid chromatography mass 
spectrometry (LC-MS) before performing additional analysis or applying 
parameter estimation algorithms.  This work relied on the method developed by 
Fernandez et al. [276] for natural isotope correction to account for the non-
linearity inherent in natural isotope abundance.  A program written in Matlab was 
used to generate a set of corrected MIDs that was then used as input to the MFA 
algorithm.  
5.3.2 Mass isotopomer analysis 
Acetyl-CoA M2 enrichment 
As depicted in Figure 5.3, when [1,213C] glucose is used as a tracer, 
acetyl-CoA (ACOA) is expected to exhibit 13C enrichment in the M2 isotopomer.  
When cells were grown in the M* medium lacking labeled glucose, the normal-
like MCF10A and the IBC SUM-149 were the only cells to exhibit M2 label in 
ACOA (Figure 5.4).  In contrast, when cells were grown in M** medium, all four 
cell lines exhibited M2 enrichment in ACOA.  These data suggest that all ACOA 
flux is glucose derived in MCF-7 and MDA-MB-231 cells and that some ACOA 
flux is glutamine derived in MCF10A and SUM-149 cells.   
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Very little labeled ACOA was found across all the cell lines as a 
percentage of the total ACOA pool.  When [1,213C] glucose (which was used in 
the M** media) is the tracer, ACOA is expected to become labeled when DHAP 
isomerizes to GAP. Thus, it is reasonable to expect approximately half of ACOA 
to be labeled under these conditions in normal cells with active isomerization 
from DHAP to GAP.  SUM-149 cells exhibited the most ACOA labeling at 
approximately 20% of the total pool, and most of this label appeared to be 
glutamine derived.  In contrast, in a pilot study performed on MDA-MB-231 cells 
with [U13C] glucose, approximately 90% of ACOA was labeled within 5 h (data 
not shown).  The most likely explanation for the lack of significant label in the 
ACOA pool is that a significant flux to GAP (from intermediates of the non-
oxidative branch of the PPP) takes place in all the cells.   
 
 
Figure 5.4.  Enrichment of 13C in M2 Acetyl-CoA. (A)  MIDs of Acetyl-CoA (ACOA) produced by labeling 
with [U13C] glutamine (M*) or [U13C] glutamine and [1,213C] glucose (M**), normalized by total protein.  Data 
represent the average of 4 experimental repeats. (B) The same MIDs were normalized to 1.0 to reveal the 
proportion of enrichment of each isotopomer.  (C)  Comparison of M2 enrichment in ACOA after M* and M** 
labeling.  Data represent the average +/- the standard deviation of 4 experimental replicates.  M2 fractions 
statistically different from MCF-10A are indicated by * on each plot (p < 0.05).  All data were corrected for 
natural abundance of stable isotopes. 
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Figure 5.5.  Evidence of oxidative and non-oxidative flux in the pentose phosphate pathway. (A)  
MIDs of 6-phosphogluconate (6PG), an intermediate of the oxidative pentose phosphate pathway (PPP) 
branch, produced by labeling M* or M** media were normalized by total protein. (B) The same MIDs were 
normalized to 1.0 to reveal the proportion of enrichment of each isotopomer.  (C)  Comparison of M2 
enrichment in 6PG after M* and M** labeling. (D) MIDs of sedoheptulose-7-phosphate (S7P), an 
intermediate of the non-oxidative PPP branch, produced by labeling with M* or M**, were normalized by total 
protein. (E) The same MIDs were normalized to 1.0 to reveal the proportion of enrichment of each 
isotopomer.  (F)  Comparison of M4 enrichment in S7P after M* and M** labeling.  (G) Simplified schematic 
of the PPP pathway (blue nodes).  Ribose generated in the oxidative branch can be used for nucleotide 
synthesis (NTS).  All data represent the average of 4 experimental repeats and error bars reflect the 
standard deviation. M2 fractions statistically different MCF10A are indicated by * on each plot (p < 0.05).  All 
data were corrected for natural abundance of stable isotopes. 
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Pentose phosphate flux 
Cells utilize the pentose phosphate pathway (PPP) to generate reducing 
power and ribose for nucleotide biosynthesis. The PPP consists of oxidative and 
non-oxidative branches that operate in distinct modes, depending on the cell’s 
need for reducing power, ATP, and ribose [278].  The oxidative branch 
irreversibly converts glucose 6-phosphate (G6P) to ribulose 5-phosphate (R5P) 
and generates 2 molecules of NADPH, while the non-oxidative branch involves 
the reversible conversion of R5P to fructose 6-phosphate (F6P) or 
glyceraldehyde 3-phosphate (GAP) (Figure 5.1B and Figure 5.5G)   When the 
cell’s need for reducing power is very high, reverse glycolytic flux is possible from 
fructose 1,6-bisphosphate (FBP) to G6P and from G6P back into the oxidative 
branch of the PPP.  The glycolytic reaction that converts F6P to FBP is catalyzed 
by phosphofructokinase 1 (PFK1) and is effectively irreversible.  As a 
consequence, it is considered the first committed step of glycolysis.  The 
gluconeogenic enzyme fructose 1,6-bisphosphatase can catalyze the reverse 
reaction of FBP to F6P, however.  If a cell’s need for reducing power in the form 
of NADPH exceeds its need for ATP production, glycolytic flux can drive PPP 
cycling from the non-oxidative back to the oxidative branch of the PPP [278], 
presumably via this enzyme.  
6-phosphogluconate (GPG) is an intermediate of the oxidative branch of 
the PPP whose 6 carbon backbone comes from G6P (Figure 5.5G). In M** 
labeled samples with [1,2 13C] glucose, at least two thirds of the 6PG pool was 
labeled in all four cell lines, suggesting that there is significant oxidative PPP flux 
in these cells.  Surprisingly, when M* samples lacking labeled glucose were 
analyzed, MCF10A cells exhibited an M2 6PG pool of almost 20%, suggesting 
that some glutamine derived carbon is utilized via reverse glycolytic flux to 
generate reducing power in the oxidative branch of the PPP.  While some M2 
6PG was observed in the cancer cell lines after M* labeling, it represented a 
significantly smaller proportion of the total 6PG (Figure 5.5B), indicating that this 
behavior is likely to be characteristic of a normal metabolic phenotype.  
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Figure 5.6.  Enrichment of glycolytic intermediates. (A)  MIDs of the glucose 6-phosphate (G6P) and 
fructose 6-phosphate (F6P) pools, produced by labeling with M* or M**, were normalized by total protein. 
The G6P and F6P pools cannot be distinguished via LC-MS. (B) The same MIDs were normalized to 1.0 to 
reveal the proportion of enrichment of each isotopomer.  (C)  Comparison of M2 enrichment in 6PG after M* 
and M** labeling. (D)  MIDs of fructose 1,6-bisphosphate (FBP), produced by labeling with M* or M**, were 
normalized by total protein. (E) The same MIDs were normalized to 1.0 to reveal the proportion of 
enrichment of each isotopomer.  (F)  Comparison of M2 enrichment in FBP after M* and M** labeling.  All 
data represent the average of 4 experimental repeats and error bars reflect the standard deviation. M2 
fractions statistically different from MCF10A are indicated by * on each plot (p < 0.05).  All data were 
corrected for natural abundance of stable isotopes. 
103 
Sedoheptulose 7-phosphate (S7P) is an intermediate of the non-oxidative 
branch of the PPP (Figure 5.5G) and participates in highly reversible non-
oxidative reactions that involve R5P and GAP or erythrose 4-phosphate (E4P) 
and F6P.  In M** labeled samples, more than 80% of the S7P pool was labeled 
as M1 or higher in all cell lines, indicating non-oxidative PPP flux exists in all cell 
lines. In M* labeled samples lacking labeled glucose, no significant labeling was 
observed in S7P, however, indicating that the non-oxidative flux to S7P is largely 
glucose derived (Figure 5.5E).  While an M2 and M4 peak can be observed in 
SUM-149 cells under M* labeling conditions, the large error bars and lack of 
statistical difference with MCF10A cells suggests that the SUM-149 M2 
isotopomer may be the product of measurement errors (Figure 5.5F). 
The 6PG MIDs produced from M* labeling suggest that some amount of 
glutamine derived carbon makes its way to the oxidative branch of the PPP.  The 
MIDs of G6P/F6P (which cannot be separated via LC-MS) and FBP also suggest 
that a very small portion of their respective pools are in the M2 form when M* 
media is used (which contains labeled glutamine and no labeled glucose) 
(Figure 5.6).  While the data is equivocal, it does suggest that some form of 
reverse gluconeogenic-like flux may play a role in all of the cells, perhaps in an 
early transient phase prior to isotopic steady state.  In the future, more detailed 
time course experiments where MIDs of glycolytic and PPP intermediates are 
measured prior to isotopic steady state could help elucidate the mechanism by 
which 6PG becomes labeled with glutamine derived carbon.  Potential 
mechanisms include glycolytic oscillations and/or futile cycles, which are 
important in a number of tissues but have not, to my knowledge, been 
systematically explored within cancer cells. 
Reductive carboxylation in SUM-149 cells 
Several recent studies have demonstrated the importance of reductive 
carboxylation of alpha-ketoglutarate (AKG) in aggressive cancers.  In this type of 
metabolism, the conversion of glutamine derived AKG to isocitrate and CO2 is 
catalyzed by isocitrate dehydrogenase (IDH).  Isocitrate isomerizes to citrate, 
which ultimately generates ACOA for cytosolic fatty acid synthesis [279-282].  
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This type of reductive metabolism appears to be especially important in cancer 
cells with mitochondrial impairment [281].  
Cells use citrate to maintain both anaplerotic reactions in the TCA cycle 
and macromolecular synthesis in the cytoplasm [279].  Under sufficient oxygen, 
normal cells primarily generate citrate from glucose derived ACOA.  Under 
hypoxic conditions, however, glutamine has been shown to be a primary cellular 
source of citrate via reductive metabolism.  A variety of mutations in isoforms of 
IDH have been identified in cancer cells that drive reductive carboxylation of AKG  
[279-281], underscoring the importance that this metabolic process may have in 
cancer.   
When [U13C] glutamine is used as a tracer in cells undergoing reductive 
carboxylation of AKG, M5 citrate is expected to form [279, 280].  In Figure 5.7, 
citrate MIDs produced from M* and M** labeling are presented.  SUM-149 cells 
produce approximately 5 times as much M5 citrate compared to the other cell 
lines (Figure 5.7C), suggesting that the SUM-149 cells are actively metabolizing 
AKG via reductive carboxylation. 
When M5 citrate is formed from reductive carboxylation of AKG, the M5 
citrate can be metabolized in the cytoplasm to form M2 ACOA and M3 
oxaloacetate (OAA) via a reaction catalyzed by ATP citrate lyase. M3 OAA can 
then form M3 aspartate (via transamination) or M3 malate.  In contrast, in the 
mitochondrial oxidative reactions of the TCA cycle, M5 AKG will generate M4 
succinate, followed by M4 fumurate, M4 malate, and M4 OAA [279, 280]. 
The MID profiles of aspartate (Figure 5.8A-B) and malate (Figure 5.8D-E) 
after labeling with M* and M** are very similar. In the TCA cycle and in the 
cytoplasm, malate is converted to OAA, which equilibrates to form aspartate via a 
transaminase reaction.  Therefore, even though the OAA pool cannot be 
observed by LC-MS, its presence and labeling patterns can be inferred from 
malate and aspartate.  SUM-149 cells exhibit substantially more M3 aspartate 
(Figure 5.8C) and M3 malate (Figure 5.8F) than the other cell lines.  Together 
these data are in agreement with other studies that have identified reductive 
carboxylation as essential to glutamine dependent fatty acid synthesis under 
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hypoxic conditions. Evidence suggests that SUM-149 cells are adapted to 
hypoxia [283].  
Another possible metabolic pathway for M2 ACOA and M3 aspartate 
generated from reductive carboxylation of AKG in SUM-149 cells is the formation 
of the 5 carbon N-acetylaspartate (NAA), a free amino acid found in very high 
concentrations in the brain that is associated with a number of neuronal 
disorders.   There is some evidence to suggest NAA may also be a marker of 
neuronal mitochondrial dysfunction [284].  High concentrations of NAA were 
recently reported in ovarian tumors [285, 286].  In addition, NAA levels, along 
with the related compound N-acetyl-aspartylglutamate (NAAG), were found to 
strongly correlate with primary epithelial ovarian cancer and metastatic ovarian 
tumor samples in a large scale metabolomics analysis of 100 ovarian tumor 
biopsy samples [287].  In the brain, NAA is thought to control osmotic stress as 
well as play a role in fatty acid and myelin synthesis [284, 287]. It is possible that 
NAA also plays some role in the fatty acid synthesis of aggressive breast and 
ovarian cancer cells.   
The MIDs of NAA after M* and M** labeling are presented in Figure 5.9.  
All cell lines except for MCF7 exhibit some amount of 13C labeling in NAA, though 
the majority of the NAA pool in all cell lines in unlabeled.  In the MDA-MB-231 
and SUM-149 metastatic cell lines, the MIDs suggest that NAA labeling is almost 
exclusively glutamine derived (given that there is no observable difference in 
labeling between the M* and M**).  In MCF10A, however, the NAA label appears 
to derive from both glucose and glutamine.  It is also interesting that, while MCF7 
and SUM-149 cells appear to exhibit similarly large NAA pool sizes in the MIDs 
normalized by total protein (Figure 5.9A), virtually no labeled NAA is found in the 
MCF7 primary tumor cells.  These data suggest the glutamine derived NAA may 
be important to the metastatic metabolic phenotype but not to the non-invasive 
phenotype.   
The functional role of NAA in breast and ovarian cancer is unknown. The 
large NAA pool size in SUM-149 cells (approximately 20% of which is labeled) 
suggest that NAA could play a metabolic role in these cells. Given the large 
106 
unlabeled pool size in MCF7, the data presented here are equivocal.  It is 
possible that the NAA in SUM-149 cells represents a sink for access M2 ACOA 
and M3 aspartate generated from reductive carboxylation reactions.  Given the 
aggressiveness of IBC, additional investigation of the role of NAA in SUM-149 
and other IBC cell lines is warranted.  
 
 
Figure 5.7.  Enrichment of 13C in M5 Citrate in SUM-149 cells. (A)  MIDs of citrate produced by labeling 
with M* or M**, normalized by total protein.  (B) The same MIDs were normalized to 1.0 to reveal the 
proportion of enrichment of each isotopomer.  (B)  Comparison of M5 enrichment in citrate after M* and M** 
labeling.  Data represent the average +/- the standard deviation of 4 experimental repeats.  M5 fractions 
statistically different from MCF10A are indicated by * on each plot (p < 0.05).  All data were corrected for 





Figure 5.8.  Enrichment of 13C in M3 Malate and M3 Aspartate in SUM-149 cells. (A)  MIDs of malate 
produced by labeling with M* and M**, normalized by total protein. (B) The same MIDs were normalized to 
1.0 to reveal the proportion of enrichment of each isotopomer.  (C)  Comparison of M3 enrichment in malate 
after M* and M** labeling. (D)  MIDs of aspartate produced by labeling with M* or M**, normalized by total 
protein. (E) The same MIDs were normalized to 1.0 to reveal the proportion of enrichment of each 
isotopomer.  (F)  Comparison of M3 enrichment in aspartate after M* and M** labeling.  All data represent 
the average of 4 experimental repeats and error bars reflect the standard deviation.  M3 fractions statistically 
different from MCF10A are indicated by * on each plot (p < 0.05).  All data were corrected for natural 




Figure 5.9.  Evidence of glutamine derived 13C enrichment in N-acetylasparate in SUM-149 cells. (A)  
MIDs of N-acetylasparate (NAA) produced by labeling with M* or M**, normalized by total protein. (B) The 
same MIDs were normalized to 1.0 to reveal the proportion of enrichment of each isotopomer.  All data were 
corrected for natural abundance of stable isotopes. 
 
5.3.3 Estimation of extracellular flux 
The extracellular flux of glucose, lactate, and glutamine was estimated by 
measuring the change in the concentration of these metabolites in each cell line’s 
media after 5 h of incubation in labeled media (Figure 5.10A).  In pilot studies, 
the concentration of glucose was observed to increase significantly in incubated 
media when no cells were present.  This change is assumed to be caused by 
evaporative water loss.  In addition, glutamine concentration has also been 
observed to decrease in incubated media when no cells were present (data not 
shown), which is a known phenomenon [239].  To control for changes in 
extracellular metabolite concentration not related to cellular uptake or secretion, 
control media were also incubated for 5 h without cells.  The concentrations in 
the control media after 5 h were used to calculate the rate of extracellular flux in 
cell culture media (see Methods for more details). 
The estimated flux in mM/h of glucose uptake, lactate production, and 
glutamine uptake in each cell line’s media is presented in Figure 5.10B. The net 
concentration change in mM of each metabolite after 5 h is also shown as a 
function of total protein (Figure 5.10C).  From these data, it is apparent that 
SUM-149 cells are producing a large of amount of lactate relative to the other cell 
lines.  Of interest is the observation that the ratio of glucose to lactate in SUM-
149 cells is approximately 1 to 2, which is the stoichiometric ratio expected when 
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all or most glucose is converted to lactate via glycolysis.  This finding suggests 
that very little glucose is oxidized in the mitochondria of SUM-149 cells.   
Extracellular and intracellular flux values are typically represented as 
nmol/min/mg protein.  The estimated extracellular flux values in Figure 5.10B 
were converted to nmol/min/mg units for comparison with other flux studies 
(Figure 5.10D).  For MCF10A, the rate of glucose uptake was estimated to be 
8.9 nmol/min/mg, which compares favorably to the glucose uptake rate of 13.3 
nmol/min/mg reported for MCF10A cells in a study by Richardson et al. [288].   In 
a study using the A549 lung cancer cell line, Metallo et al. [273] reported 
extracellular rates of 45, 75, and 10 nmol/min/mg for glucose uptake, lactate 
production, and glutamine uptake, respectively.  The order of magnitude of these 
rates is similar to the rates estimated for the cancer cell lines in this study 
(Figure 5.10D).  
 
 
Figure 5.10.  Estimation of extracellular flux.  (A) The concentration of glucose, lactate, and glutamine 
were measured in fresh media (0 h), media incubated without cells for 5 h (control), and media incubated 
with cells for 5 h.  For the 0 h and 5 h control samples, bars represent the average of 3 experimental repeats 
+/- the standard deviation. For the 5 h samples with cells, bars represent the average of 8 experimental 
repeats +/- the standard deviation for each cell line. Metabolite measurements were obtained using a YSI 
2900D analyzer.  (B)  The rate of change (mM/h) of each metabolite in each cell line’s media after correction 
and (C) the change after 5 h of each metabolite after correction and normalization by total protein.  (D) The 
extracellular flux rates converted to nnmol/min/mg. All cells were cultured in 5 mL of media. 
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5.3.4 Estimation of intracellular TCA cycle flux 
Metabolic Flux Analysis 
Metabolic flux analysis (MFA) is a technique developed in the metabolic 
engineering field [271, 272, 289, 290] for the absolute estimation of the steady 
state flux in cells.  MFA requires knowledge of carbon atom transitions involved 
in glucose metabolism (Figure 5.3), measurements of MIDs after the introduction 
of a tracer, and a system at isotopic steady state (Figure 5.2). If all metabolic 
fluxes are known, a unique mathematical solution exists for the isotope 
distribution generated for any tracer combination at metabolic steady state [272, 
291]. The objective of MFA is to solve the more difficult inverse problem of 
identifying unknown fluxes from a small subset of measured MIDs.  In steady 
state 13C MFA, the set of reactions involved in the metabolic network under study 
are mathematically represented as balance equations describing the system at 
steady state.  
 The system can be expressed as Sv = 0, where S is a stoichiometric 
matrix of the metabolic reactions and v is the vector of unknown fluxes [272, 291-
293].  The problem is made more complicated by the fact that each possible 
positional isotopomer of a metabolite must be accounted for in the balance 
equations.  For a metabolite containing n carbon atoms, there are 2n positional 
isotopomers [271] and this large number of positional isotopomers generates an 
extremely large system of equations.  While the mathematics of MFA are well 
understood [272, 291, 293-297], a number of different computational approaches 
for solving the underdetermined metabolic system in MFA have been developed 
[271, 291, 296, 298].  Importantly, each of these methods have been shown to 
converge to the same solution [271].  The most common computational approach 
presently used is the elementary metabolite unit (EMU) method [271]. The EMU 
approach eliminates unnecessary computational overhead by only including 
those isotopomers in the balance equations that can theoretically be obtained 
from the tracer used and the atom transitions involved in the metabolic network.  
In this work, an open-source implementation of the EMU framework called 
OpenFlux [299] was used.  
111 
Regardless of the underlying computational approach used to generate 
balance equations, ultimately MFA must solve a constrained least squares 
optimization problem where the difference between experimentally observed 
MIDS and simulated MIDs is minimized [271, 300].  In addition to the assumption 
of isotopic steady state, 13C MFA requires explicit knowledge of all carbon atom 
transitions involved in the network under study (Figure 5.3).  Many of the 
reactions involved in central carbon metabolism are well characterized and this 
information can be found in the literature [270, 273] and in many biochemistry 
text books  [301].   
MFA has traditionally relied on MIDs determined by gas chromatography 
GC-MS [267].  As a consequence of the fairly high turn-over and relatively low 
concentrations of metabolic intermediates, methods based on GC-MS and 
nuclear magnetic resonance (NMR) typically must infer 13C labeling patterns in 
metabolic intermediates.  This inference is usually accomplished by obtaining 
MIDs of biomass components involved in central carbon metabolism, such as 
protein-bound amino acids [267, 302]. Recently, however, LC-MS has also been 
used for MFA.  In contrast to GC-MS, LC-MS allows for the direct measurement 
of several metabolic intermediates involved in central carbon metabolism [302]. 
TCA Cycle model 
MFA was used to estimate the intracellular flux in a simplified model of the 
TCA cycle in all four cell lines.  The reactions and associated carbon atom 
transitions used in the model are summarized in Figure 5.11 and Table 5.1.  
Measured MIDs of aspartate, citrate/isocitrate (which cannot be distinguished by 
LC-MS), glutamate, lactate, malate, and ACOA after labeling with M** media 
were used as model input.  The fitted fluxes generated by the model and their 




Figure 5.11.  Metabolic model of TCA cycle used in metabolic flux analysis.  Numbers to the bottom 
right of a metabolite indicate the number of carbons.  Glycolytic and pentose phosphate reactions have been 
neglected.  For bidirectional reactions, the direction treated as the forward direction is represented by a 
larger arrow head. Metabolites in colors other than light grey indicate the metabolite appears in more than 
one reaction.  For clarity, colored arrow pairs indicate all reactants involved in an overall reaction.  
Abbreviations: AKG – alpha-ketoglutorate, FAS – fatty acid synthesis, OAA – oxaloacetate. 
 
Extracellular flux rates can be used as constraints for solving the 
underdetermined system in MFA.  In these simulations, the glutamine uptake 
was set to 1 nmol/min/mg and the final fluxes were scaled by the measured 
glucose uptake flux (Figure 5.10D).  The simulations did not explicitly constrain 
the glucose and lactate fluxes in the fitting procedure because it is informative to 
see how closely the measured extracellular fluxes are to the fitted extracellular 
flux when they are allowed to fit freely.  For MDA-MB-231 and SUM-149 cells, 
the glucose uptake and lactate production rates estimated by MFA are very close 
to the measured values (Figure 5.10D and Table 5.2).  For MCF7, however, 
MFA estimated the lactate production to be 14.7 nmol/min/mg, which is larger 
than the measured value of 4.1 nmol/min/mg.  For MCF10A, MFA estimated the 
lactate production rate to be 18.0 nmol/min/mg, which is also larger than the 




Acetyl-CoA and citrate flux 
In the pyruvate dehydrogenase (PDH) reaction that converts pyruvate to 
ACOA, the fitted flux values for MCF10A and SUM-149 cells were very low (0.2 
and 0.4 nmol/min/mg, respectively).  In contrast, the fitted fluxes in MCF7 and 
MDA-MB-231 reactions were much higher (10.1 and 15.8 nmol/min/mg, 
respectively).   This difference can be attributed to the fitted lactate production 
fluxes in MCF10A and SUM-149 cells.  In these cells the lactate production rate  
was fitted at almost exactly two times the glucose uptake rate, which effectively 
means the model simulated that virtually all glucose in the system was eventually 
converted to lactate, leaving little excess pyruvate for the PDH reaction.    
The ACOA and OAA condensation reaction that forms citrate had a net 
negative fitted flux in all the cell lines. For simplicity, the model did not assume 
any compartmentalization and treated all ACOA as a single pool.  In reality, the 
reactions involving ACOA are very different in the mitochondria and the 
cytoplasm.  In the mitochondria, citrate synthase catalyzes the reaction between 
ACOA and OAA to form citrate.  In the cytoplasm, ATP citrate lyase cleaves 
citrate to make OAA and ACOA and requires the input of ATP.  The availability of 
cytoplasmic ACOA is important for biosynthetic processes, such as fatty acid 
synthesis.  As previously discussed, this reaction is also very important in 
reductive carboxylation reactions in some cancer cells.   
While the MCF7 and MDA-231 cells had negative net fitted flux toward 
citrate of -0.7 and -9.0 nmol/min/mg, they both had relatively large forward 
reaction fluxes of 94.3 and 13.1 nmol/min/mg, respectively.  This result suggests 
that, while the ATP citrate layase reaction fluxes were larger in these cells, the 
mitochondrial citrate synthase reaction was still very active.  In contrast, both 
MCF10A and SUM-149 cells had fitted flux toward citrate of 0.0 nmol/min/mg, 
indicating that the mitochondrial citrate synthase reaction was not active in these 
cells in the simulations. The lack of citrate synthase flux is likely a function of the 
very low fitted flux to ACOA in these cells.  While there is some evidence from 
work in the Merajver lab that citrate synthase may be less active in SUM-149 
cells (data not shown), it is unlikely that there would be no flux to mitochondrial 
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citrate in the normal-like MCF10A cells.  Additional experimental validation of this 
result is warranted. 
Treating ACOA as two distinct pools in the model, rather than one, may 
improve the predictive power of the model.  At least one other MFA study of 
cancer cells treated ACOA as two distinct pools [273].  That study used GC-MS, 
however, and ACOA MIDs were not used as model input as they were in this 
study.  With LC-MS ACOA can be directly measured.  The inclusion of direct 
measurement of ACOA labeling is expected to be important for discerning flux to 
the TCA cycle.  If ACOA is treated as two spatially separate pools in the model, 
then ACOA MIDs should not be used as input to the model.  This is because the 
model would assume both pools have identical labeling, which is not likely to be 
the case.  A future iteration of the model will explore the effect of treating ACOA 
as a mitochondrial pool and a cytoplasmic pool.   
Pyruvate flux 
The fitted flux estimates suggest that the pyruvate carboxylase reaction, 
which converts pyruvate directly to OAA, was not very active in the MCF10A and 
MCF7 cells but was very active in the MDA-MB-231 and SUM-149 cells (with 
fitted flux values of 15.8 and 17.1 nmol/min/mg, respectively).  MFA also 
estimated that all cells had a positive net flux in the malic enzyme reaction that 
converts malate to pyruvate.   Malic enzyme has been suggested as important in 
some cancers [6, 303], possibly because the reaction can be used to produce 
additional NADPH [6].  Separate studies of MCF10A cells [288] and MCF7 cells 
[304] concluded that malic enzyme is not active in these cells. The latter study 
looked at intra-mitochondrial malic enzyme, however.  It is possible that cytosolic 
malic enzyme is important in breast cancer [303].  Additional isotope experiments 
and kinetic studies will be necessary to elucidate the nature of pyruvate flux and 






Table 5.1.  Carbon atom transitions used in metabolic flux analysis model of the TCA cycle. 
Reactions assumed to be non-reversible in the model are indicated by NR.  The forward (F) and reverse (R) 
directions of a reversible reaction in the model are listed sequentially and shaded the same color. Letters are 
used to identify carbon scrambling in a reaction.   
Reaction Carbon Transitions Enzyme Type 
glucose → PYR + PYR abcdef → cba + def glycolytic enzymes NR 
PYR + CO2 → OAA abc + d → abcd citrate synthase NR 
MAL → PYR + CO2 abcd →  abc + d 
malic enzyme 
F 
PYR + CO2 → MAL abc + d →  abcd R 





ACOA + OAA → CIT ab + cdef → fedbac citrate synthase F 
CIT → ACOA + OAA fedbac → ab + cdef ATP citrate lyase R 




AKG + CO2 →  CIT abcde + f → abcdef R 





SUC + CO2 → AKG bcde + a → abcde (not generally reversible) R 




MAL → 0.5 SUC + 0.5 SUC abcd → 0.5 abcd + 0.5 dcba R 
OAA → MAL abcd → abcd malate 
dehydrogenase 
F 
MAL → OAA abcd → abcd R 
glutamine → GLU abcde →   abcde glutanimase F 
GLU → glutamine abcde → abcde glutamine synthetase R 
GLU → AKG abcde → abcde glutamate 
dehydrogenas 
F 
AKG → GLU abcde → abcde R 
PYR + GLU → ALA + AKG abc + defgh → abc + defgh transaminase NR 
OAA + GLU → ASP + AKG abcd + efghi → abcd + efghi 
transaminase 
F 
ASP + AKG → OAA + GLU abcd + efghi → abcd + efghi R 
PYR → lactate abc →  abc lactate 
dehydrogenase  
F 
lactate → PYR abc → abc R 
ACOA → FA ab →   ab acetyl-CoA carboxylase, others NR 
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Table 5.2.  Estimated TCA cycle flux.  Foreword reactions are on the left side of the reaction.  Net flux in 
nmol/min/mg is displayed with the 95% confidence interval. For all reversible reactions, identified by a 
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ACOA + OAA ↔ 
CIT 
-0.7 (0.0) [-0.7,    -0.7] 
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0.0] 
PYR ↔ LAC 18.0 (47.4) 
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Succinate is formed in the TCA cycle from AKG in a reaction catalyzed by 
enzymes associated with the oxoglutarate dehydrogenase complex.  This 
reaction is considered one of the non-reversible steps in the TCA cycle.  I was 
not able to achieve an acceptable convergence of the flux solution with MFA 
without making the AKG to succinate reaction reversible, however.  The fitted net 
fluxes reported in Table 5.2 for AKG to succinate are negative in all cell lines.  
Given the low probability that all four cell lines have a mutation that renders this 
reaction reversible, it is likely that the model is structurally incomplete with 
respect to succinate. Succinate cannot be measured by LC-MS but is frequently 
measured in GC-MS [273, 280] and NMR [288] flux studies.   At least a few 
studies have reported a significant dilution flux in succinate [273, 280], the source 
of which was not identified. The predictive power of the model presented may be 
improved by including a dilution flux of an unknown source.  Additional 
clarification of the pathways involved in succinate formation and metabolism is 
needed.   
5.4 Discussion 
The experimental data and computational fitted flux values presented in this 
chapter suggest that some observable network differences exist in the 
metabolism of the four cell lines studied.  It is likely that metabolic transformation 
occurs as a cancer continues to adapt and become more aggressive over time.  
Metabolic changes that are representative of distinct stages of breast cancer may 
suggest dependence by those cells on certain metabolic processes that are not 
relevant to normal cells (for example, a dependence on reductive carboxylation 
for proliferation).  Importantly, the identification of such differences may help 
identify therapeutic targets that are non-lethal to normal cells.   
The fitted flux values of the TCA cycle suggest some interesting metabolic 
differences across the cell lines, including variations in ACOA, citrate, pyruvate, 
and AKG flux. In addition, there were significant differences in the fitted flux 
values from ACOA to fatty acid synthesis (Table 5.2).  It is important to note, 
however, that the fitted flux values presented here are based on a model that 
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considered the TCA cycle reactions only (Figure 5.11).  The next iteration of this 
model is under construction (Figure 5.12) and will include the PPP and glycolytic 
reactions.  It is expected that the larger model will be more predictive and able to 
further elucidate differences in flux related to the malic enzyme, citrate synthase, 
ATP citrate lyase, and fatty acid synthesis reactions as well as differences in 
oxidative and non-oxidative flux in the PPP.  The source of ACOA flux will be 
particularly important to resolve in all the cell lines.  MCF10A and SUM-149 cells 
exhibited MIDs that suggest ACOA flux is derived from both glucose and 
glutamine.  In contrast, MCF7 and MDA-MB-231 MIDs suggested that ACOA flux 
in these cells is only derived from glucose (Figure 5.4).    
Glutamine is clearly a very important substrate in cancer [4, 7, 280, 282, 
305] and significant glutamine derived 13C labeling was observed in many 
metabolites in this study (Figure 5.4, Figure 5.7, Figure 5.8, and Figure 5.9).  
Despite the importance of glutamine, the glutamine uptake rate is significantly 
lower than the glucose uptake rate making it more sensitive to measurement 
errors. Using more accurate measurements of the extracellular flux of glutamine 
in cell culture media to constrain the MFA model may improve the predictive 
power of the MFA simulations.  While total protein was used to normalize for cell 
density differences across the cell lines at the time of labeling, a few of the cell 
lines exhibited confluence around 60% rather than the 80% of the other cell lines. 
Lower confluence may have been a source of measurement error in the 
glutamine flux because fewer cells will consume fewer moles of glutamine, 
affecting the detectable concentration changes in solution.  Another possibility for 
improving the accuracy of glutamine concentration measurements in media is to 
culture cells for 5 h in 3 mL of media rather than 5 mL.  For example, if we 
assume the glutamine uptake rate is 1.4 nmol/h, then after 5 h the concentration 
change expected in 5 mL is 0.084 mM, while the concentration change expected 
in 3 mL is 0.14 mM. The latter net change should be more resistant to 
experimental and technical errors.   
The isotopomer data strongly supports a role for reductive carboxylation of 
AKG in the highly aggressive SUM-149 cells.  This process provides cancer cells 
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with an additional source of NADPH as well as precursors for cytosolic fatty acid 
synthesis. Evidence suggests that a reliance on this type of metabolism is 
induced by hypoxia [279].  Silvera et al. referred to SUM-149 cells and other IBC 
cells as “constitutively adapted to hypoxia” because of their upregulation of a 
number of genes and proteins associated with a hypoxic response [283].  These 
workers suggested that the hypoxic phenotype may confer the ability to produce 
proteins that promote the proliferation and survival of the highly angiogenic 
emboli associated with IBC.  It is also possible that a prolonged state of hypoxic 
like conditions confers certain metabolic advantages, perhaps related to 
reductive carboxylation.  Studying the metabolism of other IBC cells to identify if 
reductive carboxylation is a universal IBC phenotype or if it is specific to some 
subtypes will be important for future studies.   
 
 
Figure 5.12.  Larger model of central carbon metabolism.  Numbers to the bottom right of a metabolite 
indicate the number of carbons.  Glycolytic and pentose phosphate reactions have been neglected.  For 
bidirectional reactions, the direction treated as the forward direction is represented by a larger arrow head. 
Metabolites in colors other than light grey indicate the metabolite appears in more than one reaction.  Refer 
to list of abbreviations for metabolite names.  
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Chapter 6  




New approaches for treating aggressive breast cancer are needed.  
Targeted molecular inhibitors frequently induce off-target effects as well as drug 
resistant clones capable of evading therapy.   The complexity of intracellular 
networks makes the prediction of off-target effects difficult.  Developing new 
basic science approaches that integrate experimental and theoretical methods to 
study breast cancer as a complex and adaptive system should generate 
predictive models that can be used to make rational predictions about candidate 
drug targets as well as the likelihood of potential off-target effects.   
This thesis includes a set of models that represent a step toward that goal. 
Chapter 2 introduced the theory of parameter-free logic-based network models 
for studying the dynamics of signaling networks, while Chapter 3 presented an 
application of this theory for studying the PI3K signaling network in progressively 
tumorigenic breast cancer cells.  Chapter 4 introduced the concept of 
retroactivity and presented a differential equation based model designed to 
investigate the likelihood that retroactivity may be a cause of off-target effects 
from targeted kinase inhibitors.  Chapter 5 relied on experimental and theoretical 
applications of 13C based isotope tracers to help elucidate differences in 
intracellular reaction rates in progressively tumorigenic breast cancer cells. 
An objective of systems biology is the elucidation of systems level 
properties associated with a complex phenomenon that cannot be readily 
observed via experimental methods alone.   A critical component of successful 
systems biology is the iterative development of theoretical models from 
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experimental data.  The models in Chapter 3 and Chapter 5, which relied 
directly on experimental data collected from breast cancer cells, should be 
refined, as discussed in each chapter, to improve each model’s predictive 
capacity.   
6.2 Future work 
Cancer exhibits a number of emergent and adaptive behaviors.  A typical 
solid tumor contains 109 cells and each cell contains a set of complex 
intracellular networks that control gene regulation, signal transduction, cell cycle 
progression, and metabolism.  Cancer cells seem remarkably well equipped to 
survive in a variety of inhospitable conditions.  Changes in a tumor’s macro 
environment, such as the presence of anti-cancer therapeutics, increased 
acidification, or hypoxia, select for cells that will survive and thrive in these 
conditions, giving rise to new, perhaps more virulent, sub-clones within the 
tumor. To design new and effective strategies for treating aggressive cancers, we 
must consider the underling complexity inherent to a tumor as well as a single 
cancer cell.  We must build models that can more accurately predict the outcome 
of introducing a perturbation within a single cell as well as within a population of 
cells.  To do so requires the development of models that span the varied spatial 
scales within a tumor and incorporate the process of clonal evolution. 
The importance of metabolic regulation  
Warburg was the first to observe the high rate of glucose uptake and 
lactate production associated with tumors. FDG-PET scans are a routine cancer 
diagnostic tool because they provide evidence of the glucose uptake rate in a 
tumor, which correlates with proliferation and aggressiveness. The in vitro model 
of breast cancer progression used in this thesis recapitulated this phenotype, as 
shown in Figure 5.10.  The near universality of the Warburg effect across very 
different cancers in very different tissues (compared to the extreme heterogeneity 
of genetic lesions and protein deregulation in cancer), suggests that cancers are 
most likely exploiting an existing (rather than evolving a new) metabolic program.   
If tumors were actively selecting for novel metabolic programs via somatic 
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evolution, more metabolic variation than has been reported thus far would be 
expected.   It appears, instead, that cancer cells rely on an evolutionarily 
conserved form of proliferative metabolism.  As cancers continue to progress 
they appear to acquire mutations that help sustain this metabolic program.   
Future predictive models of cancer will ideally incorporate metabolism and its 
regulation. 
Developing a hybrid model of glucose metabolism and PI3K signaling  
I plan to further develop the model of PI3K signaling presented in Chapter 
3 by completing a detailed sensitivity analysis to evaluate the relative importance 
of each feedback regulation included in the network and by validating successive 
iterations of the model with experimental data.  Once satisfied that the normal 
like-model is representative of normal-like breast epithelial PI3K signaling, it will 
become the normal-like baseline for future models.   
Likewise, once the next iteration of the metabolic flux model presented in 
Chapter 5 has been refined, the estimated intracellular flux values for each 
reaction can be used to estimate kinetic parameters for a normal-like ODE model 
of central carbon metabolism as well as for models representative of distinct 
stages of breast cancer progression.   The continuous ODE model of metabolism 
and the discrete logic model of PI3K signaling (with links to glucose metabolism 
and the MAPK pathway) can then be combined into a hybrid discrete continuum 
model as discussed in the Future directions section of Chapter 3.  Because 
most models and control theories of metabolism assume constant enzyme 
concentrations, a primary objective of this model will be the inclusion of enzyme 
synthesis and regulation. 
Developing a multiscale model of breast cancer  
Tumors are highly complex, consisting of many layers of spatial 
complexity that dynamically interact across a wide range of timescales, spanning 
seconds for post-translational modification to years for cancer progression and 
metastatic growth.  Some of the models presented in this thesis can be used to 
develop a multiscale model of breast cancer.  Multiscale models incorporate the 
effects of multiple non-linear processes into coherent structures that can then be 
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used for hypothesis testing or the generation of experimentally testable 
predictions.   
In addition to the intracellular models presented in this thesis, I have also 
developed a discrete agent based model (ABM) of neural crest cell migration 
[306].  ABMs are simulation techniques that rely on computing power to 
investigate complex phenomena that cannot readily be explored by experimental 
methods. ABMs consist of autonomous decision-making entities called agents 
that execute behaviors according to a set of rules defined from empirical or 
experimental observations.   
A long term goal is to extend the ABM framework already developed to 
support a model of mammary cell proliferation capable of simulating malignant 
transformation in mammary epithelial tissue. The planned ABM simulation 
domain will consist of a circular layer of luminal epithelial cells arranged to mimic 
a normal hollow mammary duct (Figure 1.1A). Each luminal epithelial cell will be 
represented as an autonomous agent whose behavior is determined by a set of 
pre-defined rules based on interactions with other agents and scales in the 
model.  Ultimately, the full model will link several additional spatial and temporal 
scales of ductal epithelial growth, including a large genetic network, a cell cycle 
clock, and tissue level dynamics (such as oxygen consumption and lactate 
production rates, which will be outputs of the metabolic scale of the model).  The 
planned hybrid model of glucose metabolism and PI3K signaling will be an 
integral part of this model.   
A primary output of this future model will be the extent of ductal 
proliferation, oxygen consumption, and tissue acidification rates under a variety 
of initial conditions. The ultimate goal will be the generation of predictions related 
to system level differences between normal and malignant mammary cell 
proliferation, which can be used to elucidate details of metabolic control within 
cancer cells.   
Although the integration of intracellular molecular networks as a means of 
understanding targeted therapy resistance and off-target effects is often 
mentioned as a goal in the literature, tools to accomplish this have not been 
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developed for broad application.  This thesis provides a framework for building 




Appendix A  
Additional Analyses for Chapter 2 
 
 
Network node reductions are often essential in complex logic networks. An 
example of node reduction from in a logic network is presented in Figure A1.  In 
this example, AKT inhibits BAD in the interaction network (Figure A.1A). Both 
BAD and P53 are positive regulators of BAX, which is a direct regulator of 
apoptosis in this network.  It is assumed in this logic network that both the 
activation of BAD (by AKT inhibition) and the activation of P53 are required to 
induce apoptosis: the activation of only one or the other will not induce apoptosis.   
Given the logic network in (Figure A.1B) and the linear relationship between 
AKT and BAD, the logic network can be further simplified by removing the BAX 
node and making AKT a direct inhibitor of apoptosis (Figure A.1C). 
 
Figure A.1.  Network reduction example with linear regulations. (A) Interaction network with AKT 
inhibiting BAD.  (B)  Logic network assuming that both P53 and BAD are both needed activate BAX. (C) 
Equivalent logic network after BAX is removed 
Importantly, node network reductions should generate the same 
qualitative behavior in a network.  In Figure A.2, the comparison of output from 
the full and reduced hypothetical network examples with 12 nodes and 4 nodes, 
respectively, is presented.  As can be seen in the synchronous plots at the top of 
Figure A.2A and Figure A.2B, the same qualitative output is produced in both 
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forms of the network model.  The most striking difference in this example is the 
length of the oscillations produced by the two models.  Depending on the initial 
conditions chosen (this example was randomized), the length of the oscillations 
may be shorter than that observed in Figure A.2A (data not shown). 
 
 
Figure A.2.  Qualitative comparison of output from the full and reduced hypothetical network 
examples with 12 nodes and 4 nodes.  (A)  Synchronous (top) and asynchronous (bottom) simulations for 
the 12 node network presented in Figure 2.2 of the main text.  (B) Synchronous (top) and asynchronous 
(bottom) simulations for the reduced 4 node network presented in Figure 2.3 of the main text.  The reduced 
logic network was derived by lumping linear regulations into a single regulation, as described in the main 
text.  Input conditions used for the simulations:  input node ON in all cases; all other node values randomly 
selected.  Asynchronous simulations included 100 repeated simulations to get a probability that a node was 




Appendix B  
Additional Analyses for Chapter 3
 
Table B.1 summarizes simulation results for the network model in Figure 3.5 
when the AND logic function is used to regulate AKT instead of the OR logic 
function (Table 3.4).  Under AND regulation of AKT, the MCF10A and MDA-MB-
231 cells compared most favorably to conditions where PTEN is OFF.  The 
experimental data indicate that PTEN is present and activate in these cell lines, 
however.  In contrast, both cell lines compared more favorably to network 
simulations where PTEN is ON in the version of the network model that regulated 
AKT with an OR logic function, which is the expected outcome. 
 
Table B.1. Oncogenic perturbations to the PI3K/MAPK cross-talk model with AKT regulated by AND.  
The table summarizes the difference in in silico simulated results and the experimental in vitro results by 
displaying the total AKT, total ERK and total combined cost penalty for each cell line and each condition.   
The conditions that generated the lowest total cost penalty are displayed in green and the conditions that 
generated the highest total cost penalty are displayed in red for each cell line. A penalty of 0.00 indicates 






Appendix C  
Additional Analyses and Model Details for 
Chapter 4 
 
C.1 Non-dimensionalization of the n = 3 network  
In order to reduce the complexity of the networks studied, model 
parameters were non-dimensionalized.  The following explains the non- 
dimensionalization of the n = 3 network.  The dimensionless parameters of the n = 
5 and n = 7 vertical and lateral networks’ were obtained in a similar manner.  The 
ODEs and conservation laws governing the n = 3 network (Figure 4.2C) at steady 




= 𝑘1[𝐶1] −  𝑎1′ [𝑌𝑖∗]�𝐸𝑝1� +  𝑑1
′ [𝐶1′] 
 − 𝑎2[𝑌2][𝑌1∗] + (𝑑2 + 𝑘2)[𝐶2]   
 − 𝑎3[𝑌3][𝑌1∗] + (𝑑3 + 𝑘3)[𝐶3] = 0    
𝑑[𝐶1]
𝑑𝑡
= 𝑎1[𝑌1]�𝐸𝑘1� − (𝑑1 + 𝑘1)[𝐶1] = 0    
𝑑[𝐶1′]
𝑑𝑡
= 𝑎1′ [𝑌𝑖∗]�𝐸𝑝1� − (𝑑1
′ +  𝑘1′ )[𝐶1′] = 0    
𝑑[𝑌2∗]
𝑑𝑡
= − 𝑎2′ [𝑌2∗]�𝐸𝑝2� + 𝑑2
′ [𝐶2′] + 𝑘2[𝐶2] = 0 
𝑑[𝐶2]
𝑑𝑡
= 𝑎2[𝑌2][𝑌1∗] − (𝑑2 + 𝑘2)[𝐶2] = 0    
𝑑[𝐶2′]
𝑑𝑡
=   𝑎2′ [𝑌2∗]�𝐸𝑝2� − (𝑑2
′ +  𝑘2′ )[𝐶2′] = 0    
𝑑[𝑌3∗]
𝑑𝑡
= − 𝑎3′ [𝑌3∗]�𝐸𝑝3� +  𝑑3
′ [𝐶3′]   + 𝑘3[𝐶3] 
 − 𝑘𝑜𝑛[𝑌3∗][𝐷] + 𝑘𝑜𝑓𝑓[𝐶𝐷] = 0 
𝑑[𝐶3]
𝑑𝑡





=   𝑎3′ [𝑌3∗]�𝐸𝑝3� − (𝑑3
′ +  𝑘3′ )[𝐶3′] = 0    
𝑑[𝐶𝐷]
𝑑𝑡
=   𝑘𝑜𝑛[𝑌3∗][𝐷] − 𝑘𝑜𝑓𝑓[𝐶𝐷] = 0    
𝑌1𝑇 =  [𝑌1] + [𝑌1∗] + [𝐶1] + [𝐶1′] + [𝐶2] + [𝐶3]    
𝑌2𝑇 =  [𝑌2] + [𝑌2∗] + [𝐶2] + [𝐶2′]    
𝑌3𝑇 =  [𝑌3] + [𝑌3∗] + [𝐶3] + [𝐶3′] + [𝐶𝐷]    
𝐸𝑘1T = [ 𝐸𝑘1] + [𝐶1]    
𝐸𝑝1T = [ 𝐸𝑝1] + [𝐶1
′]    
𝐸𝑝2T = [𝐸𝑝2] + [𝐶2
′]   
𝐸𝑝3T = [𝐸𝑝3] + [𝐶3
′]   
𝐷𝑇 = [𝐷] + [𝐶𝐷]   
Dimensionless Parameters 






          
Ei =   
𝐸𝑘iT
𝑌𝑖𝑇




Ki =  
𝑑𝑖 + 𝑘𝑖
𝑎𝑖  𝑌𝑖𝑇
 =  
𝐾𝑚𝑘𝑖
 𝑌𝑖𝑇
       






    
KB  =  
𝑘𝑜𝑓𝑓/𝑘𝑜𝑛
𝑌3𝑇
 (for 𝑛 = 3) 
KB  =  
𝑘𝑜𝑓𝑓/𝑘𝑜𝑛
𝑌𝑛𝑇




(for 𝑛 = 3)   I =
𝐷𝑇
𝑌𝑛𝑇
(for all 𝑛) 




𝑖 = 1, 𝐸𝑘1T
𝑖 = 2, 𝑖 = 3, 𝑌1𝑇
𝑖 > 3 (vertical), 𝑌(𝑖−1)𝑇




𝑦𝑖 =  
[𝑌𝑖]
𝑌𝑖𝑇
    𝑦𝑖∗ =
[𝑌𝑖∗]
𝑌𝑖𝑇




Finally, algebraic rearrangement and substitution yield the following 
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= 0  
(4) − 1 + 𝑦2  �1 +  E2
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K2
� + 𝑦2∗ 
          + E'2
𝑦2∗
𝑦2∗ + K'2









(6) − 1 + 𝑦3  �1 +  E3
𝑦1∗
K3
� + 𝑦3∗ 





𝑦3∗ +  KB
= 0   
 
C.2 Mapping of dimensionless parameter values to dimensional parameter 
values for numeric simulation 
It was numerically more efficient (and in some cases more accurate) to 
solve the system of ODEs for a long period to ensure steady state was obtained 
rather than directly solving the set of non-linear steady state equations for each 
network.  Prior to solving the ODE system, a set of dimensionless parameter 
values was mapped to dimensional parameter values and initial conditions.  The 
example below applies to the n = 3 network (all dimensionless parameters are in 
bold). 
Initial conditions     
[𝑌1] = 1               𝑌1𝑇  =  [𝑌1]        [ 𝑌1∗] = 0    
[𝑌2] = 𝑌1𝑇/E2     𝑌2𝑇 =  [𝑌2]         [𝑌2∗] = 0 
[𝑌3] = 𝑌1𝑇/E𝟑     𝑌3𝑇 =  [𝑌3]         [𝑌3∗] = 0 
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𝐸𝑘1T =  E1 𝑌1𝑇      𝐸𝑝1T =  E'1 𝑌1𝑇     
𝐸𝑝2T =  E'2 𝑌2𝑇     
𝐸𝑝3T =  E'3 𝑌3𝑇 
[𝐶1] =  [𝐶′1] =  [𝐶2] =  [𝐶′2] =  [𝐶3] =  [𝐶′3] = [𝐶𝐷] = 0 
 
Kinetic parameters 
𝑘′1 = 𝑘′2 = 𝑘′3 =  1    
𝑘1 = (P1 𝐸𝑝1T  𝑘′1)/𝐸𝑘1T     
𝑘2 = (P2 𝐸𝑝2T  𝑘′2)/𝑌1𝑇       
𝑘3 = (P3 𝐸𝑝3T  𝑘′3)/𝑌1𝑇     
𝑑1 = 𝑑′1 = 𝑑2 = 𝑑′2 = 𝑑3 = 𝑑′3 = 𝑘𝑜𝑛 = 1    
𝑎1 = (𝑑1 + 𝑘1)/(K1 𝑌1𝑇)    𝑎′1 = (𝑑′1 + 𝑘′1)/(K'1 𝑌1𝑇   ) 
𝑎2 = (𝑑2 + 𝑘2)/(K2 𝑌2𝑇)    𝑎′2 = (𝑑′2 + 𝑘′2)/(K'2 𝑌2𝑇) 
𝑎3 = (𝑑3 + 𝑘3)/(K3 𝑌3𝑇)    𝑎′3 = (𝑑′3 + 𝑘′3)/(K'3 𝑌3𝑇) 
𝑘𝑜𝑓𝑓 = KB 𝑌3𝑇 𝑘𝑜𝑛 
 
C.3 Randomly selecting 50,000 parameter sets instead of 5000 produced 
the same percentage of off-target effects 
As described in the Methods section of Chapter 4 and in Figure C.1, 5,000 
randomly selected parameter sets were used to determine a probability of off-
target effects in a given parameter space.   When the default parameter ranges 
defined in Table 4.1 were used, the probability of off-target effects (i.e., the 
percentage of off-target effects in the randomly selected parameter sets) was 
1.6%.  We also selected 50,000 parameter sets using the same ranges and 
found a probability of 1.5%.  Histograms of all parameter values in the 50,000 
sampled parameter sets indicate a uniform distribution across all ranges sampled 
as expected based on the LHS selection method used (Figure C.2A).  
Histograms of the 745 parameter sets (out of these 50,000) that produced off-
target effects reveal specific ranges that favor an off-target effect in cycle 2 
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(Figure C.2B).  These ranges are in general agreement with the ranges 
identified by the perturbation method in Figure 4.3.  
 
 
Figure C.1.   Determination of the number of parameter sets to sample.  The percentage of off-targets 
in the n = 3 network (Figure4.2C) was measured in q randomly selected parameter sets using the full 
parameter ranges defined in Table 4.1.  The values of q tested were 500, 1000, 2000, 3000, 5000, and 
10,000.  The test was repeated six times.  The variation in the percentage off-target effects in the parameter 
space appeared to stabilize for repeats greater than or equal to 5000.  We, therefore, selected 5000 as the 
number of parameter sets to sample.  A similar test was performed with the extended n = 3 network 
(Figure4.2D).  No significant differences was found with the extended n = 3 network when values of q tested 






Figure C.2  Histograms of parameter values in 50,000 randomly sampled parameter sets in the n =  3 
network.  When 50,000 parameter sets were sample from the original n = 3 parameter space (depicted in 
Figure 4.3H and defined in Table 4.1). 1.5% of the sampled parameter sets produced off-target effects in 
cycle 2.  (A) Histograms of all parameter values in the 50,000 parameter sets sampled indicate uniform 
sampling distributions.  (B) Histograms of the 745 out of the 50,000 parameter sets sampled which produced 




C.4 Application of Xenopus MAPK Model Parameters 
 
The following values were extracted from the Huang and Ferrell [260] 
Xenopus model: 
𝐸𝑘1T = 0.0003µM   
𝑌1T = 0.003µM          𝑌2T = 1.2µM                𝑌3T = 1.2µM 
𝐸𝑝1T = 0.0003µM     𝐸𝑝2T = 0.0003µM      𝐸𝑝3T = 0.12µM 
Km𝑘1 = 0.3µM           Km𝑘2 = 0.3µM            Km𝑘3 = 0.3µM 
Km𝑝1 = 0.3µM           Km𝑝2 = 0.3µM            Km𝑝3 = 0.3µM 
𝑘1 = 150 min−1        𝑘2 = 150 min−1         𝑘3 = 150 min−1 
𝑘1′ = 150 min−1        𝑘2′ = 150 min−1         𝑘3′ = 150 min−1 
 
Kd (the disassociation constant of the inhibitor binding to Y3*) was not part of 
the original model and was arbitrarily set to .10 µM.  Substituting these values 
into the dimensionless parameter formulas found in Section C.1 gives the values 
listed for the Xenopus parameter set in Table 4.2.  The concentrations and first 
order rate constants used were based on  published values in Huang and Ferrell 
[260], the representation of their MAPK model in the Biomodels repository [307]  
(http://www.ebi.ac.uk/biomodels-main/BIOMD0000000009), and a MAPK model 
published by Blüthgen and Herzel [308] which also used the Huang and Ferrell 
parameters.  The Huang and Ferrell Xenopus model included double 
phosphorylation of the MAPK cascade, while our model only considered single 
phosphorylation, however.   
 
C.5 Additional analysis of the extended n = 3 network with amplification 
A numeric perturbation analysis (as described in the Methods) was 
performed on the extended n = 3 network parameter space depicted in Figure 
C.4H.  In this analysis, off-target effects in cycle 4 which were amplified from 
cycle 2 were considered.  The results indicated that a generally inefficient kinase 
reaction in cycle 2 (K2 >> 1) favored amplification of off-target effects in cycle 4 
(Figure C.3D).  This result is similar to the behavior of K2 in the restricted n = 3 
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parameter space (Figure C.3D).  In contrast, a more efficient kinase reaction in 
cycle 4 that operated near the zero-order regime (K4 < 1) favored amplification of 
off-targets in cycle 4 (Figure C.4D).  Amplification of off-target effects in cycle 4 
were more likely for smaller values of E2 or E’2 (Figure C.4A-B).  Because E2  is 
the total enzyme to substrate ratio of the kinase reaction in cycle 2 (i.e., Y1T/Y2T), 
these results suggest that amplification of off-target effects are more likely to 
propagate downstream from cycle 2 if the Y2  protein pool is larger than the Y1 
protein pool.   In contrast, off-target effects in cycle 2 were favored in the n = 3 
network when E2 or E’2 was greater than 1 (i.e., the Y2  protein pool was smaller 
than the Y1 protein pool) (Figure C.3A-B).   
The results also indicate that in the extended n = 3 network, analogous 
parameters in cycle 2 and cycle 4 work against each other. For example, large K2 
and small K4 values contributed to amplification of off-target effects in cycle 4 
(Figure C.4E).  Similarly, large P4 and small P2 values favored amplification of 
off-target effects in cycle 4 (Figure C.4C).   
 
 
Figure C.3.  A numerical perturbation analysis revealed parameter value ranges that promote off-
target effects when the n = 3 network’s parameter space was restricted. A perturbation analysis of the 
restricted parameter space (depicted in Figure 43I) of the n = 3 network was performed.  The baseline in 
each plot is 74% (the percentage of off-target effects when 5000 parameter sets were randomly sampled 
from this parameter space). All other bars reflect the results of systematically perturbing each parameter 




Figure C.4. A numerical perturbation analysis revealed parameter value ranges that promote off-
target effects with amplification in extended n = 3 network.  A perturbation analysis of the partially 
restricted parameter space (depicted in H) of the extended n = 3 network (G) was performed.  The baseline in 
each plot is 23.4% (the percentage of off-target effects which amplified from cycle 2 to cycle 4 when 5000 
parameter sets were randomly sampled from this parameter space).  All other bars reflect the results of 
systematically perturbing each parameter (one at a time) using the given sub-ranges (A-F).  Next, cycle 2 
and cycle 4 parameter ranges were further restricted based on the results in (A-F) to produce a new 
restricted parameter space for the extended n = 3 network. (I) This parameter space produced off-target 
effects in 67.4% of sampled parameter sets and produced off-target effects with amplification from cycle 2 to 
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